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 ABSTRAK 
S. aureus veroorsaak ernstige infeksies in die hospitaalomgewing en in die 
gemeenskap. Wêreldwyd, neem metisillien-weerstandige S. aureus (MRSA) infeksies 
vinnig toe. Huidiglik by Tygerberg hospitaal is ongeveer ‘n derde van S. aureus 
isolate MRSA. Hierdie is die eerste epidemiologiese studie by Tygerberg hospitaal 
wat prospektiewe kliniese data van pasiënte met S. aureus bakteremie saam met spa 
tipering en aantoning van die mecA en pvl gene in ‘n multipleks PKR insluit. Klonale 
groepe (spa-CC) van MRSA en MSSA isolate is deur BURP analise verkry, en 
vergelyk met internasionaal belangrike klone. Die molekulêre epidemiologie van 
hospitaalverworwe (HA), gesondheidsorgverworwe (HCA) en gemeenskapsverworwe 
(CA) S. aureus bakteremie by hierdie hospitaal is ondersoek. Laastens, oorspronklike 
en daaropvolgende herhaal isolate is gekollekteer om moontlike organisme- faktore 
geassosieerd met persisterende en herhalende bakteremiese episodes te analiseer.  
Ons het in totaal 113 S. aureus isolate van 104 pasiënte ondersoek (70% MSSA, 30% 
MRSA). Nege isolate (van 5 pasiënte) was herhaal isolate. Alle isolate was afkomstig 
vanaf bloedkulture wat gedurende die periode Maart 2008 tot Mei 2009 gekollekteer 
is. Fenotipiese en genotipiese aantoning van metisillien weerstandigheid het goed 
gekorreleer. Volgens die literatuur kan die meeste CA-MRSA isolate van HA-MRSA 
isolate onderskei word op grond van die teenwoordigheid van die PVL toksien. Geen 
CA-MRSA is egter in ons studie gevind nie, dus kon die assosiasie tussen HA-MRSA 
en CA-MRSA isolate nie ondersoek word nie. CA-MSSA was in 22% van alle MSSA 
geidentifiseer teenoor 0% CA-MRSA. PVL is in MSSA isolate gevind (22.7% van 
alle MSSA) maar glad nie in MRSA nie. Dit is opgemerk dat MRSA isolate 
hoofsaaklik in spa CC 701 en CC-012 kloongroepe voorkom, teenoor kloongroep CC-
002 wat slegs MSSA isolate bevat het. Soortgelyk het HA-isolate wat die meerderheid 
van MRSA isolate verteenwoordig het ook in kloongroepe 1 & 2 gegroepeer.  
 
Nege-en-veertig spa tipes is geïdentifiseer in 89.3% of alle isolate en 9.7% was nie-
tipeerbaar. Vyf nuwe spa tipes is getoon. Ons het ‘n diverse aantal spa-tipes 
geïdentifiseer wat met internasionale klone gekorreleer het. Die mees dominante spa 
tipe in ons omgewing was t037 (slegs in MRSA), gevolg deur t891. Volgens die 
literatuur word t037 met die Brasiliaanse/Hongaarse kloon geassosieer (SCCmec tipe 
III; ST 239). Ons bevindings, asook ander Suid Afrikaanse studies, dui aan dat t037 in 
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 kliniese isolate vanaf talle provinsies in Suid-Afrika aangetoon is. Van belang is dat al 
die isolate van spa tipe t891 MSSA en PVL positief was.  
 
Bakteremiese gevalle was hoofsaaklik geassosieer met kateter-sepsis, gevolg deur vel 
en sagteweefsel infeksies (SSTI). Slegs een persisterende bakteremiese geval was 
geïdentifiseer geassosieer met HA-SSTI. Herhalende bakteremiese episodes is in 
pasiënte op dialise vir kroniese nierversaking en in brandwonde pasiënte met intra-
vaskulêre kateter infeksies aangetoon. Die lokale epidemiologie van S. aureus en die 
prevalensie koers van verskillende stamme is van belang. Hierdie inligting dra by tot 
kennis van die epidemiologie van stafilokokkale stamme wat in ons omgewing 
bakteremie veroorsaak. Hierdie insigte is nuttig vir optimale diagnostiese en 
terapeutiese riglyne. Die tegnieke wat ontwikkel is, kan gebruik word om uitbrake en 
herhalende infeksies te identifiseer.  
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 ABSTRACT 
S. aureus causes serious infections in the hospital and community settings. The rate of 
MRSA infections are rapidly increasing worldwide. Currently, at Tygerberg hospital, 
approximately a third of S. aureus isolates are MRSA. This was the first 
epidemiological study of S. aureus conducted at Tygerberg Hospital that included 
prospective clinical data on patients with S. aureus bacteraemia together with spa 
typing of strains and the detection of the mecA and pvl genes in a multiplex PCR. 
Clonal cluster groups of S. aureus isolates were obtained by BURP analysis and 
compared to international important clones. The molecular epidemiology of hospital 
acquired (HA), health-care associated (HCA) and community acquired (CA) S. aureus 
bacteraemic strains at this hospital was examined. Lastly, repeat isolates of patients 
were collected to analyse any possible organism-related factors associated with 
persistent and recurrent bacteraemia.  
We investigated a total number of 113 S. aureus strains from 104 patients (70% 
MSSA, 30% MRSA). Repeat strains consisted of nine isolates (from 5 patients). All 
isolates were obtained from blood cultures collected during the period March 2008 to 
May 2009. Phenotypic and genotypic detection of methicillin resistance correlated 
well. According to the literature, most CA-MRSA strains are distinguishable from 
HA-MRSA strains based upon the presence of the PVL toxin. However, no CA-
MRSA was detected in our study, therefore the association between HA-MRSA 
versus CA-MRSA strains could not be analysed. In this study, CA-MSSA was 
identified in 22% of all MSSA isolates versus 0% CA-MRSA. PVL positive strains 
were found in 22.7% of all MSSA isolates with no detection in MRSA isolates. It was 
noted that MRSA strains clustered in spa CC-701 and CC-012, whereas CC-002 only 
contained MSSA strains. Likewise HA-strains representing the majority of MRSA 
strains also clustered in spa CC-701 and CC-012. 
 
Forty nine spa types were identified in 89.3% of all isolates, whereas 9.7% of these 
strains were non-typeable. Five novel spa types were revealed. We detected a diverse 
number of spa-types that correlated to international clones. The most predominant spa 
type found in our setting was t037 (only in MRSA), followed by t891. According to 
the literature, t037 is associated to the Brazilian/Hungarian clone (SCCmec type III; 
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 ST 239). Our findings, as well as other South African studies, indicate that t037 has 
been identified in clinical strains from numerous provinces in South Africa. 
Interestingly, all isolates from spa type t891 were PVL positive MSSA.  
 
Bacteraemia cases were predominantly related to catheter sepsis, followed by skin and 
soft tissue infections (SSTI). Only one persistent bacteraemia case was identified 
related to a HA-SSTI. Recurrent bacteraemia cases were found in patients on dialysis 
for chronic renal failure and in burns patients related to intravascular catheter 
infections. The local epidemiology of S. aureus and the prevalence rate of different 
strains are important to investigate. The information provided contributes to the 
epidemiology of staphylococcal strains causing bacteraemia in our setting. These 
insights are useful for optimal diagnostic and therapeutic measures. The techniques 
developed can be used to identify outbreaks and recurrent infections. 
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 CHAPTER ONE 
 
1 INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Introduction 
 
Staphylococcus aureus is one of the most virulent microbial pathogens to cause 
nosocomial and community acquired infections. S. aureus frequently causes 
bloodstream infections, skin and soft tissue infections, pneumonia and post-operative 
wound infections (Orrett & Land, 2006; Randrianirina et al., 2007). Other severe 
infections include septic arthritis, osteomyelitis and endocarditis with significant rates 
of morbidity and mortality. Furthermore, community-acquired methicillin resistant S. 
aureus (CA-MRSA) infections and hetero-resistance to the glycopeptides in the 
hospital setting have emerged worldwide, especially in the United States (Orrett & 
Land, 2006; Shittu & Lin, 2006). 
 
Deep-seated staphylococcal infections are common in patients admitted to Tygerberg 
Hospital. These infections include bacteraemia associated with line-sepsis, 
osteomyelitis, septic arthritis, deep organ abscesses, and infective endocarditis. 
Previous experience has shown that bone and soft tissue S. aureus infections 
particularly tend to relapse or become chronic. Persistence may be related to a number 
of factors, namely endovascular sources, vancomycin treatment, metastatic infections, 
diabetes (Khatib et al., 2006), HIV status or inappropriate therapy (Chang et al., 
2003). Another possible reason may be a population of S. aureus strains with 
enhanced virulence and antimicrobial drug resistance.  
 
There is a paucity of local studies on the genotypic characterisation of invasive S. 
aureus strains as well as on the incidence of CA-MRSA infections. In 2007, the first 
report documenting a variety of MRSA epidemic clones throughout South Africa was 
presented. The typing methods used in the study included SCCmec typing using 
multiplex PCR, spa typing and PCR for the detection of PVL toxin (Oosthuysen et 
al., 2007). In 2009, another South African study was published, reporting the first 
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 multilocus sequence typing (MLST) of S. aureus strains collected from public 
hospitals in Kwazulu-Natal (Essa et al., 2009). 
  
Data on the genotypic characteristics of local S. aureus strains in relation to the 
clinical presentation of S. aureus infections, in particular with regards to persistent 
infection, and community-acquired versus hospital acquired infections, is lacking. 
This is the first study that was performed at Tygerberg Hospital (an academic hospital 
situated in the Western Cape province of South Africa), which included spa typing, 
together with the detection of the mecA and pvl genes. The information provided in 
this study contributes to the understanding of local epidemiology of S. aureus and the 
pathogenesis of different strains in our setting. 
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 1.2 Literature Review 
 
1.2.1 Characteristics of Staphylococcus aureus  
 
The genus Staphylococcus is derived from the family Staphylococcaceae, which 
consists of more than thirty species of Gram positive spherical bacteria (Todar, 2008). 
In 1880, Sir Alexander Ogston revealed S. aureus as an important human pathogen, 
responsible for the formation of pus in wounds (AL-Haj et al., 2009; Archer, 1998). 
Skinner and Keefer (1941) provided proof of its virulence as 82% of 122 patients with 
S. aureus bacteraemia died of this infection at Boston City Hospital, Harvard Medical 
School. From the 122 cases, only 22 patients recovered (Skinner & Keefer, 1941). 
 
Bacteria of this genus are microscopically observed as single organisms, in pairs, but 
mainly forming grapelike clusters. The latter is derived from the Greek term staphyle 
meaning a bunch of grapes. The cell wall has a Gram positive structure, containing 
peptidoglycan and teichoic acid (Ryan & George Ray, 2004; Tolan et al., 2009). In 
most S. aureus strains, the peptidoglycan layer is covered with surface proteins. One 
of these proteins, namely protein A is discussed in more detail in section 1.2.7, 
Staphylococcal Protein A (spa).  
 
Although S. aureus are constituents of the normal flora of the skin and nose in 
carriers, they are also found in the oral cavity and gastrointestinal tract (Todar, 2008). 
Studies report that most S. aureus infections are thought to be derived from 
colonization of the anterior nares with 30% of the population being colonized at any 
given time (Melles et al., 2004; Sinha & Herrmann, 2005).  
 
All species of staphylococci are catalase positive and can therefore be clearly 
distinguished from streptococci and enterococci which are catalase negative bacteria. 
A catalase test can be performed, which converts hydrogen peroxide (H2O2) to water 
and oxygen in order to differentiate between catalase positive and negative bacteria 
(Todar, 2008). S. aureus grow well aerobically but are facultative anaerobes that form 
relatively large yellow to golden colonies when grown on rich media. The organism is 
also non-spore forming, non-motile and non-flagellate. In addition, it has the ability to 
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 resist high temperatures up to 50° C, drying, as well as high salt concentrations (AL-
Haj et al., 2009; Tolan et al., 2009). 
 
The genus is classified into two main groups based upon the presence of the enzyme 
coagulase. S. aureus, being the most virulent pathogen is a coagulase positive 
bacterium which possesses the ability to clot blood plasma. The second group are the 
coagulase-negative staphylococci (CoNS) which form relatively small white colonies 
when grown on rich media. There are a number of CoNS species, such as S. 
epidermidis, S. haemolyticus and S. saprophyticus. For many years, CoNS have been 
considered to be harmless bacteria that form part of normal skin flora. However, this 
perception changed over time as the pathogenicity of these organisms was recognized. 
Heubner & Goldmann (1999) reported CoNS as being the most common cause of 
bacteraemia related to indwelling devices in nosocomial infections (Heubner & 
Goldmann, 1999). Virulence factors of these organisms are not well understood, but 
their ability to grow as biofilms on catheters or medical implants are of utmost 
importance (Mims et al., 2004). 
 
1.2.2 Infections caused by S. aureus 
 
Over the past several decades, S. aureus has been associated with a diverse range of 
mild to life threatening clinical infections. Strains of this human pathogen can arise 
from colonized sites and be transmitted in the community or hospital settings (Shittu 
& Lin, 2006). These infections may vary from superficial skin lesions namely 
impetigo, furuncles, carbuncles and urinary tract infections, to serious infections like 
pneumonia, meningitis, endocarditis and osteomyelitis (Figure 1.1). 
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Reproduced from (Todar, 2008) 
Figure 1.1: Diseases and infection sites of S. aureus  
 
At least 30% of the population is colonized with S. aureus, mostly in the anterior 
nares but also in the axilla, perineum or vagina (Archer, 1998; Fischetti et al., 2006). 
From a two week period up to a few months, the organism can be passed on 
asymptomatically onto the mucous membranes but only transiently carried on intact 
skin (Archer et al., 1996). S. aureus is spread by means of hand carriage, as the 
rganisms spread from the hands to other areas of the body. When colonization with 
ntry through skin abrasions and cause 
kin infection, which could with further spread lead to more serious infections like 
e usually patients on dialysis, intravenous (IV) drug 
sers, diabetics, and patients with HIV-AIDS (Fischetti et al., 2006). 
o
S. aureus takes place, the organism may find e
s
endocarditis, osteomyelitis or toxemias (Fischetti et al., 2006). 
 
Community-acquired outbreaks are more often than not related to poor hygiene and 
fomite transmission from person to person. For instance, because S. aureus has the 
ability to survive lengthy periods of drying, clothing contaminated with pus from a 
previous infection could produce recurrent skin infections (Ryan & George Ray, 
2004). The immune system also plays an important role as individuals who are at high 
risk of S. aureus colonization ar
u
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 Hospital-acquired outbreaks normally include patients who have undergone surgery or 
other invasive procedures. S. aureus can spread directly from infected open wounds to 
other patients on the hands of hospital staff (Ryan & George Ray, 2004). For this 
reason, health care workers and hospitalized patients have a much greater chance of 
becoming colonized with S. aureus for long periods of time (Fischetti et al., 2006).  
 
1.2.3 Methicillin resistant S. aureus (MRSA) 
 
The introduction of penicillin in the 1940s resulted in a decrease in mortality rates due 
nicillin binding protein 2 (PBP2) to 
BP 2a, mediated by the mecA gene. This target change caused resistance to 
 of MRSA have been reported worldwide, especially in 
eveloping countries (Feng et al., 2008; Randrianirina et al., 2007). Afroz et al 
to S. aureus infections for a brief period. Soon after, penicillin-resistant S. aureus 
(PRSA) strains producing β-lactamase was established. Within the following 10 years, 
this resulted in a rise in penicillin resistance in up to 90% of hospital-acquired strains. 
In the late 1950s, methicillin was the treatment of choice for PRSA infections. Only 
six months after methicillin was marketed, methicillin-resistant S. aureus (MRSA) 
strains emerged in 1959, primarily in nosocomial settings (Boyle-Vavra & Daum, 
2007; Grundmann et al., 2006). 
 
MRSA emerged due to the alteration of the pe
P
penicillinase-resistant penicillins (PRPs) and conferred resistance to all beta-lactam 
agents (Oosthuizen et al., 2005). Since then, MRSA rates gradually increased, until it 
remarkably surged from the late 1990s (Amod et al., 2005; Boyle-Vavra & Daum, 
2007). Due to the dramatic increase in MRSA in nosocomial infections, the 
glycopeptides, vancomycin and teicoplanin, were until recently the last choice 
available for therapy (Boyle-Vavra & Daum, 2007; Nunes et al., 2002; Robinson & 
Enright, 2003). These antibiotics and their resistance are further discussed in section 
1.2.3.1 (Reduced susceptibility to vancomycin). 
 
Currently, increasing rates
d
(2008), reported high MRSA rates of 32-63% in various cities of Bangladesh, which 
compares to countries in Europe and the United States (Afroz et al., 2008). At present, 
hospital MRSA rates are more than 50% in Japan and the United States, whereas 
Sweden and Norway MRSA rates are less than 1% (Nübel et al., 2008). The high 
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 prevalence and growing rates of MRSA in hospitals is becoming a global problem, 
with intermediate occurrences in most of Australia, Europe, and several countries in 
South America and Africa (Nübel et al., 2008).  
 
Recent data on the prevalence rates of staphylococcal infections in Africa are limited. 
Early studies of MRSA in South Africa were reported during the 1980s and early 
1990s (Shittu & Lin, 2006). A study conducted from 2001 to 2002 by the Pan-
European Antimicrobial Resistance Using Local Surveillance (PEARLS), showed 
18/54 (33%) of S. aureus isolates as MRSA in South Africa (Bouchillon et al., 2004; 
Marais et al., 2009). The PEARLS study provided baseline data of extended-spectrum 
β-lactamase (ESBL) producers in selected Enterobacteriaceae, vancomycin-resistant 
E. faecium (VRE) and MRSA strains from 17 participating countries. South Africa 
was one of these countries, together with 13 European and 3 Middle Eastern countries 
(Bouchillon et al., 2004).  
 
At Tygerberg hospital, (Cape Town, South Africa) during 1985, MRSA was isolated 
from 18% of 2681 pus swabs and 25% of 100 blood cultures (Peddie et al., 1988). 
Currently, at this hospital, the laboratory statistics report showed that approximately a 
third of S. aureus isolates are methicillin resistant. This figure increases to 
approximately 60% for isolates from ICUs and approximately 45% for blood cultures 
isolates (Table 1.1). 
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 Table 1.1: Percentage of S. aureus that are methicillin resistant isolated from (a) all 
specimens received from all hospital wards, (b) all specimens received from ICUs and 
(c) from blood cultures at Tygerberg Hospital. The time line for each year was from 
the 1st January to the 31st December. 
 
Percentages 2006 2007 2008 
(a) All specimens from 
all wards  
34% 30% 29% 
(b) All specimens from 
ICUs 
64% 56% 64% 
(c) Blood cultures 49% 42% 44% 
 
 
Studies report that patients with MRSA bacteraemia have increased morbidity and 
mortality rates, higher medical costs and a longer duration of hospital stay, compared 
to patients with methicillin susceptible S. aureus (MSSA) bacteraemia (Nübel et al., 
2008; Shittu & Lin, 2006). The treatment of MRSA can be problematic if the location 
is at anatomical sites (for example in the treatment of bone infections or endocarditis) 
where there is reduced antimicrobial penetration (Duckworth, 2003; Shittu & Lin, 
2006). 
 
1.2.3.1 Reduced susceptibility to vancomycin 
 
Vancomycin and teicoplanin are glycopeptides that are crucial for the treatment of 
life-threatening infections caused by multi-resistant Gram-positive bacteria (Tenover 
et al., 2008). In the 1980s, empiric therapy for nosocomial staphylococcal infections 
changed to vancomycin, due to the universal occurrence of MRSA in many hospital 
settings (Tiwari & Sen, 2006). Vancomycin was believed to retain activity against all 
strains of S. aureus, but MRSA strains with reduced susceptibility to vancomycin 
have emerged during the last decade (Srinivasan et al., 2002; Walsh & Howe, 2002). 
 
GISA (glycopeptide intermediate S. aureus) and heteroresistant GISA (h-GISA) are 
the acronyms used when resistance occurs in both vancomycin and teicoplanin (Walsh 
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 & Howe, 2002). Heterogeneous intermediate resistant strains test susceptible by 
standard susceptibility methods, but contain subpopulations composed of small 
numbers of bacterial cells with variable degrees of resistance to glycopeptides (Nunes 
et al., 2006; Srinivasan et al., 2002). Nonetheless, these isolates possess a minimum 
inhibitory concentration (MIC) below susceptible breakpoints, while containing 
bacterial subpopulations (ca. 10-6) which grow in the presence of 4 µg/ml of 
vancomycin (Oosthuizen et al., 2005). These strains, which are seen in both coagulase 
negative Staphylococci and S. aureus, are thought to occur more frequently than 
vancomycin intermediate S. aureus (VISA) or GISA (Oosthuizen et al., 2005; 
Srinivasan et al., 2002). 
 
The automated VITEK 2 system and the vancomycin agar screening methods are not 
sensitive enough in detecting hetero-resistance. Therefore, it is recommended that the 
E-test macromethod, which correlates well with the gold standard, a modified 
population analysis profile- area under the curve ratio (PAP-AUC), should be used for 
selected isolates from patients not responding to vancomycin therapy (Walsh et al., 
2001). For the E-test macromethod a higher inoculum (2 McFarland) and a richer 
medium (brain heart infusion agar) is used to detect heteroresistance. This test 
performs well with a sensitivity of 96% and a specificity of 97%, thus making it a 
reliable and sensitive method (Oosthuizen et al., 2005; Walsh et al., 2001). 
 
VISA and h-VISA strains have been reported from Asia, USA and Europe. In Africa, 
reports of VISA infections are limited. Two MRSA isolates from Johannesburg, 
South Africa, appeared to be intermediately resistant to vancomycin (Standard E-test 
of 6 and 8 µg/ml). However, these strains were not confirmed to be VISA or h-VISA 
by the broth dilution MIC or the population analysis results (Amod et al., 2005). 
Nevertheless, Amod et al (2005) reported the first confirmed clinical h-VISA 
infection from a South African patient. The patient presented with a ventriculitis 
caused by a MRSA strain with reduced susceptibility to vancomycin. The MRSA 
strain was confirmed to be an h-VISA by both the macro-dilution E-test and the PAP-
AUC method. However, no genotyping methods were included in this study. 
 
In 2007, at Tygerberg hospital, a study was performed using the E-test macromethod 
to determine the presence of staphylococcal isolates with resistance to the 
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 glycopeptides (Salaam, 2007). No GISA and h-GISA was detected in this study. 
However, soon after the completion of the above mentioned study, the first strain of 
hetero-glycopeptide intermediate resistant S. aureus (h-GISA) was isolated from an 
infant on vancomycin therapy at Tygerberg hospital. This infant developed a 
bacteraemia following umbilical catheter site infection. Despite removal of the 
catheter and vancomycin therapy, osteomyelitis of the tibia developed. The child 
subsequently improved after numerous surgical debridements and linezolid therapy. 
Due to the lack of strain typing methods available at that stage, it could not be 
established if the hetero-resistant strain evolved from the initial vancomycin-
susceptible strain isolated from the same patient.  
 
The detection of resistance is important in order to optimize treatment and guide 
preventative measures to contain further spread of these multi-resistance organisms in 
the hospital setting. The current procedures to detect h-GISA strains at Tygerberg 
Hospital are described in Chapter 3 (section 3.2). 
 
1.2.3.2 Hospital, Health-Care and Community acquired infections 
 
MRSA isolates from the community amongst previously healthy individuals with few 
or no record of healthcare associated risk factors for MRSA have recently been 
described (Boyle-Vavra & Daum, 2007). The first community-acquired MRSA (CA-
MRSA) strain was reported in Western Australia during 1993 in patients with no 
known risk-factors for MRSA colonization (Deurenberg et al., 2007). This signified 
remarkable changes in the epidemiology of MRSA, as previously all Staphylococcal 
community-acquired infections were due to MSSA (Boyle-Vavra & Daum, 2007; 
Deurenberg et al., 2007). 
 
Hospital acquired bloodstream infections are defined by a positive blood culture 
collected more than 48 hours after admission without evidence of a S. aureus 
infection at the time of admission. If the patient was transferred from another hospital, 
the duration is considered from the date of the first hospital admission. Health-care 
associated bloodstream infections are defined by positive blood cultures at the time or 
within 48 hours of hospital admission from patients with the following history: 
 10
  Patients who have been to a hospital or hemodialysis clinic or obtained 
intravenous chemotherapy within 30 days before the infection 
 Patients who have been hospitalized for 2 or more days within 90 days (3 
months) before the infection 
 A patient who is a resident in a nursing home or long-term care facility 
(Friedman et al., 2002) 
 
Community acquired bloodstream infections are defined by a positive blood culture 
collected in an outpatient setting or within 48 hours of hospital admission from 
patients without a history of health-care exposure. Therefore, these patients should not 
have a history of MRSA infection or colonisation, surgery, dialysis, admission to a 
nursing home and also no history of hospitalization in the past year. Lastly, to be 
considered in this category is that the patient must have no permanent indwelling 
catheters or medical devices passing through the skin into the body (Deurenberg et al., 
2007; Friedman et al., 2002) 
 
It was primarily thought that CA-MRSA strains were nosocomial strains that spread 
from the hospital to community settings. Nonetheless, it is indicated that CA-MRSA 
strains are indeed different from those prevalent in hospital settings due to the 
susceptibility of CA-MRSA to non beta-lactam antimicrobials and the link with 
clinical syndromes that are more characteristic of MSSA strains. It has also been 
established that CA-MRSA developed from MSSA strains commonly spread in the 
community. This was concluded from studies that have shown clear genotypic 
differences between CA-MRSA and HA-MRSA (Boyle-Vavra & Daum, 2007; 
Deurenberg et al., 2007). These genotypic markers include the genetic lineages; the 
architecture of genetic elements in methicillin resistance and the presence of the 
Panton Valentine Leukocidin (PVL) gene (refer to section 1.2.4.1). 
 
CA-MRSA appears to be more virulent than HA-MRSA (Boyle-Vavra & Daum, 
2007). The clinical infections associated with CA-MRSA include severe skin and soft 
tissue infections and necrotizing pneumonia. Boyle-Vavra & Daum (2007) mentions a 
high mortality rate of patients who are hospitalised within 24-48 hours with severe 
sepsis associated with necrotizing pneumonia. Furthermore, these cases have 
occasionally been correlated to purpura fulminans, disseminated intravascular 
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 coagulation (DIC) and bilateral adrenal haemorrhage. The latter is usually related to 
Waterhouse-Friderichsen syndrome (Boyle-Vavra & Daum, 2007). CA-MRSA 
outbreaks have occurred in participants in team sports, military personnel and 
correctional facility inmates. Risk factors for these infections include poor hygiene 
and over populated areas (File, 2008).  
 
1.2.4 Virulence factors 
 
S. aureus may cause a wide range of infections due to an extensive number of 
virulence factors (Archer, 1998). Generally, S. aureus has been considered as an 
extracellular pathogen, until recent data revealed the organism’s ability to infect a 
variety of host cells, both professional and non-professional phagocytes. These non-
professional phagocytes include fibroblasts, osteoblasts, epithelial and endothelial 
cells (Fischetti et al., 2006; Krut et al., 2003; Que et al., 2005).  
 
In general, pathogenicity is associated with the bacteria’s ability to adhere to surfaces, 
invade the tissues or cells, and cause harmful toxic effects to the host. Virulence 
factors of S. aureus are comprised of cell surface components (surface proteins) and 
extracellular proteins (secreted proteins or exoproteins). Cell surface components 
include capsular polysaccharide, protein A, fibronectin-binding protein, collagen-
binding protein, elastin-binding protein and the clumping factor. Extracellular proteins 
include coagulase, hemolysins, enterotoxins, exfoliatins, toxic shock syndrome toxin, 
and Panton-Valentine leucocidin (PVL) (Figure 1.2) (Holmes et al., 2005; Jarraud et 
al., 2002; Lina et al., 1999).  
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Reproduced from Lowy 1998 
Figure 1.2: A diagram illustrating the surface and secreted proteins of S. aureus 
together with its growth phases. These growth phases are controlled by regulatory 
genes such as agr  
 
In humans, S. aureus presents itself as a highly versatile pathogen known to cause 
three basic syndromes. Firstly, it can cause superficial skin lesions such as wound 
infections and skin abscess. Secondly, it can cause deep-seated and systemic 
infections namely osteomyelitis, endocarditis, pneumonia and bacteraemia. Thirdly, it 
may cause toxaemic syndromes related to the production of extracellular proteins. 
These include toxic shock syndrome (TSS), staphylococcal food poisoning (due to 
various enterotoxins), scalded-skin syndrome (due to exfoliatins) and necrotizing 
pneumonia (due to the PVL toxin) (Dinges et al., 2000; Fischetti et al., 2006; Jarraud 
et al., 2002; Lina et al., 1999). The pathogenicity of S. aureus is multifactorial, 
particularly on a molecular basis where the precise role of any given factor is difficult 
to determine. This depends largely on the expression of accessory gene products that 
constitute of surface proteins and extracellular proteins (Figure 1.2) (Jarraud et al., 
2002). 
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 The accessory gene regulator (agr) induces the expression of extracellular proteins 
while suppressing the expression of surface proteins. Moreover, the surface proteins 
are produced during the early exponential growth phase, when the bacteria are at low 
density (Figure 1.2). As the adhesion molecules are expressed during the initial stages 
of infection, the bacteria adhere to and colonise host cells and implanted medical 
devices. On the contrary, the synthesis of secreted proteins is produced during the 
stationary phase which favours the spread to adjacent tissues (Figure 1.2). The 
bacteria therefore produce these toxic secretory proteins at higher densities, which 
allow the survival and spread of bacteria thus leading to infection (Korem et al., 2003; 
Lowy, 1998). 
 
Sinha & Hermann (2005) describes the mechanism of adherence and invasion of S. 
aureus causing serious infections, such as infective endocarditis in molecular detail. 
They report a vast diversity in the invasion of S. aureus and its effect to host cells, 
which may be due to multiple virulence factors. Therefore, further studies are needed 
in order to better understand the pathogenesis of S. aureus.  
 
Furthermore, Sinha & Hermann (2005) discuss covalently cell wall-anchored adhesins 
which are referred to as microbial surface components recognizing adhesive matrix 
molecules (MSCRAMMs). It was believed that MSCRAMMs were mono-specific for 
a given host protein. This reasoning changed as more than one ligand has been 
recognized for many of these adhesins. The members belonging to the MSCRAMMs 
class are Spa (staphylococcal protein A), FnBPs (fibronectin-binding proteins), Cna 
(collagen adhesin), ClfA and ClfB (clumping factors, and other fibrinogen-binding 
proteins). In addition, pls (plasmin-sensitive protein) exists in this class (Nashev et al., 
2004; Sinha & Herrmann, 2005). The MSCRAMMs allow bacteria to initially adhere 
to host tissue components in order to withstand phagocytosis and other host defences. 
For instance, fibronectin-binding protein facilitates incorporation by epithelial and 
endothelial cells. 
 
Although S. aureus is usually classified as an extracellular pathogen, the ability of 
these organisms to survive intracellularly has been established in epithelial cells as 
well as neutrophils (Kielian et al., 2001). The intracellular environment protects 
staphylococci from both host defence mechanisms and bactericidal effects of 
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 antimicrobial agents (Kielian et al., 2001; Lowy, 2000). It has been reported that 
variants of S. aureus, specifically small colony variants (SCV) due to their colony 
morphology, has adapted an ability to persist intracellularly (Fischetti et al., 2006; 
Krut et al., 2003). These variants, protected by the intracellular environment may 
cause persistent or recurrent infections. Hence, further studies are needed to 
investigate whether invasion and cytotoxicity are characteristic of clinical S. aureus 
isolates and if these factors are associated to their pathogenicity. 
 
1.2.4.1 Panton Valentine Leukocidin (PVL) 
 
The cytolytic toxin PVL was discovered in 1894 by Van de Velde. This toxin has the 
ability to lyse leucocytes (Ellington et al., 2007; Pathirage, 2008). In 1932, the toxin 
was named after Panton and Valentine when they associated it with severe soft tissue 
infections (Pathirage, 2008). PVL is also closely related to CA-MRSA clones that 
have recently emerged worldwide (Dumitrescu et al., 2007). Genetic analysis shows 
that these clones emerged in various continents, and not from a single clone that 
spread worldwide (Pathirage, 2008). The CA-MRSA clones, USA300 and USA400 
have been identified in Canada and the United States. The USA300 clone has been 
detected in approximately 50% of community-acquired skin infections in the United 
States (McDonald et al., 2005; Tinelli et al., 2009). Thus, CA-MRSA has become an 
increasing threat worldwide, as newly emerging strains has been reported in various 
studies with rates of 77% to 100% (McClure et al., 2006; Naas et al., 2005; Naimi et 
al., 2003; Shukla et al., 2004). Evidence that PVL is a major virulence factor in CA-
MRSA is discussed in more detail in section 1.2.4.1 a). 
 
It has been documented that the toxic effects produced by PVL is encoded by two 
contiguous genes, namely, lukF-PV and lukS-PV. These genes occur in several 
temperate bacteriophages. The two genes act as subunits that assemble in the 
membrane of host cells, mainly in neutrophils, macrophages and monocytes (Feng et 
al., 2008; Pathirage, 2008). The subunits form a ring with a central pore when in close 
contact, through which the cell contents escape, acting as superantigens (Ellington et 
al., 2007; Holmes et al., 2005; McDonald et al., 2005; Pathirage, 2008). According to 
published reports, PVL toxin is produced by 2-10% of S. aureus isolates (Ellington et 
al., 2007; Holmes et al., 2005; McDonald et al., 2005).  
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This bicomponent cytotoxin causes damage in the leucocytes and tissue necrosis, 
resulting in severe skin and soft tissue infections as well as necrotizing pneumonia 
(McClure et al., 2006; Pathirage, 2008; Tinelli et al., 2009). The mortality rates of 
these PVL-producing S. aureus infections are high (approximately 75%) (Dumitrescu 
et al., 2007). Furthermore, Melles et al (2004) reported the presence of PVL in a high 
number of S. aureus strains causing abscesses and arthritis in contrast to colonizing 
strains. Another study detected PVL genes in isolates that were responsible for burn 
infections, bacteraemia, scalded skin syndrome as well as community acquired-
pneumonia (Holmes et al., 2005). Many reports found that PVL causes severe 
necrotizing pneumonia, specifically among children, young adults and 
immunocompetent patients (Labandeira-Rey et al., 2007; Pathirage, 2008; Yamasaki 
et al., 2005).  
 
Lina et al (1999), noted the first connection between the genes for PVL and 
community acquired (CA) pneumonia in S. aureus strains. Lina and colleagues (1999) 
developed a PCR assay for the detection of PVL genes. They discovered an 
association between the presence of the locus with severe necrotizing CA-pneumonia 
in 8% of their cases in comparison to none of the hospital-acquired pneumonia cases. 
They also confirmed the findings of previous reports proving that PVL genes are 
related to primary cutaneous infections, particularly furunculosis. Furthermore, 
studies of CA-pneumonia due to PVL-positive S. aureus strains have been reported in 
the United Kingdom, the Netherlands, France and Sweden (Holmes et al., 2005). 
 
Outbreaks of PVL-associated skin infections have been reported in schoolchildren in 
Switzerland, among homosexual men in the Netherlands, and among hospital staff in 
Scotland (Holmes et al., 2005). Likewise, outbreaks of severe skin infections have 
also occurred in the United States among homosexual men, prison inmates and 
schoolchildren (Holmes et al., 2005).  
 
PVL, as well as γ-hemolysin, are derived from the synergohymenotropic toxin family. 
These toxins act on the cell membranes by the synergy of two classes of secretory 
proteins namely, S (slow-eluted) and F (fast-eluted). These proteins are further 
separated by column chromatography into the following: 
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  HIgA, HIgC, LukS-PV (belonging to class S) 
 HIgB and LukF-PV (belonging to class F) 
 
It is important to note that all PVL positive isolates produce both the S and F class 
proteins. Pathirage (2008) mentioned that PVL (LukS-PV and LukF-PV) is detected 
in less than 5% of S. aureus isolates, while the three proteins forming γ-hemolysin 
(HIgA, HIgC and HIgB) is detected in more than 99% of S. aureus isolates (Johnsson 
et al., 2004; Lina et al., 1999). Therefore, these strains have the ability to produce 
three class S and two class F proteins, which leads to six biologically active pairs in 
the S and F classes, respectively (Table 1.2) (Johnsson et al., 2004; Lina et al., 1999). 
 
 
Table 1.2: A table to illustrate the secretory protein subclasses: S (slow-eluted) and F 
(fast-eluted) 
Class (S) Class (F) 
HIgA HIgB 
HIgC LukF - PV 
LukS – PV  
6 (S + F) Biologically Active Pairs 
1.    HIgA + HIgB 
2.    HIgC + HIgB 
3.    LukS - PV + HIgB 
4.    HIgA + LukF – PV 
5.    HIgC + LukF – PV 
6.    LukS - PV + LukF – PV 
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A study was done on the purification of PVL components (LukS-PV and LukF-PV); 
from a V8 strain (ATCC 49775) (Fink-Barbancon et al., 1991; Johnsson et al., 2004). 
The size was determined to be 32 and 38 kDa, respectively. The genes are 939 and 
978 nucleotides in size while separated by a single thymine nucleotide and transcribed 
as a single mRNA molecule. This gene was found on the genomes of different S. 
aureus strains in its various prophages (Fink-Barbancon et al., 1991; Johnsson et al., 
2004). 
 
Furthermore, PVL does not produce haemolytic activity on human erythrocytes unlike 
γ-hemolysin, but is leucotoxic for human and rabbit polymorphonuclear cells and 
macrophages. PVL causes severe inflammatory lesions after intradermal injection in a 
rabbit’s skin, which may lead to capillary dilation, skin necrosis, chemotaxis and 
polymorphonuclear karyorrhexis (rupture of cell nucleus) (Holmes et al., 2005). On 
the other hand, γ-hemolysin in the rabbit’s skin model also causes inflammatory but 
no skin necrosis (Johnsson et al., 2004; Lina et al., 1999). 
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 1.2.4.1 a) Verification that PVL is a virulence factor  
 
Up to now, there have been a limited number of studies on the pathogenesis of PVL. 
Research has shown the role of PVL in dermonecrosis in rabbits; however the role it 
might play in necrotizing pneumonia, severe sepsis and necrotizing fasciitis is 
unidentified (Boyle-Vavra & Daum, 2007). A study conducted by Labandeira-Rey et 
al., (2007), showed PVL to be a virulence factor in an acute pneumonia mouse model. 
Their study used sets of isogenic strains for PVL, demonstating that PVL is a 
virulence factor (Dumitrescu et al., 2007).  
 
LukS-PV binds to an unidentified receptor on polymorphonuclear leukocytes (PMN) 
membranes, while connecting to its dimer LukF-PV (Figure 1.3). Consequently, both 
components, LukF-PV and LukS-PV eventually form a pore-forming heptamer by 
means of consistent alternate serial binding (Figure 1.3). It is important to note that 
PVL is not haemolytic (do not cause destruction to blood cells), unlike other S. aureus 
pore-forming leukocidins (Boyle-Vavra & Daum, 2007; Kaneko & Kamio, 2004). 
Furthermore, a host protein kinase (A or C) phosphorylates LukS-PV when binding to 
PMNs. This follows the induction of Ca++ ion channels (Kaneko & Kamio, 2004) 
suggesting that the events leading to signal transduction may trigger the production of 
interleukins and inflammatory mediators (Boyle-Vavra & Daum, 2007). 
Subsequently, high concentrations of PVL can cause lysis of PMN, yet low 
concentrations of PVL results in apoptosis of PMN via a novel pathway. This 
pathway involves the attachment of PVL-mediated pore formation onto the 
mitochondrial membrane, releasing cytochrome c and induction of caspases 9 and 3 
(Figure 1.4) (Boyle-Vavra & Daum, 2007).  
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(Boyle-Vavra & Daum, 2007)  
Figure 1.3: A model demonstrating how PVL might mediate tissue necrosis  
 
 
 
(Boyle-Vavra & Daum, 2007) 
Figure 1.4: Apoptosis of polymorphonuclear leukocytes (PMN) membranes via a novel pathway  
 20
 Studies have shown that neutropenia associated with PVL-positive S. aureus 
vity of PVL (Adem et al., 
005; Boyle-Vavra & Daum, 2007; Gillet et al., 2002). According to Boyle-Vavra & 
.2.4.1 b) The emergence of PVL producing CA-MRSA 
 
the origin of CA-MRSA (Figure 1.5). The 
rain. The 
ecA gene encoded by a methicillin resistant cassette (SCCmec IV, V or VT) is 
necrotizing pneumonia, is related to the PMN cytolytic acti
2
Daum (2007), the first step in pathogenesis, mediated by the evasion of the first line 
of host defence, may be defined by PVL-mediated PMN lysis and apoptosis. 
However, the pathway leading to tissue necrosis and severe sepsis is not very clear. A 
few possibilities are outlined in figure 1.3. It was observed that purified PVL does not 
have a direct necrotic effect on epithelial cells (Boyle-Vavra & Daum, 2007; de 
Bentzmann et al., 2004). Tissue necrosis and sepsis could occur from the release of 
granule contents from lysed PMNs (Boyle-Vavra & Daum, 2007). PVL-mediated 
lysis results in reactive oxygen species (ROS) being released and a variety of 
inflammatory mediators from granulocytes (Boyle-Vavra & Daum, 2007; Kaneko & 
Kamio, 2004). 
 
1
Boyle-Vavra & Daum (2007) explains 
model illustrates how a PVL phage, namely phiSLT, infects a MSSA st
m
horizontally transferred into the MSSA strain containing the pvl gene. The gene 
cassette incorporates itself into the genome in a location that is separate from that of 
the phiSLT integration site. This results in the integration of a methicillin resistant 
cassette into genomes of various MSSA ancestoral clones circulating in different 
geographic regions. HA-MRSA emerged from MSSA in the 1960s. Hence, it is 
possible that CA-MRSA also emerged from MSSA strains with the addition of pvl 
(Boyle-Vavra & Daum, 2007).  
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d from (B  
 1.5:
Reproduce oyle-Vavra & Daum, 2007)
Figure  A model illustrating the origins of community-acquired MRSA  
 
 
Glo l
one sm sisting of pvl 
oyle-Vavra & Daum, 2007). More frequently now, studies are reported on MRSA 
aPI-1, SaPI-2, SaPI-3 (S. aureus Pathogenicity Island) and so forth. These 
isla s
species ore, staphylococcal cassette chromosome with methicillin-resistance 
(SC arried on 
the m
cassette c type I-V) that vary in size and genetic structure (Boyle-Vavra & 
Daum, 2007; Enright et al., 2002; Foster, 2004; Ito et al., 1999).  
 
ba  selective pressure is emerging worldwide as diverse genetic backgrounds carry 
all methicillin resistance cassette as well as a phiSLT phage con
(B
strains carrying pvl together with community-acquired genotypes (SCCmec IV, ST8) 
in hospital acquired infections (File, 2008; Maree et al., 2006). Consequently, these 
pvl positive CA-MRSA colonizing isolates could have found a portal of entry during 
invasive procedures conducted in the hospital setting. In many hospitals, CA-MRSA 
strains may now be endemic (Boyle-Vavra & Daum, 2007). 
 
1.2.5 Staphylococcal Cassette Chromosome mec (SCCmec) 
 
Numerous pathogenicity islands have been identified in the genome of S. aureus, 
namely S
nd  are chromosomal regions which are acquired by horizontal transfer from other 
. Furtherm
Cmec) is also classified as a pathogenicity island. The mecA gene is c
se obile genetic elements, called the SCCmec cassettes. These consist of five 
s (SCCme
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 (Ito et al., 1999) described the structures and origins of SCCmec type I to IV as 
follows: 
 SCCmec type I: (34kb) Identified in 1961 in the United Kingdom in an MRSA 
strain (strain NCTC10442). 
 SCCmec type II: (52kb) Identified in 1982 in Japan in an MRSA strain (strain 
N315). 
 SCCmec type III: (66kb) Identified in 1985 in New Zealand in an MRSA 
strain (strain 82/2082) 
 SCCmec type IV: (20 – 24kb) Independently identified among representatives 
he ccr 
ene complex is mainly responsible for the mobility of these SCCmec elements. This 
of the Pediatric clone in two community-acquired MRSA strains 
 
SCCmec type V is 28kb in size (Deurenberg et al., 2007). The SCCmec are composed 
of two crucial genetic components (the mec and ccr gene complexes), and the 
junkyard (J) region DNA segments. The mec gene complex consists of IS431mec, 
mecA and regulatory genes, mecR1 and mecI. Furthermore, this complex contains 
various classes, discussed in more detail in section 1.2.6 (The mecA gene). T
g
complex consists of four allotypes namely types 1, 2, 3 and 5 (Zhang et al., 2005). 
The remaining part of these elements is comprised of the J regions (regions J1, J2 and 
J3) which are allocated between and surrounding the mec and ccr complexes as 
follows: 
 J1 region is situated between the chromosomal left junction and the ccr 
complex. 
 J2 region is situated between the ccr complex and the mec complex. 
 J3 region is situated between the mec complex and the chromosomal right 
junction. 
 
The structural organisation of SCCmec can therefore be demonstrated as J1-ccr-J2-
mec-J3. SCCmec types are distinguished by the various combinations of classes in the 
mec gene complex and allotypes in the ccr complex (Zhang et al., 2005). 
Furthermore, the SCCmec elements are classified into subtypes according to the 
differences in their J region DNA within the same mec-ccr combination. These 
regions contain non-essential components of the cassette, but in some instances they 
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 are capable of carrying further antibiotic resistance determinants (Milheirico et al., 
2007; Oliveira et al., 2002; Zhang et al., 2005). 
 associated with smaller SCCmec variants, either type IV (24 
b), or type V (or variant, VT). In contrast, HA-MRSA are usually associated with 
SA clones circulating within distinct geographic regions by using typing 
chniques, mainly pulsed-field gel electrophoresis and multi-locus sequence typing. 
For instance, the most predominant CA-MRSA strain in the United States now is 
ST8/pulsotype USA 300. Before, most CA-MRSA isolates carried SCCmec IV in the 
genetic backgrounds ST1/pulsotype USA 400. The most widespread multi-resistant 
HA-MRSA clone in the United States is ST5 which is a carrier of SCCmec II (Boyle-
Vavra & Daum, 2007). 
 
1.2.6 The mecA gene 
 
In Staphylococcus species, the mec gene complex consists of four genetic classes. In 
all of these classes, IS431 is present downstream of mecA. IS431 is one of the 
 
CA-MRSA is generally
k
large SCCmec types I, II or III (34-67 kb) (Boyle-Vavra & Daum, 2007; Deurenberg 
et al., 2007). However, studies have shown SCCmec types I, II and III linked to CA-
MRSA strains. Another study also reported a SCCmec type IV associated with HA-
MRSA strains. This clearly shows that SCCmec types do not completely distinguish 
between community and hospital acquired MRSAs (Deurenberg et al., 2007).  
 
Notably, an integrated bacteriophage (phiSLT), carrying the pvl genes in CA-MRSA, 
is important in distinguishing CA-MRSA from HA-MRSA. The pvl gene widely 
associates itself with SCCmec IV and occasionally with SCCmec V or VT. These 
associations are still unclear. Some authors have reported an association between CA-
MRSA, SCCmec type IV and PVL production, but others disagreed. However, less 
than 5% of MRSA strains with SCCmec types I-III carry pvl, but 40-90% of MRSA 
strains with SCCmec type IV also carry pvl (Deurenberg et al., 2007). Further 
investigation is thus needed in order to determine the association between pvl and 
SCCmec types in CA-MRSA. 
 
Studies have shown differences between the genetic backgrounds of CA-MRSA and 
HA-MR
te
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 insertion sequences (IS) for staphylococci (Archer et al., 1996). Insertion sequences 
are short DNA sequences, carrying no genetic information hence acting as 
transposable elements. Only class A and class B mec gene complexes have been 
found in S. aureus. The structure of class A mec gene complex is as follows: mecI-
mecR1-mecA- IS431mec. In class B, another insertion sequence, IS1272 is found. The 
structure in this class is shown as IS1272-∆mecR1-mecA-IS431. A study done by 
Archer et al (1996) showed that IS1272 is more prevalent in S. haemolyticus, 
suggesting that SCCmec type I was transferred from S. haemolyticus to S. aureus in 
the past. Class C complexes are mainly found in S. haemolyticus, whereas S. hominis 
were only identified in the class D complex. Both class C1 and C2 has a deletion in 
the left side of class A mec complex followed by an insertion of IS431. It should be 
noted that IS431 is inserted in the same direction as mecA in class C1, whereas IS431 
 to mecA in class C2. Class D demonstrates no 
tion is 
rrows in figure 1.6 (Hiramatsu et al., 2001; Katayama et al., 
001). 
is inserted in the opposite direction
insertion sequence adjacent to its deletion point.  The direction of transcrip
indicated by means of a
2
 
 
Reproduced from (Hiramatsu et al., 2001) 
Figure 1.6: Illustration of the mec gene complex with its four classes in 
Staphylococci  
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 MRSA emerged due to the alteration of the penicillin binding protein 2 (PBP2) to 
PBP 2a, mediated by the mecA gene. This target change caused resistance to 
penicillinase-resistant penicillins (PRPs) and conferred resistance to all beta-lactam 
antibiotics (Oosthuizen et al., 2005). PBP2a is also a transpeptidase that catalyzes 
crossbridge formation in the bacterial peptidoglycan cell wall (Hiramatsu et al., 
2001).  
 
The mecA gene complex contains a two-gene operon mecR1-mecI that is transcribed 
in different directions containing overlapping promoter-operator regions with mecA. 
When mecA transcription is repressed by mecI, induction by means of MecR1 can 
ccur as follows: MecR1 detects B-lactam antibiotics with its extracellular penicillin-
 has been discovered that mecA gene transcription is fully repressed by mecI and 
eptible to methicillin (AL-Haj et al., 2009; 
Katayama et al., 2001). These strains are known as pre- methicillin resistant S. aureus 
o
binding domain, thereby activating its cytoplasmic domain as a protease by 
autocatalytic cleavage. It then cleaves the MecI repressor protein by direct or indirect 
action. The binding of MecI repressor protein to the operator region of the mecA gene 
causes the release in repression of mecA gene transcription (Hiramatsu et al., 2001). 
 
β-lactamases are enzymes produced by certain bacteria, in this case staphylococci that 
become resistant to penicillin. The gene blaZ is encoded by β-lactamase. The 
production of β-lactamase is also controlled by a two-gene operon, blaR1-blaI that is 
transcribed in different directions from each other. Hence, these gene products also 
have amino acid homology to mecR1 and mecI. Experimental studies have proven that 
purified Mec1 and BlaI binds to bla promoter-operator sequences in DNase assays. 
Due to the resemblances between blaZ and mecA regulons, both BlaI and MecI 
repressor proteins are responsible for the regulation of mecA transcription. 
Furthermore, BlaR1 and MecR1 are the two signal transduction proteins responsible 
for regulating repressor activity (McKinney et al., 2001).  
 
It
mecR1 if clinical strains remain susc
(pre-MRSA) and pre-methicillin resistant coagulase negative staphylococci (pre-
MRCNS) (AL-Haj et al., 2009). These pre-MRSA strains were first isolated in Japan 
during the early 1980s, having a marginal level of resistance to methicillin (MIC < 8 
mg/liter) (Hiramatsu et al., 2001; Katayama et al., 2001). Therefore in MRSA strains, 
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 mutations occur in the mecI genes or the mecA operator regions (to where the MecI 
repressor protein should bind). As a result, the MecI repressor protein inhibits the 
ctivity of the mecA operator gene. This finding corresponds to a study done by 
n of the mecA operating gene, known as derepression. This leads to the 
ccurrence of mecA transcription in MRSA strains.  
udy conducted by Fournier & 
spa gene is regulated by DNA supercoiling in response 
ility to interact directly with the Fc 
st mammalian species (Adesida et al., 2006; 
a
Hiramatsu (1995) who found mutations in either the mecI genes or mecA operator 
regions in majority of their clinical MRSA strains (Hiramatsu, 1995). These strains 
were carrying SCCmec type II or III, in the class A mec complex. To conclude, in 
MRSA strains a loss or inactivation of the MecI repressor protein leads to the 
activatio
o
 
1.2.7 Staphylococcal Protein A (Spa) 
Protein A, historically known as Jensen’s antigen A, is one of the MSCRAMM 
surface proteins covalently anchored to the cell wall of S. aureus (Figure 1.2) (Dossett 
et al., 1969). This protein consists of approximately 2,150 base pairs with a molecular 
weight of 42,000 kilo Dalton (42kDa) (Frenay et al., 1994). Furthermore, 
staphylococcal protein A (Spa) is produced by more than 95% of S. aureus strains 
(Adesida et al., 2006; Wann et al., 1999). 
 
There are four different two-component systems in S. aureus that are responsible for 
virulence control. They are Agr, Sae, Srr and Arl. A st
Klier (2004) showed how the 
to environmental conditions like high osmolarity, and the ArlS-ArlR two-component 
system. 
 
Staphylococcal protein A is well known for its ab
region of immunoglobulins of mo
Callegan et al., 1994; Dossett et al., 1969; El-Sayed et al., 2006; Forsgren, 1970). Spa 
interacts with several host components, not only with immunoglobulins (mainly G, A 
and E), but also with platelets and von Willebrand factor (vWF) (Fournier & Klier, 
2004). The latter is a large multifunctional glycoprotein that mediates platelet 
adhesion at sites of endothelial damage. Hartlieb et al (2000) found an interaction 
between protein A in S. aureus and vWF which suggests a potential role of 
endovascular S. aureus pathogenesis. Consequently, all these factors support the role 
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 of protein A as an important virulence factor in S. aureus infections (El-Sayed et al., 
2006; Fournier & Klier, 2004; Genovese et al., 2000; Graille et al., 2000; Hartlieb et 
al., 2000; Marone et al., 1987; Palmqvist et al., 2002) . 
 
Immunoglobulin G (IgG) contain two binding sites to which protein A attaches itself 
to. They are the Fcγ constant region which is involved in effector functions and the 
Fab region responsible for antigen recognition in a non-antigen specific manner (El-
Sayed et al., 2006; Graille et al., 2000).  
 
The spa gene is composed of a N-terminal region and a C-terminal region (Frenay et 
al., 1994; Guss et al., 1985; Löfdahl et al., 1982). The N- terminal region encodes five 
homologous immunoglobulin binding units. These repeat regions are designated E, D, 
A, B and C, each unit having the ability to bind one human IgG molecule when 
isolation occurs separately (Figure 1.7) (El-Sayed et al., 2006; Guss et al., 1985; 
Palmqvist et al., 2002). The C- terminal part, also called region X, encodes the 
OOH-terminal that binds protein A to peptidoglycan of the cell wall with no IgG-
binding capacity (Figure 1.7) (Guss et al., 1985; Löfdahl et al., 1982). Region X or 
short sequence repeat (SSR) region contains a polymorphic repetitious Xr part. Xr is 
composed of a variable number of 21-24 bp repeats in length (Hallin et al., 2007; 
Kuzma et al., 2005; Moodley et al., 2006). The Xc region is located upstream to the X 
region and encodes a non-repetitive sequence for 81 amino acids (El-Sayed et al., 
2006; Shopsin et al., 1999). The sequence variation in the X region can arise from 
both duplications and deletions of repetitive units or by point mutations within the 
repeat sequence (Figure 1.7) (Mitani et al., 2002; Shopsin et al., 1999). 
 
It has also been noted that with increased amounts of protein A, S. aureus strains tend 
to resist phagocytosis (by polymorphonuclear leukocytes), causing a decrease in free 
receptor sites needed for complement C3b. On the other hand, S. aureus strains 
containing decreased or no protein A are phagocytosed. Therefore, protein A encoded 
by the spa gene, prevents the occurrence of opsonization and phagocytosis (Dossett et 
al., 1969; Kuzma et al., 2005). 
 
C
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The abbreviations signify the following: [S] signal sequ
homologous to A-D; [X] COOH terminus; [Xr] SSR re
(Shopsin et al., 1999) 
Figure 1.7: A diagram of the spa gene with ea
rse primers.  together with forward and reve
 
1.3 Genotyping of S. aureus 
 
Typing of S. aureus clinical isolates is impo
relatedness, as well as the epidemiology of ou
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 1.3.1 Pulsed-Field Gel Electrophoresis (PFGE) 
 
PFGE is currently the gold standard for typing Gram positive and Gram negative 
bacteria. This method has a high discriminatory power and is commonly used for 
studying nosocomial outbreaks (Cookson et al., 2007). This method was used 
ow the fragments to 
et al (1995) proposed a scheme for the 
 et al., 2006; Tenover et al., 1997; van 
successfully to identify the relatedness of isolates from MRSA outbreaks during the 
1980s and 1990s (Enright et al., 2002; Kim, 2009).  
 
PFGE typing of S. aureus isolates involves the digestion of purified chromosomal 
DNA with the restriction enzyme SmaI, followed by the electrophoresis of large DNA 
fragments in agarose gel. Instead of electric fields being applied in one direction on a 
standard gel electrophoresis, the orientation of electric field is alternated in opposite 
directions for defined time periods. The DNA fragments migrate through the gel by 
means of an electric field current that provides pulses that alternate from three sets of 
electrodes (Tenover et al., 1997). This allows the separation of DNA fragments 
according to size (Deurenberg et al., 2007; Palvecino, 2007). For S. aureus the SmaI 
restriction enzyme is used for macro-restriction of DNA to all
move across the gel (Kim, 2009). Tenover 
analysis of PFGE patterns using the Dice coefficient and unweighted pair-group 
matching analysis (UPGMA) settings (Deurenberg et al., 2007). 
 
The foremost disadvantage of PFGE and other methods that comparatively analyses 
DNA fragments on gels, is the difficulty in comparing the results obtained in different 
laboratories due to differences in PFGE protocols and nomenclature. At a national 
level, databases have been established to adhere to standardized protocols. However, 
international efforts have been unsuccessful in producing common nomenclature and 
databases (Deurenberg et al., 2007; Strommenger et al., 2008a). Another disadvantage 
of PFGE is that the equipment required is relatively expensive and the method is 
labour intensive. Results are obtained within two to four days depending on which 
organisms need to be tested (Moodley
Belkumm et al., 2007). Nonetheless, once this method has been established in a 
laboratory, it can be used to differentiate between strains of a variety of bacterial 
species with minimal changes necessary. 
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 Chang et al (2003) used PFGE to differentiate between S. aureus isolates in recurrent 
episodes of bacteraemia in a multicentre prospective study. In this study, recurrence 
could then further be subdivided into re-infection (different PFGE patterns) or relapse 
(the same PFGE patterns). The results showed that relapse occurred earlier than re-
infection (median, 36 and 99 days respectively, p<0.06). Another study published in 
1995 reported that at that time PFGE was the most widely used molecular typing 
method for studying the local and global epidemiology of MRSA (Bannerman et al., 
1995). More recently, Cooksen et al (2007) showed that PFGE (using common 
protocols) and spa typing data from different laboratories can be compared to 
ore expensive 
drogenase (aroE), glycerol kinase (glpF), 
uanylate kinase (gmk), phosphate acetyltransferase (pta), triosephosphate isomerase 
reference patterns or sequences which correlated well with the m
MLST/SCC mec typing method. 
1.3.2 Multi-Locus Sequence Typing (MLST) 
MLST, which was developed by Maiden et al (1998), characterizes isolates for each 
species by relying on sequences of internal fragments of housekeeping genes (Maiden 
et al., 1998). Housekeeping genes are present with variations in each species, 
resulting in various alleles of each locus. For S. aureus, seven housekeeping genes of 
about 450 base pair (bp) each are generated by PCR and sequenced in both directions 
(Fischetti et al., 2006; Trindade et al., 2003). These genes include the following: 
carbamate kinase (arcC), shikimate dehy
g
(tpi), and acetyl coenzyme A acetyltransferase (yqiL) (Deurenberg et al., 2007; 
Fischetti et al., 2006; Ward et al., 1981).  
 
Gene sequences that are identical are allocated the same allele number. The 
combination of alleles at each locus, for each strain, defines its sequence type (ST) 
(Enright et al., 2002). Furthermore, this typing technique has been developed and 
validated for S. aureus strains, providing good discriminatory power for investigating 
the clonal evolution of MRSA. The MLST online database,  http://www.mlst.net, is 
easily accessible via the internet to compare DNA sequences to previously identified 
alleles at each locus (Kim, 2009). Also, clonal complexes (CCs) can be used to 
analyse evolutionary events through this database (Enright et al., 2002). The CCs are 
based upon related sequence types (BURST). If five of the seven housekeeping genes 
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 of S. aureus strains have exactly the same sequences, they are grouped together within 
a single CC by BURST analysis (Deurenberg et al., 2007). Enright et al (2000) have 
successfully used BURST in studying the evolutionary history of MRSA (Enright et 
l., 2000). The MLST database is easily accessible for local and international 
Harmsen et al., 2003; 
alvecino, 2007). Moreover, MLST is more useful in studying long-term genetic 
PFGE which is used to study genetic changes and hospital 
outbreaks during short periods of time (Arakere et al., 2005). 
a
surveillance purposes as clinical information and geographic locations can be stored 
for each isolate (Kim, 2009). 
 
Enright et al (2000) validated the procedure of MLST using PFGE as a reference 
method. Two major clones that are circulating in British hospitals were found in this 
study namely, clone EMRSA-16 (ST36) and clone EMRSA-15 (ST22). When tested 
with MLST and confirmed by PFGE, a close similarity was found in three STs (12, 
15, 22) containing both MRSA and MSSA strains. Enright and colleagues (2002) 
considered a close relationship between the genotypes of MRSA and MSSA strains 
with the same allelic profiles. Furthermore, this suggested that MRSA strains were 
descendents of MSSA strains that acquired methicillin resistance through horizontal 
transfer of the mecA gene. Even though MLST is a highly discriminatory method of 
characterizing bacterial isolates, it can also be a quite laborious and time-consuming 
method (Deurenberg et al., 2007; Enright et al., 2002; Hallin et al., 2007). MLST 
requires the performance of seven PCRs and 14 DNA sequencing reactions per 
isolate, resulting in very high costs (Cookson et al., 2007; Kim, 2009). This makes 
MLST difficult to conduct in a routine laboratory, unless the necessary equipment and 
facilities are readily available for PCR and sequencing (
P
changes in contrast to 
 
1.3.3 SCCmec Typing 
The importance of SCCmec typing is being recognized as an increasing amount of 
community acquired clonal outbreaks is occurring around the world (Zhang et al., 
2005). In the past, traditional PCR methods were used to type SCCmec genes. These 
methods were problematic due to the need of many primer sets and multiple 
individual PCR testing (Zhang et al., 2005). As a consequence, multiplex PCR 
methods were developed that are more rapid and useful in both the clinical and 
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 research laboratory settings. This method simultaneously amplifies two or more loci 
in the same reaction. A disadvantage of this method is that it requires an increasing 
amount of primers as new alleles are being discovered rapidly (Cookson et al., 2007).  
Oliveira et al (2002) developed a multiplex PCR method for SCCmec typing. This 
method includes the detection of mecA and six different loci on SCCmec (Deurenberg 
et al., 2007). Milheirico et al (2007) reported an updated version to improve 
characterization of SCCmec type IV. In addition, this method detects the recently 
discovered SCCmec type V. Amplification by PCR of the mec and ccr complexes has 
been developed by Ito et al (2001) and Okuma et al (2002). Nonetheless, 
characterization of SCCmec type of the same MRSA strain gave diverse results with 
this method (Deurenberg et al., 2007; Okuma et al., 2002). Furthermore, a real-time 
PCR developed by Francois et al (2004) also characterized SCCmec types I-IV on the 
assification be used based on the 
MLST, resistance phenotype and SCCmec type. This proposal has been accepted by 
Union of Microbiological Societies subcommittee on S. aureus 
typing. This nomenclature may however change, as other genotypic methods such as 
pa typing are becoming more popular (Kim, 2009). 
et al (1996) by sequencing the polymorphic X region of the S. aureus protein 
basis of the mec and ccr gene complexes (Francois et al., 2004). Zhang et al (2005) 
developed a multiplex PCR assay that competently detects and classifies all the 
currently described SCCmec types (I-V), as well as their major subtypes.  
A novel classification scheme has been proposed by Chongtrakool et al (2006) for the 
nomenclature of SCCmec. A number is assigned to the ccr genes, whereas an upper-
case letter is assigned to the mec complex for example, SCCmec type 1A (type I) 
(Chongtrakool et al., 2006; Deurenberg et al., 2007). Initially, in 2002, it has been 
proposed that a standard nomenclature for MRSA cl
the International 
s
1.3.4 spa Typing 
 
For S. aureus, a single-locus sequence typing (SLST) method was developed by 
Frenay 
A (spa) gene. As mentioned in section 1.2.7 (Chapter 1), this region contains a 
variable number of 21-24 bp repeats mainly due to deletions, duplications or point 
mutations within the repeat sequence (Deurenberg et al., 2007).  
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Spa typing and MLST are the most frequently used sequence-based typing methods 
for S. aureus (Faria et al., 2008). However, spa typing involves the sequencing of 
only a single locus, making it much simpler and more affordable than MLST 
(Karynski et al., 2008). Spa typing has discriminatory power that lies between that of 
PFGE and MLST. A recent study conducted by Faria et al (2008) showed that spa 
typing had a great predicative power of the clonal relationships defined by eBURST 
(software analysis of MLST method). PFGE was less precise for that purpose. Spa 
typing provides improved typeability and discriminatory power, compared to MLST. 
According to their results, PFGE together with spa-typing provided much better 
results especially for MRSA strains, whereas spa typing alone would be sufficient for 
MSSA strains. However, irrespective of methicillin resistance, the most affordable 
combination of methods would be PFGE and spa typing without needing to perform 
LST. Faria and colleagues (2008) concluded that the use of these two methods for 
er genotyping methods (Palvecino, 2007). Hence, spa typing can be used to 
vestigate the epidemiology of hospital or community outbreaks and the molecular 
M
local and long-term epidemiological surveillance studies provides the necessary 
discriminatory power and typeability. Similarly, a study conducted by Robinson & 
Enright (2003) showed the diversity of spa typing to be greater than MLST. 
 
Other studies found spa typing to be more rapid and easier to perform and interpret 
than oth
in
evolution of MRSA and MSSA strains (Deurenberg et al., 2007). Spa typing may also 
be useful for long-term epidemiological and population-based studies (Kahl et al., 
2005). 
 
Ridom StaphType software (Ridom GmbH, Würzburg, Germany) has generally been 
used for the analysis of spa sequences in Europe. This software package determines 
various spa-types and spa-repeats, as well as implementing Based upon repeat pattern 
(BURP) clonal cluster analysis of spa types. The software also allows data 
management and retrieval, as well as Internet-based assignment of new spa types with 
automatic quality control of DNA sequence chromatograms (Harmsen et al., 2003). 
Strains that are typed are easily synchronized via the Internet with a central spa server 
(http://www.spaserver.ridom.de) so that nomenclature and access to the spa typing 
data can be viewed universally. New spa types and repeats can be submitted online to 
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 be included into the reference database. The server is curated by the European 
SeqNet.org initiative which currently includes 57 laboratories and 29 European 
countries (http://www.seqnet.org). At present the spa server database consists of 5501 
spa-types, consisting of 311 spa-repeats from a total number of 92 900 isolates that 
were typed in 66 countries. A rapid increase in numbers can be immediately noticed 
as only 1200 spa-types, 100 spa-repeats from a total number of 13 000 isolates typed 
in 36 countries was reported in the year 2007 (Deurenberg et al., 2007). Hence, for S. 
aureus this software package is one of the most leading sequence-based typing 
atabases accessible all over the world (Deurenberg et al., 2007). The database can 
URST analysis or SmaI macrorestriction and cluster analysis (Hallin et al., 
007; Ruppitsch et al., 2006; Strommenger et al., 2006). Furthermore, a study done 
 Spa 
ping might also replace MLST as the typing method of choice, since the sequencing 
of one gene is much more affordable and quicker to perform than sequencing seven 
URP analysis 
r MRSA and MSSA types is user friendly, easy to interpret and performs well. 
 
d
also be used to continuously collect spa typing data for infection control purposes. If 
preferred, an automatic warning can be assigned into the database in order to detect 
MRSA outbreaks in hospitals or regions with heterogeneous spa types.  
 
Several spa types can be detected within one sequence type (ST), as determined by 
MLST due to the high discriminatory power of spa typing. In addition, these spa 
types are still assigned to a clonal cluster. The accomplishment of BURP analysis 
makes clonal cluster groups of spa types easier to determine. It is suggested that 
future studies should interpret BURP analysis together with clonal complexes (CCs) 
that are established by MLST (Deurenberg et al., 2007). Strommenger and colleagues 
(2008) as well as other studies demonstrated that spa type groups obtained by BURP 
analysis were in agreement with the classifications obtained by other methods such as 
MLST-B
2
by Mellmann and colleagues (2008) reported BURP clustering to be 96.5% in 
concordance with MLST and a 94.9% in concordance with PFGE (Mellmann et al., 
2008).  
 
In general, single locus spa typing seems to be gaining more popularity as a useful 
and reliable method, in contrast to typing seven housekeeping genes in MLST.
ty
genes for each strain. The RidomStaph software package, including B
fo
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 1.3.5 Multiplex PCR of the mecA, pvl and spa genes 
 
Multiplex PCR is a technique that amplifies more than two loci in a single PCR 
reaction. A recent study conducted by Larsen et al (2008), validated a method to 
detect the presence of the mecA, pvl and spa genes in a single multiplex PCR. In 
addition, this multiplex PCR method allows the sequencing of one PCR gene (spa 
gene) for spa typing directly from the mixture of PCR amplicons (mecA; pvl and spa 
genes). After successful validation, this method was introduced routinely at the 
Statens Serum Institute (SSI), Copenhagen, Denmark during January 2007. 
Implementation of this method at SSI minimises the use of reagents and the amount of 
PCRs required. The method also provides reduced risk of sample mishandling and 
offers rapid typing results. Thus, the multiplex PCR method described in this study 
proves to be less expensive and less laborious than the single reaction methods for the 
for MRSA surveillance (Larsen et al., 
008).  
detection of these three important genes used 
2
1.4 Genotyping of S. aureus in South Africa 
 
In 2007, the first report documenting a variety of MRSA epidemic clones throughout 
South Africa was presented (Oosthuysen et al., 2007). MRSA isolates were collected 
from private and state laboratories from 9 provinces in South Africa. Phenotypic 
methods were used to identify and determine resistance profiles. Genotypic methods 
included SCCmec typing using multiplex PCR, spa typing and PCR for the detection 
of PVL toxin. Of the 302 MRSA isolates tested for SCCmec typing, the most 
predominant types included type IV (36.7%), type II (25.2%) and type III (23.2%), 
including its variant type IIIA. SCCmec type I and IA amounted to 13.2%, whereas 
1.7% of these isolates were non-typeable. For spa typing, 27 different spa types were 
found and grouped into five spa clonal complexes (spa-CC) via BURP analysis. 
Interestingly, only 2/314 MRSA strains (0.6%) were detected as PVL-positive in this 
study. This is in contrast to studies from Tristan et al (2009) and Aires-de-Sousa et al 
(2006), reporting an association between CA-MRSA and PVL. However, the study 
did not include clinical information with regards to hospital and community acquired 
 36
 infections. It was concluded that the population structure of MRSA consists of 
different epidemic clones. 
In 2008, ninety-one MRSA strains from hospitals within Cape Town (Western Cape 
Province, South Africa) were collected to determine the SCCmec contents (Jansen van 
Rensburg et al., 2009). It was found that SCCmec types IV (46.1% of strains) and I 
(40.7% of strains) were the mos  prevalent. MLST was used to analyse four strains 
representing each of SCCmec types I-IV. Sequence types 
t
(STs) of SCCmec types I, II 
and III strains were STs 5, 36 and 239, which are frequently identified worldwide. 
States and Asia, and Southern European countries (Zinn et al., 2004). A dominating 
E-test, as 
well as the detection of the mupA gene. This study was able to successfully 
 
mannitol-negative MRSAs were misidentified as S. lugdunensis by the API STAPH 
However, the ST of SCCmec type IV strain, ST 612 is not found frequently 
elsewhere. This suggests the emergence of a local clone.  
Zinn et al (2004) obtained S. aureus strains from twenty one hospital laboratories 
globally. They found high levels of MRSA (28-63%) in South Africa, the United 
MRSA clone as well as several other clones was distinguished as international 
epidemic MRSA (E-MRSA) by typing with PFGE. 
In 2006, a study was conducted in the KwaZulu-Natal (KZN) province, South Africa 
in order to investigate the antimicrobial resistance of S. aureus (Shittu & Lin, 2006). 
Detection of the mecA and nuc genes by PCR confirmed the identification as MRSA 
of strains resistant to oxacillin, methicillin and cefoxitin by the disk diffusion method. 
In addition, resistance to mupirocin was confirmed by the MIC value with 
differentiate between MSSA and MRSA strains with PCR-RFLP (polymerase chain 
reaction- restriction fragment length polymorphism) of the coagulase gene.  
Shittu et al (2007) published the first report on the molecular identification and 
characterization of 5/227 (2.2%) mannitol-negative MRSA isolates from clinical 
samples in KZN, South Africa. Phenotypic tests such as MSA (mannitol fementation), 
coagulase (tube method) and DNase tests, as well as PCR detection of the nuc, mecA 
and coagulase gene signified mannitol-negative isolates as S. aureus. However, 2
(Biomerieux, France) test. These MRSA isolates were confirmed as being positive 
with detection of the mecA gene. All of these isolates carried SCCmec type IV. 
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 In 2009, a study was done on the phenotypic and molecular characterization of S. 
aureus isolates with low-level (in KZN, South Africa) and high-level mupirocin 
resistance (in Nigeria and South Africa) (Shittu et al., 2009). Mupirocin is a topical 
antimicrobial agent used to treat skin and postoperative wound infections, including 
the prevention of nasal carriage of MRSA. Antibiogram, PCR-RFLP of the coagulase 
gene and PFGE was performed on 17 mupirocin-resistant (high-level) S. aureus 
isolates obtained from clinical samples from Nigeria and South Africa. PCR detection 
of the mupA gene confirmed high-level mupirocin resistant in these isolates. The 
transfer of the mupirocin plasmid by curing and conjugation experiments encoding 
high-level mupirocin resistance was determined in this study. Authors found high-
level mupirocin resistance by the conjugative transfer of the 41.1 kb plasmid alone or 
8 and 45, respectively. Also, ST 239 was found in 
SCCmec type III (13%), whereas ST8 was found in SCCmec type II (8%), 
hese 
three major pulsotypes together with the other typing techniques provided useful 
with co-transfer with other resistance determinants.  
Essa et al (2009) published a report on the first multilocus sequence typing (MLST) 
of 241 S. aureus strains collected from sixteen public hospitals in Kwazulu-Natal 
during January 2001 to December 2002. Randomly selected MRSA strains were 
subjected to agar-based methods, the E-test, screen latex agglutination methods and 
confirmed with detection of the mecA gene by PCR. The mobility of SCCmec type IV 
amounted to 79% with STs 5, 
respectively (Essa et al., 2009). 
Another study conducted in Kwazulu-Natal during March 2001 to August 2003, 
characterized MRSA isolates (Shittu et al., 2009). Genotyping included PFGE, 
MLST, SCCmec and spa typing. PFGE of SmaI- digested genomic DNA indicated 
seven types assigned A-G, with types A, F and G most commonly present. T
information on the geographical distribution of MRSA clones in KZN province. 
In 2008, a study was published on the molecular characterization of S. aureus isolates, 
acquired from uncomplicated skin infections during five phase III global clinical trials 
of retapamulin, a recent topical antibiotic agent (Goering et al., 2008). Genotyping 
techniques included MLST, PFGE, SCCmec (MRSA only) and PVL analysis. The 
most common PVL-positive methicillin-resistant clone was isolated in the United 
States, with a SCCmec type IV, multilocus sequence type 8 and a pulsed-field type 
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 USA300. Interestingly, the most common PVL-positive methicillin-susceptible clone 
was found in South Africa and the Russian Federation with a multilocus sequence 
type 121 and pulsed-field type USA1200. All other clones were limited in their 
geographic distribution and frequencies. This study demonstrated extensive genetic 
ese virulence genes than in MSSA isolates. The outcome was that virulence 
genes are distributed differently within various geographic regions (Campbell et al., 
ports of methicillin 
sistance into their genomes (Nübel et al., 2008). South African studies are therefore 
t has been conducted at Tygerberg Hospital, and the first to our 
knowledge in the region that included spa typing, together with the detection of the 
mecA and pvl genes.  
diversity within pulsed-field types and MLST clonal complexes throughout the world. 
Similarly, a study by Campbell et al (2008) genotyped a collection of S. aureus strains 
collected for an international clinical trial (FAST II) evaluating telavancin in order to 
treat complicated skin and skin structure infections (cSSSI). This trial included 99 S. 
aureus isolates from 11 sites in the United States (56 isolates) and 7 sites in South 
Africa (34 isolates). Genotyping consisted of SCCmec, agr and PFGE to determine 
the presence of 31 virulence genes. Briefly, results from South Africa showed that it’s 
more common for MSSA isolates to carry certain virulence genes which include sdrD, 
sea and pvl. In contrast, MRSA isolates from the United States were more common to 
carry th
2008). 
It was believed that the proliferation of MRSA strains resulted from the global 
distribution of a few highly epidemic clones. However, Nübel et al (2008) provided 
substantial data in their study stating that the population of MRSA in one of the 
clones (ST5) is geographically structured. This proves that MRSA emerged very 
frequently in various regions of the world through independent im
re
needed in order to understand the clonal distribution of S. aureus. 
 
Data on the genotypic characteristics of local S. aureus strains in relation to the 
clinical presentation of S. aureus infections, in particular with regards to persistent 
infection, and community-acquired versus hospital acquired infections, is lacking. In 
this present study conducted at Tygerberg Hospital, we have decided to implement the 
multiplex PCR method discussed in section 2.1.5. This is the first epidemiological 
study of S. aureus tha
 39
 The information provided in this study contributes to our understanding of the local 
epidemiology of S. aureus and the pathogenesis of different strains at Tygerberg 
hospital. 
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CHAPTER TWO 
 
2 AIM AND OBJECTIVES OF STUDY 
 
2.1 Aim of this study 
 
The aim of this study is to describe specific genotypic characteristics of S. aureus 
strains causing bacteraemia in our setting. This study forms part of a larger study 
“Characterization of Staphylococcus aureus causing bacteraemia in patients admitted 
to Tygerberg Hospital, Western Cape Province, South Africa” (approved by the ethics 
committee on 2 June 2008; N08/02/046).  
 
2.2 Objectives 
 
• To characterize staphylococcal isolates, from patients with staphylococcal 
bacteraemia, according to the presence of mecA and pvl genes, as well as to 
strain-type these isolates (stored blood culture isolates from study: 
N08/02/046) using molecular typing methods. 
• To compare genotypic profiles of staphylococcal strains (obtained from spa 
typing) with profiles of international important clones. 
• To determine clonal cluster groups by BURP (Based Upon Repeat Patterns) 
analysis via RidomStaph software. 
• To analyse the spa typing data, as well as the presence of the pvl gene, 
together with prospectively collected clinical data for possible organism-
related factors associated with persistent and recurrent bacteraemia (clinical 
data will be obtained from the database of study: N08/02/046) 
• To analyze MSSA and MRSA strains; community-acquired, health-care 
associated and hospital-acquired S. aureus strains in order to better understand 
the epidemiology of staphylococcal bacteraemia in patients admitted to 
Tygerberg Hospital. 
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 CHAPTER THREE 
 
3 MATERIALS AND METHODS 
 
3.1 Study Design 
 
This research study takes the form of a prospective descriptive study. The study was 
conducted in the molecular laboratory of the Division of Medical Microbiology, 
Tygerberg hospital. This study forms part of a larger Staphylococcal project that aims 
to describe the clinical course of deep-seated Staphylococcal infections in Tygerberg 
hospital, and to phenotypically and genotypically characterize the strains responsible 
for these infections. The larger project also aims to describe the incidence of 
persistent S. aureus bacteraemia in patients admitted to this hospital. Furthermore, 
clinical and organism-related risk factors associated with persistent infections in the 
population group will be identified in this larger project. In this specific study, 
specific genotypic characteristics of S. aureus strains causing bacteraemia in patients 
admitted to Tygerberg hospital were described. 
 
3.1.1 Ethical Considerations 
 
This research project is incorporated as part of a leading Staphylococcal group study, 
namely the ‘Characterization of Staphylococcus aureus causing bacteraemia in 
patients admitted to Tygerberg hospital, Western Cape Province, South Africa’, and 
the genotypic analyses that was undertaken in this study, comprised part of the 
objectives set for this larger study. Ethical approval for the larger integrated study has 
been granted on the 2nd June 2008, by the Committee of Human Research at 
Stellenbosch University (Project number: N08/02/046).  
 
For this specific study, ethical approval has also been granted by the same committee 
on the 8th October 2008 (Project number: N08/09/252). Patient consent for the storage 
of clinical isolates and data was obtained as part of the larger study, whereby the 
necessary clinical information regarding patient demographics and clinical data was 
collected by a research assistant (nursing practitioner). This study required no 
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 additional samples or clinical information, as the study material consisted of 
subcultures from the stored strains. As in the larger study, patient identity remained 
anonymous, as all samples were coded with specific study numbers. 
 
3.2 Phenotypic testing of bacterial strains 
 
Staphylococcal isolates were obtained from routine blood cultures processed at the 
NHLS diagnostic Medical Microbiology laboratory at Tygerberg Hospital. The 
collection studied included all methicillin-susceptible S. aureus (MSSA) strains as 
well as methicillin-resistant S. aureus (MRSA) strains. Mixed cultures and duplicate 
isolates from subsequent blood culture specimens taken less than 3 days after 
appropriate therapy initiated, were excluded from this study. All isolates were 
identified routinely in the laboratory by conventional tests, according to the 
laboratory’s standard operating procedures (SOPs). These tests included Gram stains, 
deoxyribonuclease or DNase test, mannitol salt agar (MSA) test and a latex 
agglutination test (Pastorex® Staph-Plus test, Bio-Rad, Marnes-la-Coquette, France). 
Resistance to methicillin was detected with the cefoxitin disk (30µg) diffusion test 
(Kirby Bauer method) and interpreted according to CLSI criteria (CLSI document 
M100-S19. Wayne, Pennsylvania). Furthermore, the vancomycin agar screen method 
was used to screen the strains for reduced resistance to vancomycin. Also, a standard 
vancomycin minimum inhibitory concentration (MIC) test was performed on all 
MRSA strains using the E-test method (AB Biodisk, Solna, Sweden). In cases where 
the MIC result was 1.5-2 µg/ml, an E-test macromethod (AB Biodisk, Solna, Sweden) 
was performed to detect possible heteroresistant glycopeptide intermediate S. aureus 
(h- GISA). All agar plates that were used in the laboratory and in this study were 
prepared by Greenpoint media laboratory, Cape Town. 
 
Briefly, the Gram stain differentiates between Gram positive and Gram negative 
bacteria. A suspension of the organism to be stained is mixed with a drop of saline 
solution on a glass slide. The smears are then fixed by flaming and then stained 
consecutively with crystal violet, iodine, a decolourizer (alcohol) and counterstained 
with carbol fuchsin. Consequently, Gram positive bacteria will stain purple, whereas 
Gram negative bacteria will stain pink.  
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For the DNase test, each plate was inoculated with a single colony of up to 8 selected 
strains. These included positive (S. aureus ATCC 25923) and negative (S. epidermidis 
ATCC 49134) control strains. The plates were incubated at 35ºC for 24 hours, 
followed by flooding of the plate with 1M HCl. After about a minute, the excess HCl 
was discarded, with a positive result indicated by a clear zone around the inoculum, 
whereas with a cloudy precipitate of non-hydrolysed DNA around the inoculums were 
interpreted as a negative result.  
 
MSA plates were also inoculated with a single colony of up to 8 selected strains, 
including control strains. The plates were incubated at 35ºC for 24 hours. Yellow 
colonies indicated mannitol fermentation (S. aureus), whereas pink colonies with no 
colour change to the agar indicated no fermentation of mannitol, and documented as 
MSA negative. 
 
A positive DNAse and MSA confirmed the identification of S. aureus. A negative 
DNAse and MSA was further analysed as coagulase negative Staphylococci. 
 
A latex agglutination test (Pastorex Staph Plus test®, Bio-Rad, Marnes-la-Coquette, 
France) was performed when the DNase and MSA tests were inconclusive or not in 
accordance. This test detects the fibrinogen affinity (clumping factor), protein A, and 
capsular polysaccharides of S. aureus. A drop of the latex test reagents were deposited 
onto one of the circles on the agglutination card provided in the kit. Negative and 
positive controls were deposited in one of the other circles. A few colonies were 
emulsified onto the drop of latex by means of a plastic stir rod. The card was gently 
rotated to homogenize the latex reagents with the colonies. After 30 seconds, a 
positive reaction produced aggregates of latex particles with a cloudy, pink 
background. A negative reaction did not produce aggregates and appeared to be 
milky. 
 
The coagulase test was performed to differentiate between S. aureus and coagulase 
negative Staphylococcus (CoNS) species. This test was only carried out where there 
were discrepancies between genotypic and phenotypic results with regard to S. 
aureus. Briefly, an isolated staphylococcal colony was inoculated into a glass tube 
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 containing 0.5 ml of rabbit plasma (Bio-Rad, Marnes-la-Coquette, France). The tubes 
were incubated at 35 to 37°C for 4 to 24 hours. After 4 hours of incubation, the tubes 
were observed for the presence of a clot. However, if no clot was observed after 4 
hours, the tubes were re-incubated and observed again after 24 hours. A clot 
formation at 4 or 24 hours indicated a positive reaction, confirming the identification 
as S. aureus. If no clot formed, and the plasma continued to flow freely once the tube 
is tipped, the organism was considered to be negative and identified as a CoNS. S. 
aureus ATCC 25923 and S. epidermidis ATCC 14990 were used as quality controls 
for this test. 
 
The Kirby Bauer disk diffusion antibiotic susceptibility testing method was performed 
according to the CLSI guidelines (CLSI document M100-S19, Wayne, Pennsylvania, 
January 2009). Single colonies were suspended in 1ml sterile saline solution until a 
turbidity of 0.5 McFarland (McF) (1.5 × 108 cfu/ml) was reached. The suspension was 
evenly spread onto Mueller-Hinton agar plates with a sterile cotton swab. Thereafter, 
a 30µg cefoxitin antibiotic disk was placed onto the inoculated plate and incubated at 
35ºC for 24 hours. Zone diameters were measured with the use of sliding callipers and 
interpreted according to the CLSI criteria for S. aureus. The criteria states that zone 
diameters greater or equal to 22mm are susceptible and can be classified as 
methicillin-susceptible S. aureus (MSSA), whereas zone diameters less than or equal 
to 21mm indicate methicillin-resistant S. aureus (MRSA). 
 
For the vancomycin agar screen method, brain-heart infusion (BHI) agar plates were 
used with a vancomycin concentration of 6µg/ml. A few colonies grown on blood 
agar plates were suspended in sterile saline solution to produce a suspension matching 
a turbidity of 0.5 McF. Bacterial suspensions were spotted onto BHI agar with an area 
of 10-15 mm diameter. This was done by placing a swab in the suspension and 
expressing the excess liquid. Plates were then incubated at 35°C for 24 hours before 
being viewed. Reduced susceptibility to vancomycin is indicated by more than one 
colony or a light film of growth.  Up to eight isolates and two quality control 
organisms were tested per plate. Quality control was performed using Enterococcus 
faecalis ATCC 29212 as the susceptible control and Enterococcus faecalis ATCC 
51299 as the resistant control. 
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 In the laboratory, vancomycin MICs was determined by using the E-test method (AB 
Biodisk, Solna, Sweden). E-tests consist of plastic coated strips calibrated with 
minimum inhibitory concentration (MIC) values covering 15 two – fold dilutions. A 
predefined antibiotic gradient is impregnated on the opposite side of the MIC scale.  
The MIC is read at the point where the growth intersects the E strip. A few colonies 
grown overnight were inoculated into sterile saline solution until a turbidity of 0.5 
McF was reached. Suspensions were swabbed in three directions over the entire 
Mueller Hinton agar plate. Vancomycin E-test strips was applied after plates were air 
dried for 10 minutes. The plates were then incubated at 35 °C for 24 hours. S. aureus 
ATCC 29213 was used to quality control the method. MIC results were interpreted 
according to CLSI criteria (Table 3.1). 
 
An E-test macromethod (AB Biodisk, Solna, Sweden) was performed on those strains 
with an MIC of 1.5-2 µg/ml. The E-test macromethod was performed in the same 
manner as the standard E-test method. However, a heavier inoculum adjusted to 2 
McFarland standard was used to inoculate brain-heart-infusion agar medium (BHI).  
Plates were read after 24 and 48 hours incubation at 35 °C in ambient air. S. aureus 
ATCC 29213 was used as quality control. Readings were recorded and interpreted 
according to the AB Biodisk guidelines: GISA/hGISA: vancomycin ≥ 8 and 
teicoplanin ≥ 8, or teicoplanin ≥ 12 (EAS 003, AB Biodisk). 
 
Table 3.1: 2009 CLSI Interpretive criteria (µg/ml) for MIC testing of S. aureus  
 MIC (µg/ml) 
Interpretive standard for S. aureus 
Glycopeptides 
Susceptible Intermediate Resistant 
Vancomycin ≤ 2 4 - 8 ≥ 16 
Teicoplanin ≤ 8 16 ≥ 32 
 
 
 
 
 
 
 
 
In this study, all stored S. aureus isolates from the integrated study (N08/02/046) that 
were collected since March 2008 up until May 2009 were included. In addition, repeat 
isolates from persistent bacteraemia (positive blood culture ≥3 days after appropriate 
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 therapy initiated) and from recurrent bacteraemia (defined as the return of S. aureus 
bacteraemia after documenting a negative blood culture and/or clinical improvement 
after the completion of a course of appropriate antibiotics) were included (Chang et 
al., 2003). After strain typing, recurrent bacteraemia was subdivided into re-infection 
(different strain types) and relapse (the same strain type). Clinical and demographic 
data were prospectively collected and entered on the computer database for S. aureus 
as part of the larger study (N08/02/046). 
 
3.2.1 Analyses of clinical data 
 
The origin of bacteraemia was considered hospital acquired (HA) if a positive blood 
culture specimen was collected more than 48 hours after admission without evidence 
of a S. aureus infection at the time of admission. If the patient was transferred from 
another hospital, the duration was considered from the date of the first hospital 
admission. Health-care associated (HCA) bloodstream infections were defined by 
positive blood cultures at the time or within 48 hours of hospital admission from 
patients with the following history: 
 Patients who have been to a hospital or hemodialysis clinic or obtained 
intravenous chemotherapy within 30 days before the infection 
 Patients who have been hospitalized for 2 or more days within 90 days (3 
months) before the infection 
 A patient who is a resident in a nursing home or long-term care facility 
(Friedman et al., 2002) 
Community acquired bloodstream infections were defined by a positive blood culture 
specimen collected in an outpatient setting or within 48 hours of hospital admission 
from patients without a history of health-care exposure (Deurenberg et al., 2007; 
Friedman et al., 2002) 
 
The catheter and prosthetic-device related sepsis clinical category (CSI) consisted of 
intravascular catheter as well as other catheter related infections and prosthetic-device 
related infections. Catheter sepsis was defined as the isolation of the same S. aureus 
strain (identical antibiograms) from a quantitative (>102 CFU/catheter segment) 
culture of the catheter tip as from the blood culture and/or clinical evidence of 
catheter site infection (Liao et al., 2008). Other prosthetic device related sepsis were 
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 defined as the isolation of the same organism from the culture of  the prosthetic device 
and/or clinical evidence of prosthetic device infection. Septic arthritis (SA) was 
defined as inflammation of a joint due to S. aureus infection. This category included 
osteomyelitis (Liao et al., 2008). Infective endocarditis (IE) was defined according to 
Duke criteria, as microorganisms demonstrated by culture or histological examination 
of a vegetation, a vegetation that has embolized, or an intracardiac abscess specimen. 
The definition also includes pathological lesions; vegetation or intracardiac abscess 
confirmed by histological examination showing active endocarditis (Durack et al., 
1994). Skin and soft tissue infections (SSTI) was defined as clinical skin and soft 
tissue infection with bacteraemia (Liao et al., 2008). Pneumonia (PN) was defined as 
a positive culture for S. aureus in purulent sputum samples and the presence of newly 
developed lung infiltrates; or the patient had a positive blood culture, pulmonary 
infiltrates and no other obvious source of a staphylococcus infection (Liao et al., 
2008). If no primary focus could be identified, the bacteraemia was defined as 
primary (PB) (Harbarth et al., 1998). Isolates were classified in the unknown clinical 
category when the clinical significance was not clear and blood culture contamination 
was considered e.g. no clinical evidence of infection, no antimicrobial therapy given, 
and normal septic parameters such as white cell count and C-reactive protein. 
 
3.2.2 Collection and storage of bacterial strains 
All isolates were collected daily from the routine blood culture laboratory at 
Tygerberg Hospital. The relevant microbiological and clinical data was recorded onto 
specific forms (appendix A) and then captured onto an excel sheet for the 
staphylococcal database. Colonies of pure staphylococcal isolates were selected from 
Mueller-Hinton plates by using a sterile cotton swab. The colonies were then 
inoculated into MicroBankTM (Pro-Lab Diagnostic, Cheshire, UK) beads (Figure 3.1). 
Each vial contains numerous beads for subculture of the original organism isolated.  
 
Figure 3.1:  Illustration of MicroBank storage beads 
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 MicroBankTM is a sterile cryovial, containing approximately 25 porous beads that are 
preserved in cryobroth solution (Figure 3.1). The beads allow the microorganism 
inoculated to readily adhere onto its surface. The excess cryobroth was aspirated by 
using a glass pipette, thereby leaving the inoculated beads free of liquid. The cryovial 
was labelled according to the allocated study numbers. After inoculation, each 
cryovial was stored at –80 ºC until required for further testing. This method was 
conducted aseptically and according to the instructions specified by the manufacturer. 
3.2.3 Preparation of bacterial strains for genotypic analysis 
 
All work was performed under aseptic conditions in the Medical Microbiology 
laboratory. When stored isolates were required, a single bead was removed from its 
cryovial and used directly to inoculate a suitable bacteriological culture medium as 
follows: 
 
A single bead was placed into a glass tube containing 2ml Mueller Hinton broth with 
the use of a sterile inoculating loop. The tube was then vortexed in order to release the 
micro-organisms adhering to the bead into the broth. Thereafter, tubes were incubated 
aerobically at 37 °C, where the turbidity of the broth was monitored. If broths were 
clear after a few hours of incubation, tubes were incubated overnight and evaluated 
the following day for turbidity. The turbidity was assessed against a laboratory 
standard, to fulfil the CLSI requirement of 0.5 McFarland, which indicate colony 
forming units (CFU) of 1.5 x 108 organisms / ml. The staphylococcal suspensions in 
the turbid tubes were cultured onto Tryptose blood agar plates and incubated for a 
further 24 hours at 37 °C. Effective streaking techniques were used in order to 
produce single colonies from the plates for further experimental testing of these 
isolates.  
 
3.3 DNA preparation for Multiplex PCR 
InstaGeneTM matrix solution (Bio-Rad, Marnes-la-Coquette, France) rapidly isolates 
small amounts of genomic DNA for polymerase chain reactions (PCR’s). The solution 
eliminates various steps that are required in traditional genomic DNA purification 
methods. These include deproteinization, organic extraction, dialysis and alcohol 
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 precipitation. An alternative method can also be used instead of the InstaGene matrix 
method, by using the enzyme lysozyme or lysostaphin for cell wall lysis. However, 
this alternative method requires a suitable DNA preparation kit and proves to be more 
expensive and time consuming.  For this reason, the InstaGene Matrix method was 
preferred in this study as it reduces the use of reagents and proved to be less 
expensive and easier to perform.  
InstaGene includes a cell lysis boiling step in the presence of the matrix. The cell lysis 
products interfering with the process of PCR amplification are rapidly absorbed by the 
matrix. The InstaGene matrix method includes DNA extraction protocols suitable for 
PCR amplification from whole blood, cultured mammalian cells and bacteria. For this 
study, the procedure for bacteria was performed according to the manufacturer’s 
instructions (InstaGeneTM Matrix; Catalog # 732-6030: Bio-Rad, Marnes-la-Coquette, 
France).  
The InstaGene DNA preparation method was executed by selecting a few colonies 
that grew overnight on blood agar plates (refer to section 3.2.2). These colonies were 
suspended into 2ml reaction tubes containing 500µl of distilled water. The tubes were 
then vortexed, followed by immediate centrifugation at 12.000 x g for 60 seconds. 
The excess liquid, referred to as the supernatant, was removed from the tubes with the 
use of a pipette tip, whereby 100µl of the 6% InstaGene matrix solution (Bio-Rad, 
Marnes-la-Coquette, France) was added to the remaining pellet in the tube. 
Thereafter, all tubes were incubated in a water bath at 56°C for 20 minutes. Following 
the incubation period, all tubes were thoroughly vortexed, and placed immediately in 
a heating block for 8 minutes at 100°C. After the boiling step, all tubes were again 
thoroughly vortexed and centrifuged at 12.000 x g for 3 minutes. Finally, 80µl of the 
supernatant containing the DNA was transferred into new 1.5ml reaction tubes. All 
the tubes containing the final DNA products were stored at -20°C until further testing 
with multiplex PCR.  
3.3.1 Measurement of DNA concentrations 
The DNA concentrations of all these products were measured with a Nanodrop ND-
1000 Spectrophotometer V3.1.0 instrument (Nanodrop Technologies, Inc., 
Wilmington, DE, USA) at the Division of Virology, Stellenbosch University. Briefly, 
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 a spectrophotometer is an instrument measuring the amount of molecules that absorb 
a specific wavelength of energy. The nanodrop has the ability to analyse 1 to 2 µl 
samples which can either be DNA, RNA, proteins, dyes or microbial cell culture.  
m
 
Reproduced from Nanodrop ND-1000 users manu
Figure 3.2: The Nanodrop ND-1000 spec
 
The DNA concentrations of all samples w
according to the instruction manual (Nan
USA). The ND-1000 V 3.1.0 icon on the 
selection of the Nucleic Acid icon. The 
carefully cleaned with ethanol (Figure 3.2
free water (Promega, Madison, USA) w
order to make a blank measurement. This
horizontal position so that the nanodrop
button. A new blank measurement was m
above mentioned steps. The blanking cy
well and that any samples that migh
easurements do not occur. Thereafter, 2
measurement pedestal with a pipette. Th
measurement was taken. An example of
3.3. A spectrum of DNA should be obse
nm with a peak that is close to 260 nm (fi
 
m
 Sample Arl
al. 
trop
ere
odr
com
sam
). W
as a
 wa
 co
ad
cle
t h
 µl 
e sa
 the
rved
gureMeasurement Pedestahotometer V3.1.0 instrument  
 performed on the Nanodrop instrument 
op Technologies, Inc., Wilmington, DE, 
puter desktop was opened, following the 
ple arm and measurement pedestal was 
ith the use of a pipette, 2 µl of nuclease-
dded onto the measurement pedestal in 
s done by lowering the sample arm in its 
uld initialize by clicking on the ‘OK’ 
e for a second time following the same 
 ensures that the instrument is working 
ave been carried over from previous 
of the DNA sample was loaded onto the 
mple arm was lowered whereby a DNA 
 resulting readout can be seen in figure 
 over a wavelength range of 220 to 350 
 3.3). 
51
  
Spectrum 
of DNA 
DNA concentration
(reproduced from Nanodrop ND-1000 users manual). 
Figure 3.3: Illustration of a Nanodrop spectrophotometer readout  
 
3.4 DNA amplification of Multiplex PCR 
Multiplex PCR was used to amplify the mecA, pvl and spa gene. Only the spa gene 
was sequenced for spa typing.  The QIAGEN Multiplex PCR kit was developed for 
multiplex PCR reactions, including a master mix which is easy to use, with little or no 
optimization needed. The kit provides pre-optimized concentrations of specific 
reagents. These reagents include HotStarTaq DNA polymerase, Magnesium Chloride 
(MgCl2), dNTPs and a PCR buffer. It is only necessary to add the specific primers and 
DNA templates for the preparation of the final amplification mix. Furthermore, the kit 
provides highly sensitive and specific results that are suitable for many types of 
multiplex PCR applications. These applications include the following:  
 Typing and analysis of transgenic organisms 
 Amplification and analysis of microsatellites 
 Typing and detection of bacteria and viruses 
 Amplification of multiple DNA regions for single nucleotide polymorphism 
(SNP) analysis.  
For this study, the multiplex PCR kit was applied for typing bacterial strains. All 
strains were tested by using the validated method provided by (Larsen et al., 2008). 
PCR amplification was performed in the PCR laboratory at the Division of Medical 
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 Microbiology, Tygerberg Hospital. This method worked well in our setting as no 
optimisation was necessary. Each PCR reaction contained a total volume of 50µl, 
which were placed in 0.2 ml thin-walled PCR tubes (Table 3.2). The multiplex PCR 
reaction included the spa, mecA and pvl (forward and reverse) primers as specified in 
Table 3.3.  
Table 3.2: The preparation of Multiplex PCR for simultaneous detection of spa, mecA 
and pvl genes  
PCR reagents N =1 
PCR Multiplex Mastermix 
2x 
25 µl 
PCR water 9 µl 
Primermix (spa & mecA) 8 µl 
Forward Primer: pvl  3 µl 
Reverse Primer: pvl 3 µl 
DNA 2 µl 
Final Volume 50 µl 
 
(Courtesy of Larsen A.R, Denmark) The column N =1 refers to the amount of reagents used to 
amplify one strain only. To test more than one strain, the amount of reagents in the N=1 
column should be multiplied by any preferred number of strain amplifications. 
Initially, a spa and mecA primermix was prepared, containing 100 pmol/µl of the 
reverse and forward primers. The pvl forward and reverse primers (10pmol/µl) were 
additionally included to the multiplex PCR reaction. The protocol for the standard 
multiplex PCR was conducted according to the manufacturer’s instructions (Qiagen 
Inc., Valencia, USA).  
Generally, the PCR reaction mix contains all the components required for 
amplification apart from the DNA template. For this study, these components 
contained all the relevant primers (Table 3.3), the RNAse-free PCR water together 
with the 2x Multiplex PCR Master mix (final concentration of 3mM MgCl2 (Qiagen 
Inc., Valencia, USA). 
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 Table 3.3: Description of the spa, mecA and pvl forward and reverse primers, as well 
as the 5’ to 3’ primer sequences. 
Genes Primer Sequence (5’ – 3’) 
spa– 1113f (forward primer) 5’-TAAAGACGATCCTTCGGTGAGC -3’ 
spa – 1514r (reverse primer) 5’-CAGCAGTAGTGCCGTTTGCTT – 3’ 
mecA – P4 (forward primer) 5’-TCCAGATTACAACTTCACCAGG – 3’  
mecA – P7 (reverse primer) 5’-CCACTTCATATCTTGTAACG – 3’ 
pvl – FP (forward primer) 5’-GCTGGACAAAACTTCTTGGAATAT – 3’ 
pvl – RP (reverse primer) 5’-GATAGGACACCAATAAATTCTGGATTG – 3’ 
 
Thereafter, 2 µl of each DNA sample was added to 48 µl of each of the PCR reaction 
tubes. A negative control included a tube of mastermix with no DNA template added. 
Positive controls included a pvl positive, MSSA strain (ATCC 49775) and a pvl 
negative, MRSA strain (ATCC 43300). All PCR reaction tubes as well as the negative 
and positive controls were amplified in the Thermocycler (Applied Biosystems 
GeneAmp® PCR System 9700) (Figure 3.4). Thermal cycling conditions for each 
reaction consisted of an initial activation step at 95ºC for 15 minutes, followed by 30 
cycles of DNA denaturation at 94ºC for 30 seconds, primer annealing at 57ºC for 90 
seconds, primer extension at 72ºC for 90 seconds with a final extension period at 72ºC 
for 10 minutes (Qiagen, Standard multiplex PCR protocol). 
 
Figure 3.4: Thermocycler (GeneAmp® PCR system 9700, Applied Biosystems) 
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 3.5 Gel electrophoresis  
Approximately 2 grams of Seakem® LE Agarose gel powder (Whitehead Scientific, 
Cape Town, South Africa) was measured in a weighing boat. A 2% agarose gel was 
prepared with 1xTAE buffer (Qiagen Inc., Valencia, USA). The gel mixture was 
heated in a microwave oven on full power for a few seconds until agarose granules 
have completely dissolved and the solution remained clear. The mixture was given a 
period to cool down the temperature before adding 15µl of ethidium bromide 
e coverage of the gel and electrodes with 1xTAE buffer. The 
buffer provides continuous flow of the electric current during electrophoresis and 
rmine the individual product sizes of the double-stranded DNA ranging 
om 100 – 1,500 bp. Negative and positive control PCR products were also loaded 
Subsequent to gel electrophoresis, individual DNA bands were visualized on agarose 
els. The current was switched off in order to remove the gel from its tank. The gel 
(concentration of 1 µg/µl) (Promega, Madison, USA) to the melted agarose gel. The 
necessary safety precautions were taken into account when working with ethidium 
bromide as it is carcinogenic. The beaker was swirled in order to mix the solution 
before pouring the gel into its appropriate mould. The gel was carefully poured into its 
mould in order to prevent any air bubbles before placing an appropriate size comb 
into the gel. The gel was left at room temperature for approximately 30 minutes until 
it completely solidified.   
Following solidification of the gel, the comb was carefully removed and placed into a 
gel tank ensuring effectiv
prevents melting of the gel. For each sample, 8µl of specific PCR products were then 
mixed with 3µl of a blue/orange 6x loading buffer (Promega, Madison USA) and 
loaded into individual wells of the gel with the use of a pipette. Also, a 100 base pair 
(bp) DNA molecular marker (Promega, Madison USA) was loaded into the well of 
the gel to dete
fr
into the wells of the gel. 
After loading the PCR products, a lid was placed onto the tank whereby the negative 
and positive electrodes were connected to the PowerPacTM Basic Power supply box 
(Bio-Rad, Marnes-la-Coquette, France). The power was switched on and the gel was 
run at 100 volts in a 25x20 cm gel cast for approximately one and a half hours at room 
temperature. 
 
g
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 was carefully placed in a UV machine in the Division of Chemical Pathology, 
Tygerberg Hospital, in order to visualize the DNA bands with the GelDoc XR 
computer system (Bio-Rad,Marnes-la-Coquette, France ). All DNA bands were then 
viewed, to ensure that the spa, mecA and pvl bands correspond to its relevant 
molecular sizes by comparing them to the DNA marker, as well as positive and 
negative controls. 
 
3.6 Sequencing of the spa gene 
Sequencing of all PCR products to determine gene sequences of the spa bands were 
done at the Central analytical sequencing facility at Stellenbosch University. The 
acility in order to remove any un-
incorporated dNTPs and primers. The spa reverse primers were sent to the facility at 5 
3.7 Sequence analysis with Ridom StaphType
purification of PCR products was performed at the f
µl per reaction with a concentration of 1.1 pmol / µl. Together with the primers, 5 µl 
of amplified DNA samples were also provided. Sequences were reported in ABI and 
SEQ file formats and further edited and analysed in the Ridom StaphTypeTM, version 
1.4 (Ridom Gmb, Würzburg, Germany) software package. 
 
TM  
Ridom StaphType was used to determine various spa-types and repeats (Chapter 2: 
section 2.1.4). This software package is a modernised, Internet database used to 
manage genotyping data. The software consists of three modules which include the 
following: a) a sequence editor, b) a database, c) a report generator module (Figure 
3.5). The ABI sequencing file format was chosen as an input sequence in the software. 
Other file formats such as FASTA format or SCF-chromatograms could also be used.   
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Reproduced by (Harmsen et al., 2003). The figure includes a quality-based sequence editor, a database 
and a report generator (not shown) module  
Figure 3.5: A screen shot of Ridom StaphType software.  
 
The software was utilised according to the following description: 
After the chromatogram file is loaded, a quality value is assigned to each base which 
determines any possible sequence errors depending on the quality value. The software 
then constructs a consensus sequence whereby spa repeats and spa types are 
automatically detected. No further manual editing is required in almost 90% of all 
input sequences. However if editing is required, sequences can be manually edited by 
a versatile graphical user interface. 
For a spa type code, none of the sequence information up or downstream of the repeat 
region is taken into account. The spa types are produced from chromatograms and 5’ 
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 and 3’ signatures which are unambiguously detected. The software detects 5’ – 3’ 
signature sequences at a correct distance to ensure that no beginning or end repeat is 
missed. All sequencing editing are stored in a sequence history log-file that can be 
viewed and printed by the user at any time. 
For a standardized nomenclature, the spa types and repeats consists of two groups, 
namely local and global strains. The spa type is identified with the letter “t” and a 
unique number, whereas the repeat is identified with a letter “r” and a unique number. 
Should it occur that a spa type or repeat is unknown, it is assigned a new local spa 
type or repeat in the database beginning with the letters “tx” or “rx”. These local 
strains are then synchronized with the spa server to be transferred into new global 
codes (Table 3.4).  
 
Table 3.4: The assignment of spa-types and spa-repeats (Ridom StaphType 
userguide) 
 
After all sequencing editing was completed, the spa typing results and relevant 
epidemiological data was saved locally in a database system incorporated in the 
software program. Database information is easily retrieved by Boolean searches and 
various configurable reports which are stored 
exported in a tab-delimited spreadsheet format. In addition, the integrity of the 
database is regularly ensured and its information can be backed up to protect against 
data leakage. 
For confidentiality purposes, the database contents are cryptographically secured. In 
addition, it is possible to create 
internally as PDF files. These files cannot be tampered with as it is encrypted to read-
only. Thus, Adobe Acrobat Reader software (version 5.0 or higher) has to be installed 
in order to view or print these files.  
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 To view or submit all new spa type and repeats codes, the software synchronizes with 
its website, http://www.ridom.de/spaserver/. This is achieved by either direct access 
via the http protocol or file based (e.g., via email). Preferably, all new spa types and 
repeats that meet the quality criteria can be synchronized to the spa server to acquire a 
final spa code. Furthermore, all spa types and repeats synchronized by users 
worldwide are transferred to the Ridom StaphType client software. Local or novel spa 
type frequencies are also transmitted to the server. They are assigned to a global spa 
ossible to deduct an evolutionary history from these spa types. The 
dimension of clusters were defined by implementing a value less than or equal to six 
embers of a group. Lastly, a UPGMA dendogram 
g MEGA software to show the relationship between all spa 
clonal complexes. 
type or if a newly discovered local strain, a new spa type code is allocated. The 
website is accessible to all users whereby spa types and repeats can be downloaded 
(Harmsen et al., 2003).  
BURP (Based upon repeat pattern) analysis was performed within the software in 
order to align and create various spa cluster groups or spa-clonal complexes (spa-
CC). The spa-type alignments were first downloaded before accessing the BURP 
functions. Once accessed, the strain data were selected to begin the clustering process. 
The algorithm then searches for clusters of spa types to show relatedness between 
each spa-type via a graphical representation. Each individual spa type can only be a 
member of one cluster. Spa types shorter than five repeats were excluded from the 
analysis as it is imp
as the calculated cost between m
was constructed by usin
 
3.8 Statistical analysis 
Phenotypic and genotypic and clinical data were analysed by using Statistica (Version 
8, Statsoft, USA). A chi-square test was used to analyse data where a P value less than 
0.05 was considered to be statistically significant. 
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CHAPTER FOUR 
4 RESULTS 
 
4.1 Descriptive data 
 
A total number of 113 S. aureus strains from 104 patients were collected during the 
study period. In five patients isolates from more than one bacteraemic episode were 
included in the analysis (refer to Table 4.1). These repeat isolates were assigned a 
number (patient study number) and an alphabetical letter (isolate order number), for 
instance TBH 26.b (second isolate), indicating the first repeat isolate per patient; TBH 
26.c (third isolate), indicating the second repeat isolate per patient. According to the 
laboratory results, 3 of these repeat strains were MRSA and 6 were MSSA. The 
results of these 5 patients with repeat strains are further analysed in section 4.3 
(Persistent / Recurrent bacteraemia). These repeat isolates were categorised as 
different episodes of bacteraemia based on the available clinical data and time 
intervals between isolates. 
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 Table 4.1: S. aureus repeat strains 
 
Study number Time apart  from previous strain MSSA/MRSA 
TBH 7.a (1st isolate) - MSSA 
TBH 7.b (2nd isolate) 1 month MRSA 
TBH 26.a (1st isolate) - MSSA 
TBH 26.b (2nd isolate) 3 months & 13 days MSSA 
TBH 26.c (3rd isolate) 1 month & 28 days MSSA 
TBH 30.a (1st isolate) - MSSA 
TBH 30.b (2nd isolate) 2 months & 12 days MSSA 
TBH 30.c (3rd isolate) 1 month & 23 days MSSA 
TBH 30.d (4th isolate) 4 months & 27 days MSSA 
TBH 30.e (5th isolate) 3 months & 7 days MSSA 
TBH 40.a (1st isolate) - MRSA 
TBH 40.b (2nd isolate) 9 days MRSA 
TBH 110.a (1st isolate) - MSSA 
TBH 110.b (2nd isolate) 12 days MRSA 
 
4.1.1 Phenotypic characteristics of strains 
34/113 (30.1 %) of the strains collected were identified as MRSA, whereas 79/113 
(69.9%) of the strains collected were identified as MSSA at the NHLS routine 
laboratory. Only one h-GISA (TBH 107) was detected in this study (Table 4.2).  
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 Table 4.2: Summary of phenotypic characteristics of S. aureus strains 
 
Phenotypic 
Characteristics 
Total number of 
strains (%) 
MSSA 79/113 (69.9%) 
MRSA 34/113 (30.1%) 
h-GISA (MRSA) 1/34 (2.9%)  
 
4.1.2 Description of Patient Demographics 
All descriptive and clinical data are included in appendix B. Of the 104 patients 
included in the study, 53/104 (51%) were female and 51/104 (49%) were male. 
Twenty-seven patients (26%) were less than a year old and 12 patients (12%) were 
between the ages 1 to 13 (Paediatric patients). The majority of staphylococcal isolates 
were from adult patients, defined as patients 13 years and above (65; 63%) 
[Figure4.1]. This group consisted of ages 13 to 40, 32 patients (31%); ages 40 to 65, 
22 patients (21%) and >65 years old, 11 patients (11%). 
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Figure 4.1: Age distribution of all patients admitted to Tygerberg Hospital. 
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 The distribution of patient wards is presented in appendix B (table B1). Figure 4.2 
compares the number of MRSA to MSSA strains in wards with more than 7 isolates. 
Isolate TBH 43 was excluded from this analysis because of a discrepancy between the 
phenotypic and genotypic results of this isolate (Table 4.3). The wards with the 
highest number of isolates included the burns unit (A1B) with 12 isolates, the renal 
unit (A7) with 11 isolates and the surgical ICU (A1W) with 9 isolates. The surgical 
ICU had the highest number of MRSA isolates (44% (4/9) of the isolates from A1W 
were MRSA). 
All wards were further categorised into ward groups, apart from intensive care units, 
renal and burns unit. The number of MRSA to MSSA isolates per ward group and 
units are presented in figure 4.3. It was noted that a high number of MRSA isolates 
(8) were seen in the paediatric ward group. For MSSA strains, ward groups with more 
than 7 isolates included the medical and paediatric ward groups, the renal and burns 
unit. 
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A1B = burns unit; A1W = adult surgical ICU; A7 = renal unit 
Figure 4.2: Comparison of the number of MRSA to MSSA strains in wards with 7 
isolates or more.  
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 MRSA/MSSA in Ward groups and Units
0
2
4
6
8
10
16
M A1W Pd A7 A1B N A9E KHA S
Ward groups and Units
N
o.
 o
f i
so
la
te
12
14
s
MSSA
MRSA
 
Adult medical ward group (M), Surgical ICU (A1W), Paediatric ward group (Pd), Renal unit (A7), 
Burns unit (A1B), Neonatal ward group (N), paediatric ICU (A9E), Khayelitsha hospital (KHA), 
Surgical ward group(S). 
Figure 4.3: Comparison of the number of MRSA to MSSA strains in ward groups 
and units.  
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 4.1.3 Genotypic characteristics of strains 
4.1.3.1 The mecA gene 
All genotypic results are presented in appendix B (table B2). All gel images obtained 
after multiplex PCR with detection of the mecA, pvl and spa genes are presented in 
appendix C (Figures C1 to C10). The mecA gene was detected in 33 of 34 (97%) 
strains, phenotypically characterised as MRSA. The mecA gene was absent in all 79 
(100%) phenotypically characterised MSSA strains, thus confirming methicillin 
susceptibility. 
The one isolate (TBH 43) with discrepant results was identified by the laboratory as 
MRSA (Table 4.3). However, no mecA gene was detected with multiplex PCR, even 
after repeat testing. On retesting of this strain for methicillin resistance using a 
cefoxitin disk and the Kirby Bauer diffusion method, the zone diameter was 
equivalent to 24 mm. According to the CLSI criteria for S. aureus, this signifies 
methicillin susceptibility (Refer to Chapter 3, section 3.2). However, MRSA was also 
isolated from other specimens in this patient and the possibility of an initial mixed 
culture could not be ruled out. Therefore this isolate was excluded from the analyses 
which compared MSSA and MRSA strains. 
 
Table 4.3: Discrepancies in mecA gene results 
 
Study number Phenotypic result: 
Kirby Bauer method 
Genotypic result: 
Multiplex PCR  
Retest: Kirby Bauer 
method 
TBH 43 MRSA No mecA gene MSSA 
 
4.1.3.2 The pvl gene 
18/113 (15.9%) of strains were positive for the pvl gene. All of these PVL positive 
strains were MSSA. The number of PVL negative strains amounted to 95/113 (84 %). 
All isolates were included in this analysis, including repeat isolates, because these 
represented different bacteraemic episodes. 
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 4.1.3.3 The spa gene 
The spa gene was detected in 101/113 (89.3%) of strains. In the remaining 11/113 
strains (9.7 %) no spa gene was detected on initial and subsequent testing (re-testing) 
with the multiplex PCR. These strains were therefore grouped as non-typeable strains. 
Two of the non-typeable strains were resistant to methicillin (MRSA), whereas the 
remaining nine were all sensitive to methicillin (MSSA). All isolates were spa typed, 
including repeat isolates, because these represented different bacteraemic episodes. 
 
4.1.3.4 Spa typing 
The 101 protein A positive genes were sequenced and strain typed into the Ridom 
StaphType software program. Of these strains, 31/101 (30.7%) were MRSA and 
70/101 (69.3%) were MSSA. 
After all DNA nucleotides were analysed in the Ridom StaphType program, a total 
number of 49 different spa types were identified. Of these spa types, five were 
identified as novel (local spa types) after synchronisation with the Ridom spa server 
(Table 4.4). Two of the novel spa types, t5396 (14 repeats) and t5474 (12 repeats) 
together with spa type t253 (12 repeats) were the longest. Moreover, spa types t026 
and t287 were found to be the shortest representing 3 repeats each. 
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 Table 4.4: Novel (local) spa-types identified after synchronisation with the Ridom 
spa-server. 
Study 
number 
Novel Spa-type (before      
synchronisation) 
Novel Spa-type (after 
synchronisation) 
TBH 47 txAC t5474 
TBH 85 txAD t5396 
TBH 89 txAE t5472 
TBH 91 txAF t5473 
TBH 109 txAG t5471 
 
The spa types were further divided into the most prevalent (major) and minor spa 
types. Major spa types included five or more occurrences of an individual type, 
whereas minor spa types included occurrences of three or four of an individual type 
(Table 4.5).  
The most prevalent spa types that were found in this study were spa type t037 and 
t891. t037 presented with repeat pattern 15-12-16-02-25-17-24 with nine occurrences 
in this study. t891 presented with repeat pattern of 26-23-13-23-31-05-17-25-17-25-
28, with seven occurrences in this study. The following spa types, t002, t015 and 
t1257 each occurred six times, whereas t021 occurred five times in this study.  
All spa types, including major/minor spa types that were detected in this study were 
further compared to the global frequency and international clones according to Ridom 
SpaServer (www.spaserver.ridom.de) (Table 4.5). Ridom sequences and the 
geographical spread amongst all spa types in this study is included in appendix D. 
 67
 Table 4.5: Frequencies of all spa-types compared to global frequencies in association 
with international clones:  
Spa-type 
(Major/Minor) 
No. of 
isolates 
(%) 
Global 
Frequency 
(%)* 
Clone (Comments)* 
t037 
(Major) 
9 (9%) 
  
3% 
  
CC8/239, Vienna MRSA, Brazilian/Hungarian, 
ST239 ORSA III, ST240 ORSAIII, EMRSA-1,4,7,9,11 
t891 (Major) 7 (7%) 0%   
t1257 (Major) 6 (6%) 0%   
t002 
(Major) 
  
6 (6%) 
  
  
6% 
  
  
CC5, Rhine Hesse MRSA(prototype), EMRSA-3, 
New York clone, Japan clone, Pediatric, USA 100 ORSA II, 
USA800 ORSA IV, ST5 ORSA I 
t015 (Major) 6 (6%) 1%   
t021 (Major) 
  
5 (5%) 
  
1% 
  
CC30, prototype of ST-30, cMRSA (lukS-lukF+) widely 
disseminated in Australia 
t1597 (Minor) 4 (4%) 0%   
t174 (Minor) 3 (3%) 0%   
t1443 (Minor) 3 (3%) 0%   
t701 (Minor) 3 (3%) 0%   
t012 (Minor) 3 (3%) 1%   
t064  
(Minor) 
3 (3%) 
  
0% 
  
CC8, Archaic/Iberian, USA500 ORSA IV, USA500 ORSA II, 
ST8 ORSA I, ST8 ORSA IV, ST8 ORSA III 
t451 (Minor) 3 (3%) 0%   
Other spa 
types 
  
  
40 (40%) 
  
  
  
0% 
  
  
  
spa types detected twice: t451, t030, t253, t1476, t148 
spa types detected only once: t085, t214, t287, t292, t317, 
t375, t409, t433,t465, t521, t888, t1848, t2360, t2393, t2623, 
t2763, t4576, t018, t045, t306, t318, t267, t311 t026, t127, 
t275, t346, t5474, t5396, t5472, t5473, t5471 
 
Total no. spa 
type strains 
101 
(100%)     
* According to Ridom SpaServer; 0%: spa types that are infrequently found globally 
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 Table 4.6: Spa typing BURP cluster analysis of S. aureus strains at Tygerberg Hospital. 
Cluster 
group 
 
spa-CC (Clonal 
Complex  
 
spa-types # strains  Total # strains (%) Total # spa-types (%) 
 
t064 3 
t292 1 
t451 3 
t701 3 
t1257 6 
t1443 3 
t1476 2 
t2360 1 
t5472 1 
t5473 1 
 
 
 
 
 
1 
 
 
 
 
 
 
 
spa-CC 701 
 
 
 
 
 
 t5474 1 
 
 
 
 
25 
(25% of all strains) 
 
 
 
 
 
 
11 
(22% of all spa-types) 
 
 
 
 
 
t012 3 
t018 1 
t021 5 
t030 2 
t037 9 
t253 2 
t275 1 
t318 1 
t433 1 
 
 
 
 
 
2 
 
 
 
 
 
 
 
 
 
spa-CC 012 
 
 
 
 
 t1848 1 
 
 
 
 
26 
(26% of all strains) 
 
 
 
 
 
 
 
 
10 
(20% of all spa-types) 
 
 
 
 
t002 6 
t045 1 
t214 1 
t306 1 
  
 
3 
  
  
  
  
spa-CC 002 
  
  
  t311 1 
 
10 
(10% of all strains) 
 
 
 
5 
(10% of all spa-types) 
 
 
t015 6 
t465 1 
t2623 1 
  
4 
  
  
  
spa-CC 015 
  
  t4576 1 
  
9 
(9% of all strains) 
  
  
4 
(8% of all spa-types) 
  
t127 1 
t174 3 
5 
  
  
spa-CC 174 
  
  t5471 1 
5 
(5% of all strains) 
  
3 
(6% of all spa-types) 
  
t085 1 
t346 1 
 6 
 
  
spa-CC 346/085 
  t5396 1 
3 
(3% of all strains) 
  
3 
(6% of all spa-types) 
  
t267 1 7 
  
No founder 
  t521 1 
2 
(2% of all strains) 
2 
(4% of all spa-types) 
t148 2 
t317 1 
t375 1 
t409 1 
t888 1 
t891 7 
t1597 4 
t2393 1 
 
 
 
 
Singletons 
 
 
 
 
 
Singletons 
 
 
 
 
 t2763 1 
 
 
 
19 
(19% of all strains) 
 
 
 
 
 
 
 
9 
(18% of all spa-types) 
 
 
 
 
t026 1 Excluded 
  
Excluded 
  t287 1 
2 
(2% of all strains) 
2 
(4% of all spa-types) 
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 4.1.3.5 BURP cluster analysis 
Spa types were clustered into seven cluster groups, which were assigned as either, spa 
clonal complexes, no founders, singletons or excluded spa types (Table 4.6). This was 
performed by means of the BURP algorithm that is installed in Ridom StaphType 
software. Clustering parameters excluded spa types shorter than five repeats from 
analysis as the length of repeat pattern is insufficient to deduct evolutionary history 
from these spa types. For this reason, two spa types (Table 4.6) were excluded from 
BURP analysis. The dimension of clusters were defined by implementing a value less 
than or equal to six as the calculated cost between members of a group (Faria et al., 
2008; Hallin et al., 2007).  
There is usually a repeat or several repeats commonly found in spa types that belong 
to a specific spa-clonal complex (spa-CC). Spa types can evolve due to; insertions, 
deletions or duplications of an individual repeat unit or group of repeats; or point 
mutations within a specific repeat unit, leading to the formation of a different repeat 
unit.  
Graphical representation of the relationship of spa-types in cluster groups one to 
seven is shown in figures 4.4 to 4.10. Founders of each of these cluster groups are 
coloured blue, whereas sub-founders are coloured yellow. The size of each spa-type 
node refers to the number of clustered strains belonging to each specific spa-type. In 
addition, a UPGMA (unweighted - pair group method using average linkages) 
dendogram using MEGA software, was included to show the relationship between all 
spa clonal complexes (Figure 4.11). 
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 4.1.3.5.1 Spa-Clonal Complex 701 (Cluster 1) 
The graphical representation of the relation in spa-CC 701 showed t701 as the founder 
spa type (Figure 4.4).  
 
 
Figure 4.4: The relatedness of spa-types grouped into spa clonal complex 701 
(Cluster 1) 
Six spa types, namely t064, t292, t451, t2360, t1476 and t5474 evolved from spa type 
This was followed by 
t701. In addition, two spa types, t064 and t292 were subfounders of spa type t701. It 
appears as if spa type t1257 and t5472 are more closely related to spa type t292, than 
it to spa type t701. A similar trend is seen for spa type t1443 and t5473 as they are 
more closely related to spa type t064, than to type t701. 
All repeat patterns of these spa types were aligned (Appendix E, Table E1), indicating 
the presence of motifs 11-19, 11-12 or 11-10 at the beginning. 
motif 17-34-24 (excluding t5473) and motif 34-22-25 (excluding t5472). The 
alignment of these spa types shows various deletions, duplications and insertions of 
repeat units, as well as point mutations within the nucleotide sequences of any repeat 
unit. 
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 Alignment of repeat units r19 and r12 (Appendix F, Table F1) showed two point 
mutations at the twelfth (T – C) and the last nucleotide position (C – T). Furthermore, 
the same nucleotide sequence was revealed in the alignment of repeats r19 and r10 
(Appendix F, Table F2), except for a point mutation that occurred at the last 
nucleotide (C – T). If one compares spa type t1257 and type t701, an insertion of r34 
at the beginning motif, and a deletion of r25 at the end is noted. 
 point mutation occurred in unit r21, which resulted in the formation of a new spa 
type (Appendix F, Table F3). The same pattern occurred in the alignment of repeat 
Table F4) with a point mutation at the last nucleotide 
osition (C – T). 
s repeat motif 17-34-24 was identified in all the spa types, except spa type t5473, 
the alignment of repeat units, r17 and r12 was performed. Two point mutations 
ccurred at the tenth and eleventh nucleotide positions (both G – A) (Appendix F, 
able F5). Spa type t701 acquired an additional repeat unit r25, while spa type t2360 
possessed two duplicated repeat units r25 at the end. Moreover, spa type t5474 
eveloped three duplications of repeat unit r25. 
 
A
units r21 and r12 (Appendix F, 
p
A
o
T
d
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 4.1.3.5.2 Spa-Clonal Complex 012 (Cluster 2) 
All repeat patterns of the spa types in spa-CC 012 were aligned (Appendix E, Table 
E2). It was revealed that motif 15-12-16-02, motif 02-16-02-25 and motif 17-24 were 
each detected in 70% (7/10) of the spa types. Various deletions and duplications of 
repeat units were detected amongst the spa types in spa-CC 012, whereas no point 
mutations were detected. However, there was an insertion of repeat unit r17 in motif 
15-12-16-12, which occurred in spa type t1848. 
 
 
 
Figure 4.5: The relatedness of spa-types grouped into spa clonal complex 012 
luster 2) 
 
 
 
(C
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 4.1.3.5.3 Spa-Clonal Complex 002 (Cluster 3) 
The graphical representation of spa-CC 002 showed that spa type t045, t214, t306 and 
11 evolved from spa type t002. Alignment of the repeat patterns of the spa types 
identified motif 26-23-17-34 (excluding t045), followed by motif 20-17-12-17 in all 
E, Table E3). Deletions of motif 23-
spa type t045, whereas a deletion of repeat unit r17 occurred in spa 
type t311. In spa type t306, a duplication of repeat unit r17 occurred at the end of the 
peat motif. Another duplication arose of repeat unit r16, in spa type 214 towards the 
end of the repeat motif. 
 
t3
spa types with repeat unit r16 (end) (Appendix 
17-34 occurred in 
re
 
Figure 4.6: The relatedness of spa-types grouped into spa clonal complex 002 
(Cluster 3) 
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 4.1.3.5.4 Spa-Clonal Complex 015 (Cluster 4) 
The graphical representation of spa-CC 015 showed that spa type t465, t2623 and 
t4576 evolved from spa type t015. Motif 08-16-02-16 occurred in 75% (3/4) of the 
spa types towards the beginning, followed 50% (2/4) of spa types in motif 34-13-17-
34-16-34 (Appendix E, Table E4). Spa type t015 shows that repeat unit r16 mutated to 
repeat unit r23 in spa type t465 through a point mutation (T - C) at the last nucleotide 
position (Appendix F, Table F6). Additionally, a deletion of repeat unit r02 occurred 
in spa type t465. Spa type t2623 reveals a deletion of repeat unit r34, followed by a 
point mutation of repeat unit r34 to r13. The point mutation took place at the fifteenth 
 spa type t4576, followed by a point mutation that resulted in repeat unit 
4 becoming repeat unit r13 (Appendix F, Table F7). 
nucleotide position (A - C) (Appendix F, Table F7). Lastly, a deletion of motif 13-17 
occurred in
r3
 
 
Figure 4.7: The relatedness of spa-types grouped into spa clonal complex 015 
(Cluster 4) 
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 4.1.3.5.5 Spa-Clonal Complex 174 (Cluster 5) 
ent of repeat patterns within spa-CC 174 showed that spa type t5471 and 
t127 evolved from spa type t174. Motif 21-16-34-33-13 is identified in all of the spa 
types (Appendix E, Table E5). The spa types within spa-CC 174 differ by deletions 
and point mutations leading to new repeats.  
Point mutations occurred in spa type’s t127 with repeat unit r07; and in spa type 
t5471 with repeat unit r35 instead of r14 as in spa type t174. Alignment of repeat units 
r14 and r07 (Appendix F, Table F8) showed a mutation at the last nucleotide (C – T), 
whereas alignment of repeat units r14 and r35 showed a mutation at the fifteenth 
nucleotide (C – A) (Appendix F, Table F9). Furthermore, an insertion of repeat unit 
r23 occurred in spa type t127. 
 
The alignm
 
Figure 4.8: The relatedness of spa-types grouped into spa clonal complex 174 
(Cluster 5) 
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 4.1.3.5.6 Spa-Clonal Complex 346/085 (Cluster 6) 
Spa types t346 and t085 were the two founders that arose within this clonal complex. 
Both of these spa types are closely related to t5396 (Novel spa type). When 
comparing spa type t346 to t085, a deletion of repeat unit r34 and a duplication of 
repeat unit r12 occurred. Spa type t5396 is related to t346 and t085 by an insertion of 
motif 13-23-12 and by deletions and duplications (Appendix E, Table E6). 
 
 
Figure 4.9: The relatedness of spa-types grouped into spa clonal complex 346/085 
(Cluster 6) 
 
4.1.3.5.7 No Founder (Cluster 7) 
The evolution of these spa types cannot be predicted as this clonal complex has no 
founder strain. The only difference detected between spa type t521 and t267 was that 
a duplication of r34 occurred in spa type t521 (Appendix E, Table E7). 
 
 
Figure 4.10: The relatedness of spa-types grouped into Cluster 7, No founder 
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Only one representative strain per spa type is shown. 
 
Figure 4.11: UPGMA dendogram of Tygerberg isolates determined by spa typing.  
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 4.2 Clinical data 
 
The clinical outcome data (discharged from hospital, transferred to a secondary 
hospital or death) of 102 patients were available. Of the 102 patients, 62% (63) of the 
patients were discharged from hospital, 26% (27) of the patients demised and 12% 
(12) of the patients were transferred to other hospitals. The clinical data of patients 
from which strains were included in this study can be viewed in appendix B, table B1. 
In this study, catheter and prosthetic-related sepsis (CSI) mainly constituted CVP 
catheter infection. Others catheter infections included peritoneal, hemodialysis, 
broviac, hickman and tenkoff catheters. A few cases of peripheral line sepsis, VP 
shunt sepsis and vascular graft sepsis also occurred. 
 
4.2.1 HIV status in relation to staphylococcal bacteraemia  
 
Five percent of strains in this study were from HIV positive patients and 47% from 
HIV negative patients. The HIV status of patients for the remaining 48% strains, were 
unknown (Figure 4.12). The descriptive (phenotypic/genotypic) data of the strains 
from the 5 HIV positive patients together with the clinical data on these patients were 
further analysed (Table 4.7). The majority of the strains (4/5) were MRSA and caused 
hospital-acquired infections. The clinical diagnoses included skin and soft tissue 
infections, catheter-related sepsis and primary bacteraemia (unknown source). Three 
of the strains were spa type t1257 (from 3 paediatric patients), with the remaining two 
strains, t064 and t1476 from adult patients. Interestingly, all of these strains were PVL 
negative and spa types from spa-CC 701 [Cluster 1] (Table 4.7). 
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Figure 4.12: HIV positive, negative and unknown  
 
 
 
Table 4.7: Descriptive and clinical data of HIV positive patients 
 
HIV POSITIVE PATIENTS 
Study 
# 
MRSA/ 
MSSA Gender Age 
Clinical 
Diagnosis 
HCA/ 
HA/CA PVL 
spa-
type 
Major/ 
Minor 
spa- 
CC 
TBH 
27 MSSA Female 22 years PB a neg. t1476     * 
 
701 
TBH 
29 MRSA Male 
10 
months SSTI HA neg. t1257 Major 
 
701 
TBH 
48 MRSA Female 
10 
months CSI HA neg. t1257 Major 
 
701 
TBH 
59 MRSA Male 2 years CSI HA neg. t1257 Major 
 
701 
TBH 
71 MRSA Female 34 years SSTI HA neg. t064 Minor 
 
701 
 
(PB): Primary bacteraemia; (SSTI): Skin & Soft tissue infection; (CSI): Catheter and prosthetic-device 
related sepsis 
a PB excluded from analysis for HA/HCA/CA category due to unknown source 
* <3 occurrences of spa type in study 
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4.2.2 Analysis of MRSA/MSSA association with hospital-acquired, healthcare 
associated and community-acquired bloodstream infections 
 
The clinical data of study patients were analysed to determine if any community-
acquired MRSA infections occurred during the study period. Infections were 
classified as health-care associated (HCA), hospital-acquired (HA) or community-
acquired (CA) for 86 of the 113 strains (Figure 4.13). As mentioned previously, 
isolate TBH 43 was excluded from the analysis comparing MSSA to MRSA strains. 
Also patients in whom the source for the bacteraemia was unknown (15 isolates) or 
where the isolate was considered as a possible contaminant (11 isolates) were not 
evaluated. All episodes of recurrent bacteraemia were analysed as these were 
considered to be different episodes based on the available clinical information and 
consideration of the time periods between episodes. The analysis show 13 isolates 
(22% of 60 MSSA isolates) as CA-MSSA strains and no CA-MRSA strains (Table 
4.8). This finding was statistically significant (p = 0.00009) (Figure 4.13). Twenty 
MSSA isolates (33% of MSSA) were HCA- strains, whereas only 3 MRSA isolates 
(12% of MRSA) were HCA- strains.  The majority of MRSA strains were hospital-
acquired (23/26; 88%). Also 27 HA-MSSA strains (45%) were isolated (Table 4.8). 
 
Table 4.8: MRSA and MSSA isolates causing hospital acquired (HA), community-
acquired (CA) and health-care associated (HCA) infections at Tygerberg Hospital. 
 
  HA CA HCA Total 
MSSA 27 13 20 60 
MRSA 23 0 3 26 
  
Total 
  
50 
  
13 
  
23 
  
86 
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Categorized Histogram: MRSA/MSSA vs HCA/HA/CA
Chi-square(df=2)=18.60, p=.00009
MSSA (n=60) 
45% 
22% 
33%
HA CA HCA
HCA/HA/CA 
0
2
4
6
8
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
MRSA (n=26)
 
12% 
HA CA HCA 
HCA/HA/CA
88%
Figure 4.13: A histogram comparing MRSA and MSSA strains causing hospital 
acquired (HA), community-acquired (CA) and health-care associated (HCA) 
infections at Tygerberg Hospital. 
 
 
4.2.3 Source of staphylococcal bloodstream infections according to clinical 
diagnosis 
 
A high number of 44 (39%) of the 113 isolates represented catheter or prosthetic 
related sepsis, followed by skin and soft tissue infections (20/18%) and primary 
bacteraemia where the source was unknown (15/13%) [Figure 4.14]. This was 
followed by the unknown group, which included possible contaminants or where the 
clinical significance of isolate was not clear (11/10%), pneumonia (12/11%), septic 
arthritis (including osteomyelitis) (5/4%) and infective endocarditis (3/3%). Other 
diagnoses included pericarditis and urinary tract infection (2/2%). 
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 Clinical Diagnosis
IE
3%
 
Cath
a
eter and prosthetic device-related sepsis (CSI), Infective endocarditis (IE), Pneumonia (PN), Septic 
rthritis and Osteomyelitis (SA), Skin and soft tissue infection (SSTI), Pericarditis & UTI (Other), 
Primary bacteraemia(P .
 
Figure 4.14
B), Unknown  
: Distribution of the clini l d noses gr ps.
 
The number of MRSA and MSSA isolates for each diagnosis group is presented in 
Table 4.9. Septic arthritis (including osteomyelitis) (SA), infective endocarditis (IE) 
and other clinical diagnoses cases were excluded from further analysis as the numbers 
were too small for statistical analysis. No statistical significant association was found 
between the type of clinical diagnosis and MRSA/MSSA as the P-value was more 
than 0.05 (Figure 4.15). However, the highest number of strains was found in the 
catheter sepsis group for both MSSA and MRSA strains (Figure 4.15). 
 
Table 4.9
ca iag ou   
: MRSA and MSSA isolates compared to all clinical diagnoses in patients at 
Tygerberg hospital. 
 
  SSTI PN CSI PB Unknown SA IE Other Total 
MSSA 12 11 29 13 6 3 3 2 79 
MRSA 8 1 15 2 5 2 0 0 33 
  
Total 
  
20 
  
12 
  
44 
  
15 
  
11 
  
5 
  
3 
  
2 
  
112 
Other
2%
PN
11%
SA 
4% 
CSI
39%
Unknown 
10% 
PB 
13% 
SSTI
18% 
CSI 
IE 
Other
PN 
SA 
PB 
SSTI 
Unknown 
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Categorized Histogram: MRSA/MSSA vs Clinical Diagnosis 
Chi-square(df=4)=8.08, p=.08871
 
 
Figure 4.15: Comparison of MRSA and MSSA strains to the clinical diagnosis
patients at Tygerberg Hospital.  
 in 
ospital ired  i c r A  Health-care associated 
CA) is s ver  clinical diagnosis p ented  Table 4.10. Again, septic 
rthritis ( infec e e oc tis E nd ther ical diagnoses cases were 
xcluded urth nalysis as the num rs were too small for statistical analysis. 
he primary bacteraemia (PB) and unknown diagnosis group were also excluded from 
e analysis due to unknown source and uncertainty of clinical significance, 
respectively. Catheter sepsis was the most common clinical diagnosis associated with 
infections (P= 0.00003; Figure 4.16). HCA –strains were mostly isolated from chronic 
 
 
 
H acqu (HA), Commun ty a qui ed (C ) and
(H olate sus is res  in
a SA), tiv nd ardi  (I ) a  o clin
e from f er a be
T
th
hospital-acquired and health-care acquired strains compared to community-acquired 
renal failure patients on haemo- or peritoneal dialysis with catheter sepsis. CA strains 
were associated with pneumonia and skin and soft tissue infections (Figure 4.16). 
 
No of obs 
MSSA (n=71)
17% 
15% 
41% 
18%
8%
SSTI
PN 
CSI 
PB
Unknown
Clinical Diagnosis 
0
5
10
15
20
25
30
MRSA (n=31) 
35
26%
3%
48%
6% 
16% 
SSTI
PN
CSI
PB
Unknown 
Clinical Diagnosis 
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Table 4.10: The number of HA, CA and HCA isolates versus clinical diagnosis in 
atients at Tygerberg hospital. 
ed from 
analysis. 
Figure 4.16
p
 
 
 
 
 
 
 
  SSTI PN CSI SA IE Other Total
HA 16 6 23 3 0 2 50 
CA 2 6 0 2 3 0 13 
HCA 2 0 21 0 0 0 23 
  
Total 20 12 44 5 3 
  
2 
  
86 
 
Categorized Histogram: HCA/HA/CA vs Clinical Diagnosis
      Chi-square (df=8)=35.07, p=.00003
No of obs 
          HA (n=45)
36% 
13% 
51% 
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CSI 
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24 
Clinical Diagnosis
Strains due to primary bacteraemia (PB) and clinical diagnosis that were unknown were exclud
: Comparison of Health-care associated (HCA), Hospital acquired (HA) 
and Community acquired (CA) strains to the clinical diagnosis in patients at 
Tygerberg Hospital.  
 4.2.3.1 Analysis of spa types in cluster groups compared to clinical diagnosis 
 
Due to the diverse number of spa types in this study, no clear association could be 
d   ty in ti  a s r spa cluster 
groups compared to clinical diagnosis were analysed. Th mo  pred
b a in  cl er up was the  and pro et device - related sepsis 
(CSI) (Figure 4.17).  This is because of the high numb  
in this study (Table 4.11). No clear tr d w  observe e en cluster groups and 
c e  n
 
etermined for each spa pe  rela on to clinical di gno is. The efore, 
e st ominant source of 
acteraemi all ust gro s ca ter sth ic 
ers of CSI (44; 39%) detected
en as d b twe
linical diagnosis, probably due to th low umbers of strains in each cluster group. 
Clinical diagnosis of spa type clusters
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Cluster groups 5-7, singletons, excluded spa types and non-typeable strains were not analysed due to 
small numbers. 
Figure 4.17: Comparison of clinical diagnosis and spa type cluster groups.  
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 Table 4.11: Summary of the number of strains in each clinical diagnosis group, for 
the different cluster groups, as well as designation of singletons and excluded spa 
types by BURP analysis. N also included. on-typeable (NT) strains were 
Spa Clust CSI PB PN SSTI SA Unknown IE Other Total ers 
Clust 12 3 3 4 1 2 0 0 25er 1  
Clu 10 3 4 5 1 ster 2 2 1 0 26 
Clu 3 0 1 3 1 ster 3 1 0 1 10 
Clu 4 1 1 1 0 1 1 0  9 ster 4 
Clu 2 1 0 1 0 1 0 0 5 ster 5 
Clu 0 0 1 1 0  ster 6  1 0 0 3
Clu 0 1 1 0 0  0 0  ster 7  0 2
Sin 8 3 0 5 2 0  1 gletons  0  19 
Exc 2 0  0 0  0 0  0  0  luded   2 
NT 3 2 2 1 0 0  0    3 11 
Total 44 15 12 20 5 1 3 2 112 1  
 
Clust CC 701); Cluster 2 (spa-CC 012) ster 3 CC 002); C (sp ; 
Clust CC 174); Cluster 6 (spa-CC 345 ; Clus  founder le strains) 
 
4.2.3.2 Analysis of origin and clinical nosi PVL posi  stra  
 
f the 18 PVL positive strains (all MSSA), 5 were CA, 6 were HA and 4 were HCA. 
ot be determined with the remaining 3 strains due to unknown 
ia group (PB) and were not further analysed due to 
 
ith catheter sepsis (Figure 4.18). There were no fatal cases associated with infections 
appropriate treatment. One case of osteomyelitis was chronic with persistent positive 
cultures from the site of infection but C-reactive protein values decreased over time 
indicating clinical response. Of the spa types in the PVL positive strains, t891 was the 
most predominant (7 strains) (Figure 4.19).  
er 1 (spa- ; Clu  (spa- luster 4 a-CC 015)
er 5 (spa- /085) ter 7 (No ); NT (non-typeab
diag s of tive ins
O
HA/CA/HCA could n
source in the primary bacteraem
limited clinical data (Table 4.12). The majority of strains (6 isolates) were associated
w
(with known source) due to PVL-positive-strains. All patients recovered on 
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 Table 4.12: A summary of all PVL positive MSSA strains in comparison with clinical 
data and spa typing results 
PVL positive strains (All MSSA) 
Study # 
Clinical 
Diagnosis 
HCA/ 
HA/CA spa type 
Major/ 
Minor spa-CC 
TBH 3 SSTI CA t317  * Singleton 
TBH 8 CSI HA NT  *  # 
TBH 11 CSI HA t891 Major Singleton 
TBH 15 PN CA t433  * 012 
TBH 25 Urinary Tract Infection  HA t1597 Minor Singleton 
TBH 26.a CSI HCA t174 Minor 174 
TBH 30.d CSI HCA t891 Major Singleton 
TBH 39 PB  a t891 Major Singleton 
TBH 41 CSI HCA t891 Major Singleton 
TBH 51 CSI HA t409  * Singleton 
TBH 60 SSTI HCA t891 Major Singleton 
TBH 68 SA CA t891 Major Singleton 
TBH 73 SA CA t002 Major 002 
TBH 75 Pericarditis HA t311  * 002 
TBH 101 PN HA NT  *  # 
TBH 102 PN CA NT  *  # 
TBH 105 PB  a t891 Major Singleton 
TBH 109 PB  a t5471  * 174 
 
NT  Non-typeable strains 
*  <3 occurrences of spa type in study 
#  Non-typeable strains that were excluded from BURP analysis 
a  PB (primary bacteraemia) excluded from analysis for HA/HCA/CA category due to unknown source 
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Figure 4.18: Clinical diagnosis in PVL positive strains. 
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igure 4.19F : Illustration of spa types of all PVL positive and PVL negative strains. 
4.2.4 Analysis of spa cluster groups to determine the association with 
MRSA/MSSA and HA/HCA/CA categories. 
 strains in the different spa cluster groups were 
evaluated. Statistical significance was found in differences between the cluster groups 
(p = 0.00016, figure 4.20). The majority of the MRSA isolates were found in cluster 2 
(16 isolates, 53%) and cluster 1 (13 isolates, 43%) [Table 4.13]. The MSSA strains 
were more evenly distributed between clusters 1-4. Cluster 3 only contained MSSA 
strains. The association between HCA, HA, CA strains and spa cluster groups were 
also evaluated. Similar to the MRSA distribution, a high number of HA strains was 
found in clusters 1 and 2 (Table 4.14) No trend was found in HCA and CA strains 
(Figure 4.21).  
 
 
The numbers of MRSA and MSSA
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 Table 4.13: Summary of the number of MRSA and MSSA strains in different cluster 
groups, as well as MRSA/MSSA designation of singletons and excluded spa-types 
from BURP analysis. 
 
spa-C  701 C
 
ter 1 Clus
spa-C  012C  
 
 
 
 
 
 
 
 
ter 2Clus
spa-C  002C
 
ster 3Clu
spa- C 015C
 
ster 4Clu
spa- C 174C
 
uster 5Cl
13 MRSA  16 MRSA None 1 MRSA none 
12 MSSA SA SA SA SA 10 MS 10 MS 8 MS 5 MS
 
 
spa-CC  
Cluster 6 
No founder 
Cluster 7 
Singletons Excluded 
345/085 
  
  
No no None 1 ne ne MRSA 
3 MSSA A SA SA 2 MSS 19 MS 1 MS
 
 
Cluster groups 5 – 7, singletons and excluded spa type numbers were too small for statistical analysis. 
Figure 4.20
 
Chi-square(df=3)=20.06, p=.00016 
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43%
53%
3%
Cluster 1
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Cluster 3
spa-type Clusters 
Categorized Histogram: MRSA/MSSA x spa-type Clusters 
18
 
: Histogram of spa cluster groups 1 – 4 with the number of MSSA and 
MRSA strains in each group.  
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 Table 4.14: Summary of the number of hospital-acquired (HA), health-care 
ssociated (HCA) and community-acquired (CA) strains in all cluster groups, 
ingletons and excluded spa-types from BURP analysis.  
 
spa-CC 701 
 
Cluster 1 
spa-CC 012 
 
Cluster 2 
spa-CC 002 
 
Cluster 3 
spa-CC 015 
 
Cluster 4 
spa-CC 174 
 
Cluster 5 
a
s
14 HA 15 HA 3 HA 2 HA 1 HA 
4 HCA 4 HCA 3 HCA 3 HCA 2 HCA 
2 CA 2 CA 3 CA 2 CA 0 CA 
5 (NA) 5 (NA)  - 2 (NA) 2 (NA) 
spa-CC 
345/085 
 
Cluster 6 
No founder 
 
Cluster 7 
Singletons 
 
Excluded 
Spa types 
0 HA 1 HA 9 HA 0 HA 
0 HCA  0 HCA 5 HCA 2 HCA 
1 CA 0 CA 2 CA 0 CA 
2 (NA) 1 (NA) 3 (NA)  -  
 
uncertain clinical significance (unknown clinical diagnosis group). 
(NA) = not applicable, refers to strains excluded from the analysis due to unknown ource of 
bacteraemia (PB) or 
 s
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Cluster groups 5 – 7, singletons and excluded spa types were excluded as numbers are too low for 
statistical analysis. 
Figure 4.21: Histgram of number of HA/HCA/CA strains in spa cluster groups 1-4. 
 
 
4.2.5 Analysis of spa types to determine association with MRSA/MSSA and 
HA/HCA/CA categories 
 
In this study a diverse number of spa types were detected. Due to the low number of 
isolates for each spa type, no statistical significance could be determined for spa types 
in various categories. Therefore, only the most frequent spa types in this study were 
further evaluated in relation to MRSA/MSSA and HCA/HA/CA categories. Notably, 
the most frequent spa types for HA-MRSA strains were t037, t1257 & t021 (Table 
4.15). MSSA strains most frequently typed as t891 (also predominant PVL+ strain
infections 
(Table 4.15).  
 
 
type), t002, t015 & t1597. Furthermore, t1597 was a frequent spa type for HA-MSSA 
strains, whereas t891, t002 & t015 were isolated from HA, HCA & CA-
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 Table 4.15: Summary of trends observed with analysis of most frequent spa types for 
RSA/MSSA (phenotypic & genotypic data) and HA/HCA/CA (clinical data) M
categories.  
 
Categories Spa types 
HA-MRSA 
t037 (cluster 2) 
t1257 (cluster 1) 
t021 (cluster 2) 
HA-MSSA t1597 (singleton) 
HA/HCA/CA-MSSA 
t891 (PVL+; singleton)  
t002 (cluster 3) 
t015 (cluster 4) 
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Figure : Most frequent (major/minor) spa types of MRSA and MSSA strains. 
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 4.3 Persistent / Recurrent bacteraemia 
 
After strain typing, the results of 5 patients with repeat strains (refer to table 4.1) were 
analysed for persistent or recurrent bacte  achieved by comparing the 
spa type tr  the initial strain for each patien sistent 
m 3 d r r e
itiated. nt bacteraem as ned a the re rn of au eus 
ia after documenti ga bl ulture r c im e
 c of appropriate antibiotics (Chang et 2 3). 
ore, recurrent bacteraem subdivided into re-infection (different 
e e p in ).  The escriptive and c al ata 
ersistent and recurrent bacteraemia is presented in tables 4.16 to 4.18. No h-
s were detec  in any  s . 
 presented with a 
hospital-acquired skin infection with subsequent abscess formation (Table 4.16). Both 
the initial and the repeat blood culture isolate was identified as MRSA, typed as spa -
type t021 (spa CC 012) and were PVL negative. 
 
Relapse was identified in 2 patients (TBH 30, 26). Both of these patients had 
underlying chronic renal failure and received renal dialysis. Bacteraemia was due to 
catheter-related sepsis with MSSA (Table 4.17). Both patients initially responded 
after the dialysis catheters were removed, but in both cases patients were treated with 
vancomycin although cloxacillin was advised by the resident microbiologist. Spa 
types t015 (spa CC 015) and t253 (spa CC 012) was identified for the respective 
cases.  
 
Re-infection was noted in 4 patients, predominantly due to intravascular catheter 
infections (TBH 7, 26, 30, 110) (Table 4.18). The first blood culture isolate collected 
from TBH 7.a was a MSSA, whereas the second isolate (TBH 7.b) was a MRSA. The 
same pattern occurred for TBH 110.a and TBH 110.b. Both these patients were 
admitted to the burns unit. In patient 7 the initial MSSA bacteraemia was due to burn 
wound infection, and the subsequent bacteraemia due to catheter sepsis of the CVP. 
Patient 110 initially acquired CVP-sepsis, but the source for the subsequent 
raemia. This was
of the repeat s ain with t. Per
bacterae ia was defined as a positive blood culture ≥ ays afte  approp iate th rapy 
was in Recurre ia w defi s tu S. r
bacteraem ng a ne tive ood c  and/o linical prov ment 
after the completion of a ourse al., 00
Furtherm ia was spa 
strain typ s) and relapse (th  same s a stra  type  d linic  d
of p
GISA ted of these trains
 
Persistence was noted in patient TBH 40. This 7-day old infant
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 bacteraemia was unknown (categorized as primary bacteraemia). This patient had one 
temperature spike which resolv  intravascular catheter, but S. 
aureus was not cultured on the C o patients (TBH 26 & TBH 30) 
developed episodes of relapse (table 4.17) and re-infection (table 4.18) which occurs 
frequently in these chronic renal failure patients on dialysis due to invasive 
procedures (dialysis catheter) and frequent hospital exposure. Interestingly, these 
ed on removal of the
VP-tip. The other tw
HCA-infections were due to MSSA-strains.  
 
 
Table 4.16: Descriptive data of S. aureus strain and clinical data for the one persistent 
bacteraemia case 
PERSISTENT 
Study # 
Time apart from 
previous strain 
MRSA/ 
MSSA PVL spa-type Gender Age 
Clin.  
Diag HIV  
HCA/ 
HA/CA
TBH 40.a 
TBH 40.b 
 - 
9 days 
MRSA 
MRSA 
neg. 
neg. 
t021 
t021 
Male 7days SSTI Unknow
    SSTI 
n 
  
HA 
  
 
 
Table 4.17: Cases of recurrent bacteraemia due to relapse - descriptive and clinical 
data 
 
RELAPSE 
Stud
HCA/ 
HA/CAy # 
Time apart from 
previous strain 
MRSA/ 
MSSA PVL spa-type Gender Age 
Clin. 
Diag HIV  
TBH 30.a 
TBH 30.b  
TBH 30.c 
 - 
2 months & 12days 
1 month & 23 days 
MSSA 
MSSA 
MSSA 
neg. 
neg. 
neg. 
t015 
t015 
t015 
Male  
  
  
20 yrs 
  
  
CSI 
CSI 
CSI 
Negativ
  
  
e HCA 
HCA 
HCA 
TBH 26.b e HCA 
HCA TBH 26.c 
3 months & 13days 
1 month & 28 days 
MSSA 
MSSA 
neg. 
neg. 
t253 
t253 
Male  
  
36 yrs 
  
CSI 
CSI 
Negativ
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 Table 4.18: Cases of recurrent bacteraemia due to re-infection - descriptive and 
clinical data 
 
RE-INFECTION 
Study # 
Time apart from 
previous strain 
MRSA/ 
MSSA PVL spa-type Gender Age 
Clin. 
Diag HIV  
HCA/ 
HA/CA
TBH 7.a  HA 
HA TBH 7.b 
 - 
1 month 
MSSA 
MRSA 
neg. 
neg. 
t002 
t037 
Male 
  
37 yrs 
  
SSTI 
CSI 
Unknown
  
TBH 26.a 
TBH 26.b 
 - 
3 months & 13days 
MSSA 
MSSA 
pos. 
neg. 
t174 
t253 
Male 
  
36 yrs 
  
CSI 
CSI 
Negativ
  
e HCA 
HCA 
TBH 30.c 
TBH 30.d 
1 months & 23days 
4 months & 27days 
3 months & 7 days 
MSSA 
MSSA 
MSSA 
neg. 
pos. 
neg. 
t015 
t891 
t012 
Male 
  
  
20 yrs 
  
  
CSI 
CSI 
CSI 
Negativ
  
  TBH 30.e 
e HCA 
HCA 
HCA 
TBH 
110.a 
TBH 
 - 
 
MSSA neg. t1476 Male 35 yrs 
 
CSI Unknow
110.b 12 days 
 
MRSA 
 
neg. 
 
t037 
   
PB 
n 
 
 
HA 
 
- 
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 CHAPTER FIVE 
 
In the first part of this study, a multiplex PCR was performed on staphylococcal 
oses. 
5 DISCUSSION 
(MRSA/MSSA) isolates to determine the presence of the mecA and pvl genes, as well 
as to strain type these isolates using spa typing. Clonal cluster complexes were 
determined by the BURP algorithm installed in Ridom StaphType software program, 
where spa-types were compared to international important clones. The genotypic 
profiles of staphylococcal isolates were then further analysed in context of the clinical 
data (clinical diagnosis and HA/HCA/CA categories) for epidemiological purp
Lastly, persistent and recurrent bacteraemia cases were analysed for possible 
association to organism related factors at our hospital. 
 
5.1 Analysis of descriptive data 
5.1.1 Phenotypic characteristics of strains 
Phenotypically, a high prevalence rate of MRSA (30%) at Tygerberg Hospital was 
reported in this study. S. aureus methicillin susceptible strains amounted to 69.9%. In 
hospitals, high prevalence rates of MRSA have been found to be associated with 
increased patient mortality and higher healthcare costs (Deurenberg et al., 2007). In 
Europe, the MRSA prevalence rates vary, as the Netherlands and Scandinavian 
countries present with lower MRSA rates (0.6%) compared to other European 
countries (up to 44.7%). Low prevalence rates (0.6%) were due to a low antibiotic 
selection pressure and screening of ‘high risk’ patients in hospitals for MRSA before 
or at the time of admission (Tiemersma et al., 2004). In order to decrease high 
prevalence MRSA rates in nosocomial settings, more effective disinfection 
procedures and hand hygiene guidelines could perhaps reduce the spread of MRSA. 
Furthermore, only one MRSA isolate (TBH 107) was reported with heteroresistance 
to glycopeptides (h-GISA) in this present study.  
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 5.1.2 Patient demographics 
The distribution of gender was fairly equal in this study with 51% females and 49% 
males. Thirty-eight percent of staphylococcal isolates were found in paediatric 
patients, 26% were less than a year old and 12% were between the ages 1 to 13 
(Figure 4.1). Generally, infants and the elderly are more prone to infections than other 
develop skin infections within a few days 
fter birth, for example skin infection of the umbilicus or at intravascular catheter 
009). 
age groups. In the current study, the proportion of paediatric patients (38%) was 
predominantly higher than the elderly group (11%). This may be due to colonisation 
of S. aureus in the nose and skin, which can occur in newborn babies through 
transmission from their nursing mothers. Staphylococcal strains could spread around 
the newborn babies’ nursery if healthcare workers become colonized. Thus, this leads 
to the babies becoming colonized and may 
a
sites (Tinelli et al., 2
CA-MRSA infections have been reported from predominantly young and healthy 
individuals in community settings such as sports facilities, the military and prisons. 
On the other hand, HA-MRSA has been associated with immunocompromised 
patients in hospital settings (Jappe et al., 2008). As no CA-MRSA was detected in the 
current study, the association between HA-MRSA versus CA-MRSA could not be 
analysed. 
MRSA colonization could occur due to previous exposure to antibiotics, prolonged 
duration of antimicrobial therapy, hospitalization in an intensive care or burns unit, 
severe underlying illness, invasive procedures, surgical wounds or burns and contact 
with patients colonized with MRSA (Boyce et al., 1981; Boyce et al., 1983; Crossley 
et al., 1979; Deurenberg et al., 2007; Jernigan et al., 1996; Peacock et al., 1980; Ward 
et al., 1981). In the present study, the ward with the highest percentage of MRSA 
isolates compared to MSSA was seen in the surgical ICU when compared to the burns 
and renal unit (44%; 4/9). The wards with the highest number of S. aureus isolates 
were the burns unit (12 isolates), renal unit (11 isolates) and the surgical ICU (9 
isolates). After categorising the wards into ward groups, the paediatric ward group 
had the highest number of MRSA isolates. These were due to intravascular catheter-
related sepsis in the majority of cases.  
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 5.2 Genotypic characteristics of strains in relation to Clinical data 
The following section will include a discussion on the mecA, pvl and spa genes. Each 
of these sub-sections will feature the results obtained using the clinical data (section 
4.2) that is applicable to each gene. 
5.2.1 The mecA gene 
The phenotypic detection of methicillin resistance correlated very well with the 
genotypic detection of the mecA gene using the multiplex PCR method. Only one 
discrepancy was found amongst the mecA gene results (Table 4.3). Isolate, TBH 43 
was phenotypically reported as MRSA, but no mecA gene was detected in this strain. 
lan et al., 2005). It has also been proven that some 
CA-MRSA strains are closely related directly or indirectly to the health-care setting 
Upon re-testing this strain tested sensitive to methicillin. This could have arisen due to 
initial incorrect readings in the laboratory or because of an initial mixed culture. 
S. aureus is an important cause of hospital-acquired (HA), health-care associated 
(HCA) and community acquired (CA) infections. CA-MRSA has rapidly emerged in 
many communities, but has also been reported to spread to hospitals causing hospital 
outbreaks (Regev-Yochay et al., 2005). In the USA, at Texas children hospital, 
figures as high as 70% for CA-MRSA isolates have been reported from 2001 to 2004 
(Kaplan et al., 2005). The rate of increase in CA-MRSA isolates was significantly 
higher compared to an insignificant increase of CA-MSSA isolates in the study 
(Kaplan et al., 2005). In 2001, the percentage of community-acquired S. aureus 
isolates that were methicillin resistant was 71.5% (551/771) and increased to 76.4% 
(1193/1562) in 2004 (p=.008) (Kap
(Aires-de-Sousa & de Lencastre, 2003). Characteristically, the PVL gene is associated 
with CA-MRSA infections, primarily with skin and soft tissue infections and 
necrotizing pneumonia. These associations are further discussed in section 5.2.2 (The 
PVL gene). The prevalence rate of HA-MRSA infections differs among various 
countries. In Israel, S. aureus bloodstream isolates that were HA-MRSA were 
reported as 44% according to the European antimicrobial resistance surveillance 
system (EARSS) (Chmelnitsky et al., 2008). In the present study, the clinical data of 
study patients were analysed to determine the occurrence of CA-MRSA infections at 
Tygerberg Hospital. No CA-MRSA was detected compared to 22% of MSSA isolates 
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 that were CA-MSSA (Figure 4.13). This finding was found to be highly significant (p 
= 0.00009, Figure 4.13). Furthermore, 88% of MRSA were HA-infections and 12% 
HCA-infections. MSSA was also most commonly isolated in the hospital-setting 
(45%) and health-care associated setting (33%) (Section 4.2.2: Analysis of 
MRSA/MSSA to determine the association with HA/HCA/CA categories).  
The majority of bacteraemia cases were related to catheter sepsis (CSI) for both 
MRSA (48%) and MSSA (41%) strains. The second commonest source for 
bacteraemia was skin and soft tissue infections (SSTI) (Figure 4.15). No clear trends 
ristan et al., 2009). However, even though CA-MRSA infections are of great 
were observed between MRSA and MSSA strains in relation to clinical diagnosis as 
numbers were relatively low (Section 4.2.3: Source of staphylococcal bloodstream 
infections according to clinical diagnosis).  
 
5.2.2 The pvl gene 
PVL positive MSSA strains were detected in 15.9% (18/113) of the total number of S. 
aureus strains in this study. These PVL-positive strains were all MSSA, constituting 
22.7% (18/79) of total number of MSSA strains. The number of PVL negative strains 
amounted to 95/113 (84%). All patients with PVL positive MSSA in this study were 
HIV negative (Section 4.2.1: HIV status and staphylococcal bacteraemia in this 
patient group).  
It has been reported that PVL is more commonly found in MRSA isolates than in 
MSSA isolates, specifically amongst CA-MRSA strains (Aires-de-Sousa et al., 2006; 
T
concern, MSSA infections may present with the same epidemiological and clinical 
characteristics (Miller et al., 2007; Mongkolrattanothai et al., 2003). Thus, PVL genes 
are not only found in MRSA isolates (Kim, 2009; Tinelli et al., 2009). This is not only 
a recent finding, as historical MSSA isolates that carried the PVL genes, were 
pandemic in the 1950’s and 1960’s. These strains include the “Oxford 
Staphylococcus” and the phage type 80/81 (Kearns et al., 2006; Robinson et al., 
2005). Our findings correlate with these observations, as only MSSA isolates were 
found harboring the PVL gene (Table 4.11). Moreover, no CA-MRSA infections were 
detected in our study (Figure 4.13). It was found that only 5/18 (28%) PVL positive 
MSSA isolates caused community-acquired infections in our study (CA-MSSA) 
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 (Table 4.11). These included two cases of pneumonia, two septic arthritis cases and 
one skin and soft tissue infection. On the other hand, 6/18 (33%) PVL positive MSSA 
olates caused hospital-acquired infection and 4/18 (22%) HCA infection, mainly 
lli et al., 2009). The PVL positive MSSA 
in was identified as spa type t005 and sequence type ST22. This clone (ST22) is 
esistance background or, on the contrary, by 
e acquisition of a SCCmec element of strains that were PVL positive (Strommenger 
is
intravascular catheter-related sepsis (sections 4.2.3 and 4.2.5). A study conducted by 
Perez-Vazquez et al (2009), detected PVL genes in 42/203 (20.7%) S. aureus blood 
culture isolates from 21 Spanish hospitals. PVL positive strains were detected in 
41/113 MSSA isolates and in only one MRSA isolate (1/90 of all MRSA). In contrast 
to our study, a high percentage of 48.8% (20/41) PVL positive MSSA isolates were 
found in the community and 36.6% (15/41) of the isolates were found in the hospital 
setting (details of 6 isolates were not available) (Pérez-Vázquez et al., 2009). 
Results of a study performed in Northern Italy showed that a PVL positive MSSA 
strain associated with prolonged community and hospital outbreaks of skin infections 
closely resembled a CA-MRSA strain (Tine
stra
related to one of the predominant MRSA clones spreading in hospitals in the United 
Kingdom, namely EMRSA-15 (Johnson et al., 2001). Both MRSA and MSSA 
isolates, as well as PVL genes can be found in clonal group ST22 (Enright et al., 
2002). ST22-IV is also found carrying SCCmec type IV and is emerging in Portugal 
and Australia, with rare findings in the United States (Tinelli et al., 2009). It was 
suggested that the MSSA clone (ST22) found in Northern Italy, could correspond to 
the ancestor of a hospital MRSA clone, or, less likely, to have been derived from a 
hospital MRSA clone with deletion of the SCCmec  gene, in order to emerge into a 
MSSA clone (Tinelli et al., 2009). 
It is uncertain whether PVL positive CA-MRSA clones were acquired through the 
PVL phage by strains with a methicillin r
th
et al., 2008b; Tristan et al., 2007). CA-MRSA can be differentiated from HA-MRSA 
in that these strains retain susceptibility to non-beta-lactam antibiotics and are 
associated with SCCmec type IV (Miller et al., 2005; Vandenesch et al., 2003). 
However, these distinctions are conflicting to the evidence that suggest that hospital 
and community acquired MRSA strains share a common ancestor (Robinson et al., 
2005). Goering et al (2008) reported a study on the molecular characterization of S. 
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 aureus isolates, acquired from uncomplicated skin infections from 10 different 
countries, during five phase III global clinical trials of retapamulin, a recent topical 
antibiotic agent. The most common PVL-positive MRSA clone was isolated in the 
United States, with a SCCmec type IV, multilocus sequence type 8 and a pulsed-field 
type USA300. Interestingly, the most common PVL-positive MSSA clone was found 
in South Africa and the Russian Federation with a multilocus sequence type 121 and 
pulsed-field type USA1200. In addition, PVL positive MSSA isolates from South 
Africa and India displayed pulsed field types related to EMRSA-15. 
In another study by Campbell et al (2008), the genotypic differences between strains 
from different geographic regions is illustrated. A collection of S. aureus strains 
collected for an international clinical trial (FAST II) evaluating telavancin for 
treatment of complicated skin and skin structure infections was analyzed. The trial 
included 99 S. aureus isolates from 11 sites in the United States (56 isolates) and 7 
sites in South Africa (34 isolates). No MRSA were collected from South African 
 
et al (1999) suggested that necrotizing pneumonia and primary skin and soft 
isolates, whereas more than three-quarters of the U.S isolates were MRSA. 
Genotyping consisted of SCCmec, agr and PFGE to determine the presence of 31 
virulence genes. Briefly, results from South Africa showed that it’s more common for 
MSSA isolates to carry certain virulence genes which include sdrD (p=0.01), sea 
(p<0.01) and pvl (p=0.01). In contrast, MRSA isolates from the United States more 
frequently carried these virulence genes than MSSA isolates. Furthermore, PFGE 
patterns of South African and U.S isolates were distinctively different. The outcome 
was that virulence genes are distributed differently within various geographic regions. 
 
Lina 
tissue disease are associated with S. aureus strains producing PVL toxin. They did not 
detect PVL-producing S. aureus strains in infective endocarditis, mediastinitis, 
urinary tract infections or enterocolitis infections (Lina et al., 1999). Similarly, 
Holmes et al (2005) did not detect invasive infections, such as endocarditis and 
osteomyelitis, nor toxic shock syndrome or food poisoning associated with S. aureus 
isolates harbouring PVL. Furthermore, a high prevalence of PVL positive strains 
(38.9%) associated with arthritis and skin abscess were detected by (Melles et al., 
2006). A relationship was found between skin and soft tissue infections and PVL 
isolates, but not for bacteraemia (Melles et al., 2006). This suggests that 
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 staphylococcal bacteraemia is not a common factor of PVL-positive strains, which is 
in agreement to a study by (Johnsson et al., 2004).  
 
Moreover, Ellington et al (2007) detected a very low incidence of 1.6% (4/244) PVL 
positive MSSA strains, with no PVL positive MRSA from 244 bacteraemic patients 
from the UK and Ireland. The source for bacteraemia in these four patients included 
skin and soft tissue infection, indwelling line-related sepsis, surgical site infection and 
one unknown source. In another study, Holmes et al (2005) noted S. aureus 
bacteraemia in 2% of all PVL positive strains in England and Wales. It was also found 
that CA-MRSA strains in patients presenting with pneumonia, did not develop an 
portant 
teraemia (Ellington et al., 2007). Studies have noted that the most 
likely reservoir of PVL-positive strains are found in skin infections (Holmes et al., 
 most predominant, followed by 
o PVL-positive isolates. The incidence of 
staphylococcal bacteraemia due to PVL-positive stains was also higher (15.9%) 
associated bacteraemia (Etienne, 2005). On the contrary, Seybold et al (2006) 
detected up to 20% bloodstream infections that were due to the PVL positive CA-
MRSA strain, USA300. This clone is currently not prevalent in the UK or in Europe, 
as only isolated cases are being found.  
 
Due to the low incidence rates of PVL in S. aureus bacteraemia, it has been suggested 
that a complex combination of host and/or pathogen related factors play an im
role in S. aureus bac
2005; Lina et al., 1999). Holmes et al (2005) detected 8/515 (1.6%) PVL positive S. 
aureus isolates from various sites of infection from patients in the UK. Skin and soft 
tissue infections (especially abscesses) were the
community acquired pneumonia, burn wound infections, bacteraemia and scalded skin 
syndrome. Of the PVL positive MSSA strains, most belonged to sequence types ST22 
and ST30, which is associated with the most prevalent MRSA clones in the United 
Kingdom, EMRSA-15 and EMRSA-16.  
 
Overall, our findings are in agreement with these published reports. PVL positive CA-
MSSA strains were associated with pneumonia, soft tissue infections and septic 
arthritis (Table 4.10). However, in our study catheter sepsis was more common in 
HA-infections and HCA-infections due t
compared to the UK study (1.6%, Ellington study) and more in line with the incidence 
of 20% reported in the American study (Seybold et al., 2006). 
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 Of the six major spa types detected in this study (Table 4.5), all seven isolates of spa 
type t891 (singleton) and one isolate from spa type t002 (spa-CC 002) were positive 
for PVL. Other major spa types were all negative for PVL. Of the remaining PVL 
positive strains, spa types t311 (spa-CC 002), t433 (spa-CC 012) and three other 
singletons (t317, t1597, t409) were detected. From spa-CC 174, spa types t174 and 
t5471 (novel type) were also PVL positive as well as three non-typeable S. aureus 
strains (Table 4.10). It was noted that the strains of six spa types (t891, t311, t317, 
t409, t433, t5471) were all PVL positive (Figure 4.18). This may indicate that the 
PVL positive strains in our study are associated with certain spa types. However, as 
e MSSA strains in our study was low, this cannot be 
VL-converting phages 
(Holmes et al., 2005). This was noted in a study by Narita et al (2001), where only 
ere infected with the temperate phage 
SLT, thus converting into a PVL positive S. aureus strain. It has also been reported 
 positive S. aureus rates 
r colonizing and blood culture isolates (von Eiff et al., 2004). On the other hand, a 
er studies in which high rates 
the number of PVL positiv
concluded (Section 4.2.5). A Spanish study by Pérez-Vázquez et al (2009), also 
observed a broad distribution of spa clonal complexes and singletons for MSSA that 
were PVL positive. Of the PVL positive MSSA strains found in their study, only spa 
types t002 and t311, belonging to spa-CC 002, were also detected in our study. 
 
As only a low number of S. aureus strains are PVL-positive, it has been suggested that 
only a few S. aureus strains are susceptible to infection with P
3% of clinical PVL negative S. aureus strains w
φ
that various S. aureus strains harbor various PVL-carrying phages (Kaneko et al., 
1997; Kaneko et al., 1998; Narita et al., 2001; Zou et al., 2000). Nonetheless, it is 
unclear whether these phages are able to infect PVL negative strains, leading to the 
expression of PVL toxin (Holmes et al., 2005). 
 
A few studies from European countries report a low prevalence of PVL positive S. 
aureus infections. In the Netherlands, the PVL gene was identified in 0.6% (5/829) of 
colonizing MSSA strains and in 2.1% (3/146) of blood culture isolates (Melles et al., 
2006). Another study from Germany also reported low PVL
fo
study from Spain reports a high prevalence rate (36.4%) of invasive PVL positive S. 
aureus infections (Pérez-Vázquez et al., 2009). The authors stated that the prevalence 
of PVL positive MSSA infections were increasing rapidly in Spain, since the 
prevalence was 1.6% in 2006 (Cuevas et al., 2006). Oth
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 of PVL were detected include a study from Argentina where 61.3% (19/31) of MSSA 
 this study, 49 different spa types were identified in 89.3% (101/113) of 
ese eight isolates were 
assigned as protein A negative strains. Guzman et al (1992) identified 5% (10/196) of 
their S. aureus strains as protein A negative. Interestingly, it was also found that two 
organisms namely, S. hyicus and S. intermedius, yielded negative results (Guzman et 
al., 1992). These organisms were misidentified as S. aureus as they also produced 
staphylocoagulase (Guzman et al., 1992). 
Therefore, there are various reasons for absence of the spa gene. This could be due to 
either isolates not being S. aureus, or due to the fact that these strains are protein A 
isolates produced PVL (Sola et al., 2007) and from the Cape Verde region, 35% of 
nosocomial MSSA isolates were PVL positive (Aires-de-Sousa et al., 2006). A study 
conducted in Singapore presented with a high incidence of MRSA (43%) with no 
PVL detection in these MRSA strains (Hsu et al., 2005). Of all the S. aureus strains, 
PVL was found in 11.6% MSSA strains only. The majority of the MSSA strains 
(27.2%) were detected in skin and soft tissue infections (Hsu et al., 2005). These 
findings were similar to our current study, as PVL positive strains were only detected 
in MSSA and not in MRSA strains (Table 4.11). 
In summary, infections caused by PVL positive MSSA isolates have been reported 
since the 1930’s (Melles et al., 2006). However there has been a vast increase in these 
infections from certain geographic areas, particularly Spain and Argentina. PVL-
positive CA-MRSA has emerged in the United States, but this USA300 strain, is still 
rare elsewhere. PVL is found predominantly in MSSA strains in our setting. Further 
epidemiological studies are required to monitor if infections associated with these 
strains are increasing and to monitor for the emergence of CA-MRSA. 
5.2.3 The spa gene 
In
staphylococcal isolates. Non-typeable strains that failed to yield the spa gene 
constituted 9.7% (11/113) of the strain collection.  
A study conducted by Larsen et al (2008) revealed 9/759 (1.2%) isolates that failed to 
yield the spa gene. These isolates were identified as S. aureus by coagulase tests and 
PCR detection of the nuc and femA gene. Similarly, a study by Forsgren (1970) 
identified 8/700 (1.2%) isolates lacking the spa gene. Th
 106
 negative. To confirm that these isolates are indeed S. aureus strains, PCR should be 
erformed for the detection of either the nuc or femA genes (Fenner et al., 2008; 
r femA genes.  
ine various clonal cluster complexes in this study. In the 
llowing section, spa types within each spa-CC and its association to important 
3 were only identified in South 
frica thus far. All the remaining spa types in this clonal complex are geographically 
distributed in various parts of the world (Appendix D).  
p
Larsen et al., 2008). The reason is that phenotypic tests alone is not sufficient to 
identify these non-typeable isolates, as various studies have found that up to 10% of S. 
aureus strains lacking protein A (Forsgren, 1970; Kronvall et al., 1971; Lindmark et 
al., 1977; Maxim et al., 1976; Winbald & Ericson, 1973). In our study, these strains 
were only re-tested phenotypically (refer to section 3.2) and not confirmed 
genotypically via PCR detection of the nuc o
5.2.4 Spa Typing 
Spa typing, a PCR and DNA sequencing based technique, was performed to compare 
the spa types with profiles of international important clones. Furthermore, the BURP 
(Based Upon Repeat Patterns) algorithm installed in the Ridom StaphType software 
program, was used to determ
fo
clones from various countries will be discussed. In addition, the relevant genotypic 
and clinical data correlated to each spa-CC will be discussed.  
5.2.4.1 Spa-Clonal Complex 701 (Cluster 1) 
 
The most frequent (major) spa type observed in spa-CC 701 was t1257, followed by 
minor types t1443, t701, t451 and t064. These spa types were associated with hospital 
or health-care associated infections. As mentioned previously, t1257 was one of the 
major HA-MRSA strain types in our study (Table 4.14), whereas t1443 was detected 
in both MRSA and MSSA hospital acquired strains. Spa type t701 was only found in 
HA and HCA- MSSA strains and t064 in MRSA and MSSA hospital acquired and 
health-care associated strains. Spa-CC 701 (Cluster 1) and Spa-CC 012 (cluster 2) 
contained the majority of MRSA strains (96.6%) [Figure 4.19]. Cluster 1 also 
contained 30% (12 isolates) of MSSA strains (Figure 4.19).  
 
From spa-CC 701, three novel spa types (t5472, t5473, t5474) were detected from 
Tygerberg Hospital. Also, spa types, t2360 and t144
A
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A recent South African study identified t037 as the most prevalent spa type, followed 
by t012 as the second most prevalent (Oosthuysen et al., 2007). In the present study, 
spa type t037 was the most prevalent, whereas t012 was a minor spa type. Oosthuysen 
et al (2007) identified spa type t064 as the third most prevalent type in 20.3% of S. 
aureus isolates from all provinces, which belonged to SCCmec type I-pls (Oosthuysen 
et al., 2007). In contrast, the present study identified spa type t1257 (spa-CC 701) in 
6% (6/101) of the isolates, being the third most prevalent spa type at Tygerberg 
Hospital, whereas t064 was a minor spa type in our study (Table 4.5).   
 
Oosthuysen et al (2007), also found spa type t1257 in 8.9% of their isolates. Besides 
South Africa, spa type t1257 has also been detected in Denmark, Germany and 
Norway (Appendix D). Interestingly, all five strains of the HIV positive patients in 
this study were identified as spa-CC 701. Three of the spa types were t1257, one 
t1476 and one t064. All of these spa types were hospital-acquired MRSA strains, 
except for t1476. It has been previously reported that spa type t064 has been 
associated with persons living with AIDS (Gordan et al., 2005). However, to our 
knowledge, no studies have reported HIV in association with spa types t1257 and 
476.  t1
 
Chmelnitsky et al (2008) identified spa type t064, possessing SCCmec type IVc and 
PFGE clone G. Also, spa type t064 was designated ST8 ORSA I in the USA. Shittu et 
al (2009) identified spa type t064 with different sequence types ST1173/SCCmec IV 
and ST1338/SCCmec IV. Multilocus sequence types ST1173 and ST1338 are single-
locus and double-locus variants of ST8. The clone ST8 has been previously reported 
in Europe, Australia and North America (Shittu et al., 2009). 
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 5.2.4.2 Spa-Clonal Complex 012 (Cluster 2) 
 
In the present study, t037 (major), t021 (major) and t012 (minor) were the most 
frequent spa types observed in spa-CC 012. These types were associated with hospital 
and healthcare associated infections. The majority of MRSA isolates (16; 53%) were 
detected in spa-CC 012 (Cluster 2) (Figure 4.19). Ten (25%) of MSSA strains were 
also detected in this cluster group (Figure 4.19). Spa type t037 was also the most 
frequent spa type in this study (9/101, 9%). 
 
Spa type t433 was revealed as the only PVL positive MSSA strain in this cluster 
group (Figure 4.18). To our knowledge, no studies have detected an association 
between PVL and spa type t433. Spa type t1848 was only identified in South Africa 
types in this cluster group were found 
orldwide (Appendix D).  
plex by BURP analysis, even though they belonged to 
plexes by MLST, CC8 and CC30, respectively. This has been 
and France (Appendix D). All the other spa 
w
 
Studies have reported that divergent spa types t037 and t030 were found in MRSA 
isolates of ST239 (CC8), clustering with spa types t012 and t018, which is associated 
with spa-CC 012 (corresponds to MLST CC30) (Koreen et al., 2004; Malachowa et 
al., 2005; Strommenger et al., 2006). It was shown that these isolates were all grouped 
together in one clonal com
different clonal com
described previously by chromosomal DNA replacement in the MRSA isolates of 
CC8 with a large genetic element originating from CC30, which included the spa 
gene (Robinson & Enright, 2004). Similarly, a South African study found that 95% of 
strains were associated with a single SCCmec type within a spa-CC  (Oosthuysen et 
al., 2007). However, this was not the case in spa-CC 012, as the clonal complex was 
associated to both the Brazilian/Hungarian clone (n=79; spa type t037; SCCmec type 
III) and EMRSA-16 (prevalent MRSA clone in UK), or a single-locus variant (SLV) 
thereof (n=80; spa types t018/t012; SCCmec type II). We suggest that the same 
phenomenon occurred in the present study, as spa types t012, t018, t037 and t030 
were all grouped into spa-CC 012 (Figure 4.5). Nonetheless, SCCmec typing and 
MLST should be performed in order to confirm this.  
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 Spa type t037 has been reported from the United States in MRSA isolates of lineages 
ST8 and ST239 (Koreen et al., 2004). The Brazilian/Hungarian clone with SCCmec 
type III and ST 239 was identified in spa types t037 and t030 (Deurenberg et al., 
007). Fenner et al (2008) found that spa type t030 corresponded to hospital acquired 
imilarly, a South African study from hospitals in the KwaZulu-Natal province, 
7), indicating that 
pa type t037 is rapidly circulating throughout various provinces in South Africa. 
strains, containing the lukS-lukF determinant for PVL, in the 1960’s and 1980’s 
2
MRSA strains. In contrast, our study detected two isolates from spa type t030 that 
were hospital acquired MSSA strains. Spa types t030 and t037 was also detected in 
Germany and other parts of Europe in a study by von Eiff et al (2004). Khandavilli et 
al (2009) detected both spa types t012 and t018 as EMRSA-16 (ST 36), with the 
majority of strains (92%) from spa type t018 (Khandavilli et al., 2009).  
 
A recent study conducted from all cities in China, identified spa type t030 as the most 
predominant type (Liu et al., 2009). The spa type was detected in 52% of the isolates, 
with PFGE types A to E. Spa type t037 was established as the second most common 
type, constituting 25% of all isolates, with PFGE types F to G. Both spa types t030 
and t037 were designated PFGE types A to K when associated with ST239, belonging 
to CC239 (distinct branch within CC8). The Brazilian/Hungarian (ST239; SCCmec 
type III) and the New York/Japan (ST5; SCCmec type II) clones were found to be the 
most dominant in Asia (Liu et al., 2009). 
 
S
revealed spa type t037 as the second most common type (Shittu et al., 2009). The spa 
type was designated as a Brazilian/Hungarian clone with ST239, SCCmec type III and 
PFGE type F. This clone has been widely distributed throughout Brazilian hospitals 
(Teixeira et al., 1995), countries in South America (Corso et al., 1998), Europe 
(Aires-de-Sousa et al., 1998) and Asia (Feil et al., 2008; Liu et al., 2009). 
Furthermore, Smyth et al (2008) reported the geographical stratification of the 
Brazilian/Hungarian clone. According to our present study, spa type t037 was 
identified as the most predominant type at Tygerberg Hospital. This spa type was only 
found in MRSA strains in hospital and health-care associated infections (Figure 4.21 
and 4.22). This corresponds with a study by Oosthuysen et al (200
s
 
Spa type t021 has been previously identified as a major hospital pathogen in MSSA 
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 (Parker et al., 1974). However, of the PVL positive MSSA strains in this present 
study, spa type t021 was not found (Table 4.18). All strains from spa type t021 were 
HA-MRSA. In a recent study, the spa type t021 was identified in MRSA and MSSA 
isolates containing tst but not the lukS-lukF determinant for PVL (Strommenger et al., 
found in MSSA isolates of MLST 
 the United States and Poland (Koreen et al., 2004; Koreen et al., 2005; 
PVL-positive strain were also detected. Other types detected in this cluster included 
 all MSSA (25% of MSSA strains in 
ent type amongst isolates 
 Israel (Chmelnitsky et al., 2008). PFGE clones (B, D, H, J and K) with SCCmec 
positive strains were also detected in spa type t002 
2006). Spa types t012, t018 and t021 are commonly 
CC30 from
Malachowa et al., 2005). These three spa types were also found in Australian and 
South American isolates, designated ST30 (Deurenberg et al., 2007). ST30 was also 
discovered as a major clone in Asia and Oceania, which was referred to as the South 
West Pacific Clone (Tristan et al., 2007). Spa types t012 and t021 were also reported 
from a University hospital, Switzerland in a study conducted by Fenner et al (2008).  
5.2.4.3 Spa-Clonal Complex 002 (Cluster 3) 
 
In the present study, t002 was the major spa type observed in spa-CC 002 and the 
fourth most prevalent type (6/101, 6%). This spa type was found predominantly in 
PVL-negative CA-MSSA strains, but HA-MSSA and HCA-MSSA strains and one 
t045, t214, t306 and t311. These strains were
study) [figure 4.19]. 
 
Spa type t045 and t002 was detected in Germany and central Europe in a study 
(Strommenger et al., 2006). Previous studies have reported that t002 clustered with 
t045 in MRSA isolates of lineage ST5 from Central Europe, Japan, South Korea and 
the United States (Chmelnitsky et al., 2008; Harmsen et al., 2003; Koreen et al., 
2004; Koreen et al., 2005). Spa type t002 was the most frequ
in
types II or V, was identified within spa type t002. PFGE clone H exhibited SCCmec 
type IIIA variant which has been reported to exhibit amplicons of loci E and F in 
Taiwan (Lu et al., 2005). Moreover, spa types t002 and t045 has been found in the 
Paediatric clone (SCCmec IV; ST5) and in the UK EMRSA-3 (SCCmec I; ST5) strain 
(Deurenberg et al., 2007). In 2005, a PVL positive MRSA strain with ST5 (spa type 
t002) was described in an outbreak among members of a football team from Slovenia 
(Muller-Premru et al., 2005). PVL 
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 in southern Germany (Fenner et al., 2008). Liu et al (2009) found spa type t002 with 
PFGE types L to T and ST5 (CC5) to be the third most prevalent type in cities among 
mec IV). As mentioned in previous 
 Kenya were found to be the closest relatives of MRSA from South Africa 
(Shittu et al., 2009). These observations indicate that MSSA clones are distributed 
resistant through multiple independent imports of 
, 2009). Forty one PVL positive 
MSSA strains were identified, including spa types t002 and t311 (spa-CC 002) 
). In our study, one t002 and one t311 strain from this 
China.  
 
A study conducted in the KwaZulu Natal province, South Africa, found spa type t045 
(MRSA) to be the third major clone presenting with ST5, PFGE type G and SCCmec 
type III (Shittu et al., 2009). This clone is similar to the New York/Japan clone (ST5; 
SCCmec II) and the Paediatric clone (ST5-SCC
studies, spa type t002 is found in ST5, as well as in ST125 and ST231 (Pérez-
Vázquez et al., 2009). Nübel et al (2008) discovered at least six types of SCCmec 
types in association to the ST5 clone. It was revealed that ST5 MRSA clones emerged 
frequently in various regions of the world with an addition of SCCmec into a 
methicillin susceptible ST5 (Nübel et al., 2008). It was identified that MRSA in ST5 
from South Africa and Kenya developed a sublineage (ST5-D) which was not closely 
related to MRSA spa type t045 from other continents. Moreover, PVL positive MSSA 
strains from
worldwide and could become 
SCCmec in Africa. 
 
Perez-Vazquez et al (2009) found spa type t002 as the second most dominant type in 
Spain, which has also been detected in Germany (Harmsen et al., 2003), Austria 
(Ruppitsch et al., 2006) and the USA (Shittu et al.
(Pérez-Vázquez et al., 2009
cluster were identified as PVL positive MSSA strains (Table 4.10). Perez-Vazquez et 
al (2009) also identified spa type t002 and ST5 in both MRSA and MSSA isolates. 
The study identified nine isolates of the ST5 clone as PVL positive MSSA. Authors 
suggest that the acquisition of the mecA gene by ST5 could possibly lead to the 
prevalence of PVL in MRSA isolates (Pérez-Vázquez et al., 2009). 
 
A study by Otter & French (2008) from a London teaching hospital, identified spa 
type t002 in a range of health-care associated (HCA) strains as well as in hospital 
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 (HA) and community acquired (CA) infections (Otter & French, 2008). The findings 
of this study is similar to our study, as HCA, HA and CA strains were identified in 
spa types t002 (Figure 4.22).  
er 4) 
al., 2007). Spa type 127 
T1) is currently one of the most predominant CA-MRSA clones circulating within 
trommenger et al., 2008b).  
5.2.4.4 Spa-Clonal Complex 015 (Clust
 
Spa type t015 was found to be associated with ST45 and SCCmec type IV 
(Deurenberg et al., 2007) and also found to be one of the major spa types in our study 
(6/101, 6%) and the most frequent spa type in cluster 4. The majority of strains in this 
spa type were MSSA, and found in HA, HCA and CA infections (Figure 4.21 and 
4.22). Furthermore, this spa type is broadly distributed throughout the world 
(Appendix D), reported mainly from the United States (Koreen et al., 2004) and 
Poland (Malachowa et al., 2005). Other spa types detected in cluster 4 include t465, 
t2623 and t4576. Spa type t4576 has been identified only in Germany and South 
Africa, whereas type t465 was found in Germany, South Africa and Denmark 
(Appendix D). The remaining spa type 2623 from spa-CC 015 has been detected in 
the Netherlands, Austria and South Africa.  
5.2.4.5 Spa-Clonal Complex 174 (Cluster 5) 
It has been reported in USA isolates, that spa type t127 and t174 both are associated 
with multi-locus sequence type 1 (ST1). Although CA-MRSA strains are commonly 
associated with SCCmec type IV, these strains have been found in the variant 
SCCmec type IVa (ST1) (Witte et al., 2004). CA-MRSA strains with SCCmec type V 
in ST1 have been described in Singapore (Deurenberg et 
(S
Germany and Central Europe (S
 
In our study, all 5 isolates from spa-CC 174 (t127; t174; t5471) were found to be 
MSSA strains (Table 4.12) from hospital and health-care associated infections (Table 
4.13). None of the spa types from this clonal complex were found among community 
acquired strains. Otter & French (2008) most commonly identified spa type t127 as 
ST1 and PVL negative. We identified only one isolate from t127 which was a PVL 
negative strain. Furthermore, two PVL-positive isolates from t174 and novel spa type 
t5471 were isolated in this cluster. 
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 5.2.4.6 Spa-Clonal Complex 346/085 (Cluster 6) 
Interestingly, two founders arose within this clonal complex, namely spa types t346 
ion of r34 occurred in spa type t521. It was shown that spa types t267 and 
21 were both MSSA strains (Table 4.12), These spa types are distributed in many 
and t085. They are both closely related to spa type t5396, which is a novel strain 
detected at Tygerberg Hospital and in Poland (Appendix D). All three of spa types in 
this cluster group were found to be MSSA strains (Table 4.12) with one community 
acquired strain (Table 4.13). The HA/HCA/CA category could not be determined for 
the remaining two isolates (Table 4.13). 
In spa type t085, a duplication of repeat unit r34 and a deletion of repeat unit r12 
occurred. We suggested that spa types t346 and t085 are both founders due to the 
same SCCmec type and MLST. Only further studies involving other S. aureus 
genotyping techniques on both of these strains would enlighten this statement, as to 
our knowledge, no evidence is currently found. A study by Mellman et al (2008) also 
identified two founder strains in two of their spa-CC’s namely, spa-CC 382/399 and 
spa-CC 084/346. However, the findings of these founder strains were not further 
described.  
5.2.4.7 No founder (Cluster 7) 
As this clonal complex has no founder, the evolution of these strains cannot be 
deduced. The only difference detected between these two strains was that a 
duplicat
t5
countries throughout the world (Appendix D). 
5.2.4.8 Singleton spa types 
All the spa types grouped together as singletons by BURP analysis were MSSA 
strains (Table 4.12) that were not related to any other spa types or could not be 
categorized into a clonal complex. Spa type t891 was the most common singleton and 
also the second most prevalent spa type in our study (7/101; 7%). All isolates from 
this spa type were MSSA and were positive for PVL. The majority of the strains from 
this spa type were associated with health-care associated infections (Figure 4.22). Spa 
type t1597, which was also found frequently in this study, was associated with HA-
MSSA strains. The remaining singletons that were positive for PVL included spa 
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 types t317 and t409. All of these spa types that are singletons are observed widely 
throughout many countries of the world (Appendix D).  
5.3 Persistent/Recurrent bacteraemia
 
 
 
Persistent bacteraemia, commonly found among hospitalized patients, was defined in 
the current study as a repeat positive blood culture ≥3 days after appropriate therapy 
was initiated. This definition was also used in a study by Hawkins et al (2007). 
However, the literature regarding persistent S. aureus bacteraemia, poorly define 
persistence and vary in study design and study population. For instance, Fowler et al 
004) used a definition of persistence as bacteraemia for longer than 7 days in 
s only (Fowler et al., 2004). Khatib et al 
ce as bacteraemia for ≥3 days, which was observed in 38.4% 
 January 2002 to June 2006 and 
ovember 2005 to December 2006. The authors reported that the frequency of 
nly (1/104, 0.9%) (Table 4.15). This 7 day-old infant presented with MRSA 
skin infection of the umbilicus and 
ellulitis of the hand with subsequent abscess formation. MRSA was cultured from 
(2
patients presenting with MRSA infection
(2006) defined persisten
of the patients with both MRSA and MSSA isolated from January to December 2002. 
In 2009, the same authors used a more stringent definition of persistence of ≥7 days 
(Khatib et al., 2009). This study occurred from
N
persistent S. aureus bacteraemia was higher than their previous study published in 
2006 (Khatib et al., 2009). Furthermore, Chang et al (2003) subclassified persistence 
as a positive blood culture at ≥3 days or ≥7 days after appropriate antibiotic therapy in 
order to compare nafcillin therapy with vancomycin at these two time periods. 
Nafcillin was superior to vancomycin in preventing bacteriological failure (persistent 
bacteraemia >7d and/or relapse; 0% versus 19%, p=0.058). 
 
5.3.1 Persistent bacteraemia: 
 
In the current study, persistence according to our definition was proved in one patient 
o
bacteraemia due to a hospital-acquired MRSA 
c
pus swabs from both skin sites. The patient was treated with vancomycin for 11 days. 
No surgical abscess drainage was done. Spa type t021 (spa CC012/Cluster 2) was 
detected in both the initial and subsequent blood culture strain (9 days later) with no 
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 detection of pvl. Phenotypic testing for heteroresistance to the glycopeptides using the 
E-test macromethod was negative.  
 
Yardena et al (2005) found that most of the patients in their study presented with a 
secondary focus of infection serving as the site of persistence, in addition to the 
primary focus (or portal of entry). It has been reported that MRSA infections in 
neonates may vary from either superficial skin infections to severe, invasive diseases 
such as bacteraemia, bone infections and meningitis (Chuang et al., 2004). Chuang et 
al (2004) found that infants with persistent bacteraemia were commonly due to 
undrained pus or abscesses or a delay in catheter removal. Their study concluded that 
catheter-related infections were predominantly seen in neonates with MRSA 
bacteraemia. The findings in a study conducted by Khatib et al (2009), suggested that 
MRSA and the presence of risk factors were associated with persistent S. aureus 
bacteraemia. It was reported that factors related to persistence included endovasular 
sources, cardiovascular prosthesis, metastatic infections, diabetes and vancomycin 
treatment (Khatib et al., 2006). Hawkins et al (2007) associated persistence with 
methicillin resistance, intravascular catheter or other foreign body use, chronic renal 
ilure, more than two sites of infection and infective endocarditis. In another study, 
e cell wall of staphylococci become less permeable to vancomycin and other 
ntibiotics. This results in an increase in MICs after initial vancomycin therapy is 
fa
persistent and recurrent S. aureus bacteraemia has been primarily found to be 
associated with endocarditis, osteomyelitis or abscess formation (Yardena et al., 
2005).  
 
Another factor contributing to the persistence of MRSA bacteraemia is the possibility 
of reduced susceptibility to vancomycin in subpopulations. In the current study, the 
one persisting S. aureus strain did not exhibit reduced susceptibility or 
heteroresistance to vancomycin. Heteroresistance to vancomycin is associated with 
cell wall thickening due to overproduction of cell wall precursors in the peptidoglycan 
layer, th
a
given (Cui et al., 2003; Cunha et al., 2009). A study by Jang et al (2009), evaluated 
the effectiveness of linezolid with or without carbapenem in salvage treatment for 
persistent MRSA bacteraemia over a 3 year period. It was found that patients had a 
higher salvage success rate for linezolid therapy than for vancomycin-based 
combination therapy (with aminoglycosides or rifampicin) (Jang et al., 2009). 
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 Yardena et al (2005), examined the possible association of vancomycin therapy to 
persistent S. aureus bacteraemia in Israel. The first study occurred during a 2 year 
period, and included patients who completed ≥10 days of appropriate anti-
staphylococcal therapy. It was found that MRSA and MSSA persistent S. aureus 
bacteraemia, after >3 days of therapy, occurred in none of the 52 cloxacillin recipients 
and in 11/55 (20%) vancomycin recipients. The second study was done over a 4 year 
period and included all patients with persistence and/or relapse of S. aureus 
bacteraemia on anti-staphylococcal therapy. Persistence after more than 3 days of 
vancomycin therapy occurred in 94% (32/34) of the patients. In general, persistent S. 
ureus bacteraemia leads to significantly longer hospitalization of patients and high 
ecurrent bacteraemia due to relapse 
a
mortality rates (Hawkins et al., 2007). 
 
5.3.2 Recurrent bacteraemia: 
 
Recurrent bacteraemia was defined in our study as the return of S. aureus bacteraemia 
after documenting a negative blood culture and/or clinical improvement after the 
completion of a course of appropriate antibiotics.  
 
Reports on recurrence of S. aureus bacteraemia cite endocarditis, distal septic 
complications and a short duration (<10 days) of parenteral antibiotic treatment for 
catheter-related bacteraemia as risk factors (Chang et al., 2003). In order to 
distinguish between relapse of the same infection and re-infection, molecular typing 
techniques for S. aureus should be performed. Chang et al (2003) used PFGE to 
differentiate between relapse and re-infection of S. aureus bacteraemia in patients,that 
were followed up for 6 months after completion of therapy. Recurrence was detected 
in 9.4% (42/448) of the patients. Fowler et al (1999) also used PFGE to identify 
relapses where isolates were identical in recurrent episodes of S. aureus bacteraemia.  
 
5.3.2.1 R
 
In our current study, spa typing revealed identical spa types of recurrent and initial 
isolates (t015/spa-CC 015/cluster 4; t253/spa-CC 012/cluster 2) respectively in two 
patients (2/104, 2%) [Table 4.16]. These recurrent episodes were considered to be 
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 relapses, although the possibility of re-infection with the same colonizing strain 
cannot be excluded. Both patients had underlying chronic renal failure and received 
haemodialysis. HCA-MSSA was identified in both these patients, with bacteraemia 
due to catheter-related sepsis. The patients initially responded after removal of 
dialysis catheters, but both patients were treated with vancomycin although cloxacilin 
was advised by the resident microbiologist, at Tygerberg Hospital. These findings are 
in agreement to those of Fowler et al (1999), as relapses in patients were commonly 
related to a indwelling foreign body, patients receiving vancomycin therapy and in 
patients undergoing haemodialysis. The population of haemodialysis patients have a 
high prevalence of S. aureus nasal carriage (35-62%) which may be the cause of 
higher recurrent bacteraemia rates with the same colonizing strain (Mokrzycki et al., 
2006). Chang et al (2003) also found that patients on haemodialysis were significantly 
ore likely to receive vancomycin for MSSA bacteraemia (46% on vancomycin 
cular devices that did not appear to be clinically infected (Hartstein et al., 
992). 
ycin in treating S. aureus infection due to MSSA. 
m
versus 12% on nafcillin). Furthermore, multivariate analysis (adjusting for 
hemodialysis) showed that endocarditis and vancomycin therapy were predictive of 
relapse (Chang et al., 2003). Patients that presented with catheter-related bacteraemia 
had the catheter removed in 90% of the cases in that study.  
 
Hartstein et al (1992) used a typing technique by restriction endonuclease analysis of 
plasmid DNA (REAP DNA fingerprinting) and immunoblotting to differentiate 
between strains of recurrent S. aureus bacteraemia. The study included eight patients 
with ten episodes of recurrent bacteraemia. It was found that relapsing infections were 
related to the presence of intravascular foreign bodies, as well as vancomycin therapy 
of preceding episodes. Other studies have also used antimicrobial susceptibility 
patterns, phage typing and plasmid profiles to differentiate between strains of 
recurrent bacteraemia cases. Generally, relapses were commonly associated with 
intravas
1
 
Beta-lactam agents are preferred above vancomycin to treat methicillin-susceptible S. 
aureus infections. Various studies have found that patients treated with vancomycin 
for MSSA bacteraemia present with worse outcomes (Chang et al., 2003; Gottlieb et 
al., 2000; Johnson et al., 2003). For instance, Chang et al (2003) provided evidence 
that nafcillin was superior to vancom
 118
 Vancomycin therapy should therefore be restricted to patients who are infected with 
n between recurrence of 
MSSA bacteraemia and prior glycopeptide treatment in cases of central venous 
catheter sepsis where the catheter was removed (Walker et al., 2009).  
 
5.3.2.2 Recurrent bacteraemia due to re-infection: 
 
In our current study, spa types were different between the initial and recurrent 
bloodculture isolates of 4 patients (4/104, 4%) and were therefore defined as re-
infection with new strains. The majority of these re-infection cases were due to 
intravascular catheter infections. Two of the patients presented with a HA-MSSA 
infection (t002/spa-CC 002/cluster 3 and t1476/spa-CC 701/cluster 1) of the initial 
blood culture isolate, followed by a subsequent MRSA isolate (t037/spa-CC 
012/cluster 2 in both patients) [Table 4.17]. Both patients were admitted to the burns 
ICU unit. The initial MSSA bacteraemia in one of the patients (TBH 7) was due to 
burn wound infection, whereas the subsequent bacteraemia was due to catheter sepsis 
CVP. The other patient (TBH 110) initially acquired CVP sepsis, and then developed 
a subsequent primary bacteraemia of unknown source. This patient had one 
temperature spike which resolved on the removal of the intravascular catheter. 
However, only Proteus mirabilis was cultured on the CVP tip. A survey of the North 
American National Nosocomial Infection Surveillance System, reported catheter-
related infections at a high rate of 30.2 (in the burns ICU) and 2.1 (in the respiratory 
ICU) cases per 1000 central catheter days between 1986 and 1990 (Jarvis et al., 
1991).  
 
Steinberg et al (1996) detected high rates of hospital acquired S. aureus bacteraemia 
due to infected intravascular related devices (Steinberg et al., 1996). Yet, the skin is 
the most common site of infection. The infected skin area could serve as a portal of 
entry for the development of more invasive infections. If MRSA infection is endemic 
methicillin resistant strains or patients who are allergic to beta-lactam antibiotics 
(Hartstein et al., 1992). However, haemodialysis patients were more likely to receive 
vancomycin with significant association to relapse identified in a statistical model. 
The reason why vancomycin is given is that it has a long half-life in renal failure and 
can therefore be given once weekly as out-patient therapy (Chang et al., 2003). A 
study by Walker et al (2009) reported a significant associatio
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 in a setting, MRSA bacteraemia m localized skin infections and 
colonized indwelling intravascular devices (Chuang et al., 2004). The outermost 
surface of catheters may becom nisms that originate from the 
skin, whereas the inner surface of the catheter could become colonised with the 
introduction of organisms through the catheter hub (Crump & Collignon, 2000). 
s they adhere to these medical devices. Appropriate antimicrobial therapy 
 often not effective in eliminating these infections. Therefore, the removal of 
08). Catheter-
lated sepsis (22.6%) was commonly found, followed by skin and soft tissue 
ory power 
f spa typing is similar to PFGE and this method has been validated for outbreak 
investigation (Hallin et al., 2007).  
 is likely to arise fro
e colonised with orga
Crump and Collognon (2000) give evidence on the number of organisms found on 
catheters that develop into local and bloodstream infections. Organisms were cultured 
from the catheter tip using the semi-quantitative roll-plate and sonication methods 
(Crump & Collignon, 2000). Biofilms also play an important part in catheter related 
infections, a
is
catheter related devices is of utmost importance for successful patient outcome. 
 
The remaining two patients developed relapse (table 4.16) and re-infection (table 
4.17) episodes with HCA-MSSA infections. This phenomenon frequently occurs in 
chronic renal failure patients on haemodialysis, due to invasive procedures (dialysis 
catheter) and frequent hospital exposure. It was reported that catheter-related 
bacteraemia is commonly associated with patients undergoing haemodialysis (Allon, 
2004). The frequency of these cases are more likely to increase, as haemodialysis 
patients are dependent on using catheters (Maya et al., 2007). The majority (76.3%) of 
MRSA bacteraemia cases were found to be HCA in patients admitted to the 
emergency department of a medical centre in Taiwan (Liao et al., 20
re
infection (20.9%), primary bacteraemia (15.3%) and infective endocarditis (6.8%) 
(Liao et al., 2008). Robinson et al (2009) associated HCA bacteraemia predominantly 
to device related infections, or to surgical procedures in the elderly (Robinson et al., 
2009). 
 
To our knowledge, no studies have been reported using specifically spa typing to 
differentiate between strains causing persistent or recurrent S. aureus bacteraemia. 
Thus, no association of spa types with persistent and recurrent S. aureus bacteraemia 
in comparison to other studies could be deduced. However, the discriminat
o
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It is important that cases of persistent/recurrent bacteraemia should be identified at an 
early stage and followed-up by infectious diseases specialists to ensure optimal 
management of these patients. A limitation to the current study is that the numbers of 
patients with persistent/recurrent bacteraemia were too small for meaningful statistical 
analysis. Prospective studies with larger patient numbers are therefore needed in order 
to investigate persistent and recurrent S. aureus bacteraemia. 
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 CHAPTER SIX 
6 CONCLUSION 
 
Data on S. aureus epidemiology from South Africa is limited. This study provides the 
 
ospital (Tygerberg hospital in the Western Cape Province, South 
cluded in 
he multiplex PCR method for the detection of the three important genes used for 
with a 
etected spa genes and 
. A 
these 
ost 
redominant spa type found in our setting was t037 (only in MRSA) and according to 
rains 
rica. Interestingly, all strains from spa type t891 
formation provided in this study contributes to our understanding of the local 
 to the 
 
as been associated with CA-MRSA, PVL was only detected in MSSA isolates in this 
SSA strains were associated with pneumonia, soft tissue infections and septic 
first data on S. aureus genotypes linked to prospective clinical data in the setting of a
large academic h
Africa). Blood culture isolates collected over a period of 14 months were in
this study.  
 
T
MRSA surveillance: mecA, pvl and spa gene, performed well in our setting 
typeability of 89.3%. Our multiplex PCR method successfully d
spa typing proved to be a useful method to determine strain relatedness
considerable variety of spa types were detected at Tygerberg hospital. Many of 
spa types are found worldwide, but 5 novel spa types have also been found. The m
p
the literature is associated to the Brazilian/Hungarian clone (SCCmec type III; ST 
239). South African studies indicate that t037 has been identified in clinical st
om numerous provinces in South Affr
(second most prevalent) were found to be PVL positive MSSA strains.  
 
The in
epidemiology of S. aureus and the prevalence rate of different strains. A major finding 
is that no CA-MRSA isolates were detected in this study. This is in contrast
emergence of CA-MRSA reported from other countries. Furthermore, although PVL
h
study. PVL positive strains constituted 15.9% of S. aureus isolates. PVL positive CA-
M
arthritis. However, in our study catheter-related sepsis was more common in HA-
infections and HCA-infections, and often caused by PVL-positive isolates. 
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 The majority of bacteraemia cases were associated with intravascular
infections (for both MRSA and MSSA), followed by skin and soft tissue infection
MRSA strains were mainly fo
 catheter 
s. 
und to cluster in spa CC 701 and CC-012 (cluster 1 & 
rmore, the 
t 
RSA strains at 
 
 
rrent bacteraemia cases were 
 
c 
tware set up in our molecular laboratory through 
ture, spa 
ping may replace MLST as the typing method of choice, since this sequence-based 
 
LST) to 
late our strains to international epidemic clones and to provide a much larger view 
2), whereas CC-002 (cluster 3) consisted of MSSA strains only. Furthe
majority of HA-strains were found in clusters 1 & 2. This information indicates tha
pa types in clusters 1 and 2 are closely associated with HA-Ms
Tygerberg hospital.  
The number of persistent and recurrent bacteraemia episodes were low in this study
(9/113, 8%). Persistent bacteraemia was found in one patient only, presenting with a
ospital-acquired skin and soft tissue infection. Recuh
found in patients on dialysis for chronic renal failure and in burns patients related to
catheter infections. These insights are useful for optimal diagnostic and therapeuti
measures.  
The techniques and spa typing sof
this study can be used in future for MRSA surveillance, outbreak detection and 
determining strain relatedness in persistent and recurrent infections.  In fu
ty
method is much more affordable and quicker to perform. This may facilitate 
comparison of our strains with international epidemic clones. 
Further studies are needed for the surveillance of S. aureus strains using a
combination of molecular techniques (SCCmec typing, PFGE, spa typing, M
re
of molecular epidemiology of MRSA and MSSA isolates in South Africa. 
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 8.2 APPENDIX B: Descriptive data a
 
data obtained from
nd Clinical data  
Table B1: Patient demographics and Clinical  all isolates 
Patient details Patient De raphics  mog Clin
ds l Ward Groups MR A Clini iag. HC CA utcome 
ical Data 
# of 
strains Study # Gender Age 
All 
War Al SA/MSS cal D A/HA/
HIV 
status Patient o
1 TBH 1 Female      d 36 yrs A8E M MSSA SSTI HA Negative Discharge
2 TBH 2 Female   W  HA   47 yrs A1W A1 MSSA PN Unknown Discharged
3 TBH 3 Male   round   SSTI    6 yrs G g Pd MSSA CA Unknown Discharged
4 TBH 5 Female     3 mnths G4 Pd MRSA CSI HA Negative Demised
5 TBH 6 Female    45 yrs A7 A7 MRSA CSI HCA Negative Demised
6 TBH 7.a Male     SSTI    37 yrs A1B A1B MSSA HA Unknown Discharged
7 TBH 7.b         MRSA CSI HA     
8 TBH 8 Female      d 22 yrs A7 A7 MSSA CSI HA Negative Discharge
9 TBH 9 Female      65 yrs A1W A1W MRSA SSTI HA Negative Discharged
10 TBH 10 Male        75 yrs A1W A1W MSSA PB a Negative Discharged
11 TBH 11 Male      d 8 days G2 N MSSA CSI HA Unknown Discharge
12 TBH 12 Female       1 mnth G1 N MSSA PN CA Unknown Discharged
13 TBH 13 Female   1 yr G3 Pd MRSA CSI HA Negative Discharged 
14 TBH 14 Male 41 yrs   CA  D9 M MSSA IE Negative Demised 
15 TBH 15 Male         37 days A9E A9E MSSA PN CA Negative Discharged
16 TBH 16 Female      58 yrs A1W A1W MRSA CSI HA Negative Demised
17 TBH 17 Male 1 yr G7  Un n Pd MRSA know   Negative  Discharged 
18 TBH 18 Male 57 yrs A6    HCA   M MSSA CSI Unknown Discharged
19 TBH 19 Male 4 mnths und  Un n d G gro Pd MRSA know   Negative  Discharge
20 TBH 20 Female       d 7 mnths G10 Pd MSSA SSTI HA Negative Discharge
21 TBH 21 Female Un n d 7 days G2 N MSSA know   Unknown Discharge
22 TBH 22 Male    7 yrs G3 Pd MRSA CSI HCA Negative Discharged 
23 TBH 23 Female       41 yrs KHA KHA MSSA SSTI CA Negative Demised 
24 TBH 24 Male 1 day A9E E Un n o another HP A9 MSSA know   Unknown Transferred t
25 TBH 25 Female Ot d to another HP 43 yrs A4W S MSSA her(UTI) HA Unknown Transferre
26 TBH 26.a d to another HP Male 36 yrs A7 A7 MSSA CSI HCA Negative Transferre
27 TBH 26.b         MSSA CSI HCA     
28 TBH 26.c         MSSA CSI HCA     
 146 
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29 TBH 27 Female     22 yrs D9  M MSSA PB a Positive Discharged
30 TBH 28 Male 
13 
mnths G ground Pd MSSA CSI HCA Unknown Discharged 
31 TBH 29 Male 
10 
mnths G9   d Pd MRSA SSTI HA Positive Discharge
32 TBH 30.a      HCA  d Male 20 yrs A7 A7 MSSA CSI Negative Discharge
33 TBH 30.b         MSSA CSI HCA     
34 TBH 30.c         MSSA CSI HCA     
35 TBH 30.d         MSSA CSI HCA     
36 TBH 30.e         MSSA CSI HCA     
37 TBH 31 Male 61 yrs  to another HP KHA KHA MSSA SSTI HA Unknown Transferred 
38 TBH 32 Female         56 yrs A7 A7 MSSA CSI HCA Negative Discharged
39 TBH 33 Female    6 days G2 N MRSA CSI HA Unknown Discharged 
40 TBH 34 Male    HCA  59 yrs D1 S MSSA CSI Unknown Demised 
41 TBH 35 Male 40 yrs A7    HCA   A7 MSSA CSI Negative Discharged
42 TBH 36 Female     22 yrs A7 A7 MSSA CSI HCA Negative   
43 TBH 37 Female    CA  74 yrs F1 M MSSA IE Unknown Demised 
44 TBH 38 Female   A  Un n    d 63 yrs KHA KH MSSA know Unknown Discharge
45 9 Female 36 yrs F1 M MSSA PB a Unknown Demised TBH 3
46 TBH 40.a Male 7  SSTI HA days G2 N MRSA Unknown   
47 TBH 40.b SSTI HA   scharged         MRSA Di
48 TBH 41 Female 93 days 9 Pd HCA Unknown Discharged G MSSA CSI 
49 TBH 42 Male 49 yrs D5 S MRSA CSI HA Unknown Demised 
50 TBH 43 Male 22 days A9E A9E MRSA         
51 TBH 44 Male 63 yrs A1B A1B MRSA SSTI HA Unknown Demised 
52 TBH 45 Female 16 yrs D8 M MSSA Unknown   Negative Discharged 
53 TBH 46 Female 34 yrs D8 M MRSA Unknown   Negative Discharged 
54 TBH 47 Male 28 yrs A1B A1B MSSA CSI HA Unknown Discharged 
55 TBH 48 Female mnths G7 Pd MR CSI HA Positive Discharged
10 
SA  
56 TBH 49 Female 18 days G2 N MRS SA HA Unknown Discharged A 
57 TBH 50 Male 9
 
 
 yrs A9E A9E MSSA PN HA Unknown Discharged 
58 TBH 51 Female 76 yrs D4 Other MSSA CSI HA Negative Discharged 
59 TBH 52 Male 4 mnths G9  Pd MSSA PN CA Negative Discharged 
60 TBH 53 Female 7 days A9E A9E MRSA CSI HA Negative Transferred to another HP 
148 
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61 TBH 55 Male 65 yrs A6 M MSSA SSTI HCA Unknown Demised 
62 TBH 57 Female 87 yrs D5  S MSSA SSTI HA Unknown Transferred to another HP 
63 TBH 58 Female 24 yrs C2A Other MSSA PB Unknown Demised a
64 TBH 59 Male 2yrs G7 Pd MRSA CSI HA Positive Discharged 
65 TBH 60 Female 5yrs G3 Pd MSSA SSTI HCA Negative Discharged 
66 TBH 61 Female 5 d ays G2 N MRSA CSI HA Unknown Demised 
67 TBH 62 Male 23 yrs A1B A1B MSSA CSI HA Unknown Demised 
68 TBH 63 Male 47 yr S MRSA Unknown   Negative Discharged s D2 
69 TBH 65 Male 20 yrs F1 M MSSA IE CA Negative Discharged 
70 TBH 66 Female 61 yrs A2W S MRSA CSI HA Unknown Demised 
71 TBH 67 Male 38 yrs A1W A1W MSSA CSI HA Unknown Discharged 
72 TBH 68 Male 9 y rs KHA KHA MSSA SA CA Unknown Discharged 
73 TBH 69 Female 31 yrs A1B A1B MRSA SSTI HA Unknown iscD harged 
74 TBH 71 Female 34 yrs A8H M MRSA SSTI HA Positive Demised 
75 TBH 72 Male 23 yrs A1B A1B MSSA PN HA Negative Discharged 
76 TBH 73 Male 10 yrs G6 Pd MSSA SA CA Unknown Discharged 
77 TBH 75 Male 31 yrs A1B A1B MSSA Other(Pericarditis) HA Negative Demised 
78 TBH 76 Female 33 yrs A7 A7 MRSA CSI HCA Negative Discharged 
79 TBH 77 Female 75 yrs D10 M MSSA PB a Unknown Transferred to another HP 
80 TBH 78 Female 16 yrs A1W A1W MSSA PB a Negative Discharged 
81 TBH 79 Male 41 yrs A7 A7 MSSA CSI HCA Negative Discharged 
82 TBH 80 Male 46 yrs A1B A1B MSSA CSI HA Unknown Demised 
83 TBH 81 Female 22 days G1 N MSSA SA HA Negative Discharged 
84 TBH 82 Female 10 days G8 Pd MSSA CSI HA Unknown Discharged 
85 TBH 83 Female 67 yrs A2W S MRSA PB a Unknown Demised 
86 TBH 84 Male 39 yrs F1 M MSSA PN CA Negative Demised 
87 TBH 85 Male 39 wyrs A1W A1W MSSA PB a Unkno n Demised 
88 TBH 86 Male 6 mnths A9E A9E MRSA CSI HA Unknown Transferred to another HP 
89 H 1 A S A D h gTB  87 Male 28 yrs A B 1B MSSA C I H Unknown isc ar ed 
90 TBH 88 N MSSA Male 1 day G1 PB a Negative Discharged 
91 TBH 89 Male 66 yrs A4W S MSSA PN CA Unknown Demised 
92 TBH 90 Male 28 yrs D9 M MSSA PB a Negative Demised 
93 TBH 91 Female 41 yrs A7 A7 MSSA CSI HCA Negative Discharged 
Discharg94 TBH 92 Fema ve Negati  MSSA Unknown Pd G10 le 6 mnths 
 
 
ed 
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95 TBH 93 Male 9 days G1 N MSSA PB a Unknown Discharged 
96 TBH 94 Female 8 mnths KHA KHA MSSA SSTI HA 
 
Unknown Transferred to another HP 
97 TBH 95 Female 32 yrs D10 M MRSA SA HA Negative Transferred to another HP 
98 TBH 96 Male 31 yrs A1B A1B MRSA Unknown HA Unknown Demised 
99 TBH 97 Female 9 yrs G3 Pd MSSA CSI HA Negative Demised 
100 TBH 98 Male 81 yrs A1B A1B MSSA SSTI HA Unknown Demised 
101 TBH 99 Male 73 yrs A1W A1W MRSA SSTI HA Negative Transferred to another HP 
102 TBH 100 Male 21 yrs KHA KHA MSSA SSTI HA Unknown Discharged 
103 TBH 101 Female 8 mnths G9 Pd MSSA PN HA Negative Discharged 
104 TBH 102 Female 6 yrs G10 Pd MSSA PN CA Negative Discharged 
105 TBH 103 Female 53 yrs A7 A7 MSSA CSI HCA Negative Discharged 
106 TBH 104 Female 21 yrs A4W S MSSA PN HA Unknown Transferred to another HP 
107 TBH 105 Male 4 mnths A9E A9E MSSA PB a Negative Discharged 
108 TBH 106 Female 19 days G1 N MSSA PB a Negative Discharged 
109 TBH 107 Female 44 yrs A1W A1W MRSA PN HA Negative Discharged 
110 TBH 108 Female 43 yrs D10 M MSSA Unknown   Negative Discharged 
111 TBH 109 Female 60 yrs F1 M MSSA PB a Unknown Demised 
112 
TBH 
110.a Male 35 yrs A1B A1B MSSA CSI HA Unknown Discharged 
113 
TBH 
110.b         MRSA PB 
a
    
 
(CSI) = Catheter and prosthetic device-related sepsis     (SA) = Septic arthritis (including osteomyelitis) 
(PN) = Pneumonia        (SSTI) = Skin and soft tissue infection
(IE) = Infective endocarditis       (PB) = Primary bacteraemia 
(Unknown) = clinical significance not clear, possible contaminants 
(a)  = PB excluded from analysis for HA/HCA/CA category due to unknown source (Transferred to another HP) = Transferred to another hospital  
(HA) = Hospital acquired infection;  
(HCA) = Health care associated infections; (CA) = Community acquired infection
s 
 
 
 Table B2: Phenotypic and Genotypic results obtained from all isolates 
Patient details Phenotypic results Genotypic results 
# of strains Study # MRSA/MSSA mecA 
spa 
band 
pvl 
+ 
Spa-
type  Repeats Cluster groups 
1 TBH 1 MSSA  -  +  - t127 7 spa-CC 174 
2 TBH 2 MSSA  -  +  - t030 7 spa-CC 012 
3 TBH 3 MSSA  -  +  + t317 7 Singleton 
4 TBH 5 MRSA  +  +  - t1257 10 spa-CC 701 
5 TBH 6 MRSA  +  +  - t037 7 spa-CC 012 
6 TBH 7.a MSSA  -  +  - t002 10 spa-CC 002 
7 TBH 7.b MRSA  +  +  - t037 7 spa-CC 012 
8 TBH 8 MSSA  - NT  + * * * 
9 TBH 9 MRSA  +  +  - t018 11 spa-CC 012 
10 TBH 10 MSSA  -  +  - t701 10 spa-CC 701 
11 TBH 11 MSSA  -  +  + t891 11 Singleton 
12 TBH 12 MSSA  -  +  - t2360 11 spa-CC 701 
13 TBH 13 MRSA  +  +  - t1443 11 spa-CC 701 
14 TBH 14 MSSA  -  +  - t346 10 spa-CC 346/085 
15 TBH 15 MSSA  -  +  + t433 9 spa-CC 012 
16 TBH 16 MRSA  +  +  - t037 7 spa-CC 012 
17 TBH 17 MRSA  +  +  - t015 10 spa-CC 015 
18 TBH 18 MSSA  -  +  - t026 3 Excluded  
19 TBH 19 MRSA  +  +  - t451 9 spa-CC 701 
20 TBH 20 MSSA  - NT  - * * * 
21 TBH 21 MSSA  -  +  - t214 11 spa-CC 002 
22 TBH 22 MRSA  +  +  - t287 3 Excluded  
23 TBH 23 MSSA  -  +  - t002 10 spa-CC 002 
24 TBH 24 MSSA  - NT  - * * * 
25 TBH 25 MSSA  -  +  + t1597 8 Singleton 
26 TBH 26.a MSSA  -  +  + t174 6 spa-CC 174 
27 TBH 26.b MSSA  -  +  - t253 12 spa-CC 012 
28 TBH 26.c MSSA  -  +  - t253 12 spa-CC 012 
29 TBH 27 MSSA  -  +  - t1476 8 spa-CC 701 
30 TBH 28 MSSA  -  +  - t174 6 spa-CC 174 
31 TBH 29 MRSA  +  +  - t1257 10 spa-CC 701 
32 TBH 30.a MSSA  -  +  - t015 10 spa-CC 015 
33 TBH 30.b MSSA  -  +  - t015 10 spa-CC 015 
34 TBH 30.c MSSA  -  +  - t015 10 spa-CC 015 
35 TBH 30.d MSSA  -  +  + t891 11 Singleton 
36 TBH 30.e MSSA  -  +  - t012 10 spa-CC 012 
37 TBH 31 MSSA  -  +  - t015 10 spa-CC 015 
38 TBH 32 MSSA  -  +  - t002 10 spa-CC 002 
39 TBH 33 MRSA  + NT  - * * * 
40 TBH 34 MSSA  -  +  - t148 11 Singleton 
41 TBH 35 MSSA  -  +  - t002 10 spa-CC 002 
42 TBH 36 MSSA  -  +  - t045 7 spa-CC 002 
43 TBH 37 MSSA  -  +  - t1848 9 spa-CC 012 
44 TBH 38 MSSA  -  +  - t275 8 spa-CC 701 
45 TBH 39 MSSA  -  +  + t891 11 Singleton 
46 TBH 40.a MRSA  +  +  - t021 9 spa-CC 012 
47 TBH 40.b MRSA  +  +  - t021 9 spa-CC 012 
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# of strains Study # MRSA/MSSA mecA 
spa 
band 
pvl 
+ 
Spa-
type  Repeats Cluster groups 
48 TBH 41 MSSA  -  +  + t891 11 Singleton 
49 TBH 42 MRSA  +  +  - t037 7 spa-CC 012 
50 TBH 43 MRSA  -  +  - t2360 11 spa-CC 701 
51 TBH 44 MRSA  +  +  - t1257 10 spa-CC 701 
52 TBH 45 MSSA  -  +  - t085 10 spa-CC 346/085 
53 TBH 46 MRSA  +  +  - t451 9 spa-CC 701 
54 TBH 47 MSSA  -  +  - t5474 12 spa-CC 701 
55 TBH 48 MRSA  +  +  - t1257 10 spa-CC 701 
56 TBH 49 MRSA  +  +  - t021 9 spa-CC 012 
57 TBH 50 MSSA  -  +  - t267 10 No founder 
58 TBH 51 MSSA  -  +  + t409 6 Singleton 
59 TBH 52 MSSA  -  +  - t002 10 spa-CC 002 
60 TBH 53 MRSA  +  +  - t021 9 spa-CC 012 
61 TBH 55 MSSA  -  +  - t888 6 Singleton 
62 TBH 57 MSSA  -  +  - t306 11 spa-CC 002 
63 TBH 58 MSSA  -  +  - t318 10 spa-CC 012 
64 TBH 59 MRSA  +  +  - t1257 10 spa-CC 701 
65 TBH 60 MSSA  -  +  + t891 11 Singleton 
66 TBH 61 MRSA  +  +  - t451 9 spa-CC 701 
67 TBH 62 MSSA  -  +  - t1597 8 Singleton 
68 TBH 63 MRSA  + NT  - * * * 
69 TBH 65 MSSA  -  +  - t4576 8 spa-CC 015 
70 TBH 66 MRSA  +  +  - t1443 11 spa-CC 701 
71 TBH 67 MSSA  -  +  - t2393 10 Singleton 
72 TBH 68 MSSA  -  +  + t891 11 Singleton 
73 TBH 69 MRSA  +  +  - t037 7 spa-CC 012 
74 TBH 71 MRSA  +  +  - t064 10 spa-CC 701 
75 TBH 72 MSSA  -  +  - t701 10 spa-CC 701 
76 TBH 73 MSSA  -  +  + t002 10 spa-CC 002 
77 TBH 75 MSSA  -  +  + t311 9 spa-CC 002 
78 TBH 76 MRSA  +  +  - t064 10 spa-CC 701 
79 TBH 77 MSSA  -  +  - t521 11 No founder 
80 TBH 78 MSSA  - NT  - * * * 
81 TBH 79 MSSA  -  +  - t701 10 spa-CC 701 
82 TBH 80 MSSA  - NT  - * * * 
83 TBH 81 MSSA  -  +  - t1597 8 Singleton 
84 TBH 82 MSSA  -  +  - t1597 8 Singleton 
85 TBH 83 MRSA  +  +  - t012 10 spa-CC 012 
86 TBH 84 MSSA  -  +  - t015 10 spa-CC 015 
87 TBH 85 MSSA  -  +  - t5396 14 spa-CC 346/085 
88 TBH 86 MRSA  +  +  - t021 9 spa-CC 012 
89 TBH 87 MSSA  -  +  - t012 10 spa-CC 012 
90 TBH 88 MSSA  -  +  - t375 8 Singleton 
91 TBH 89 MSSA  -  +  - t5472 6 spa-CC 701 
92 TBH 90 MSSA  - NT  - * * * 
93 TBH 91 MSSA  -  +  - t5473 11 spa-CC 701 
94 TBH 92 MSSA  -  +  - t174 6 spa-CC 174 
95 TBH 93 MSSA  -  +  - t465 9 spa-CC 015 
96 TBH 94 MSSA  -  +  - t2763 6 Singleton 
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 Patient details Phenotypic results Genotypic results 
# of strains Study # MRSA/MSSA mecA 
spa 
band 
pvl 
+ 
Spa-
type  Repeats Cluster groups 
97 TBH 95 MRSA  +  +  - t1257 10 spa-CC 701 
98 TBH 96 MRSA  +  +  - t037 7 spa-CC 012 
99 TBH 97 MSSA  -  +  - t2623 9 spa-CC 015 
100 TBH 98 MSSA  -  +  - t064 10 spa-CC 701 
101 TBH 99 MRSA  +  +  - t037 7 spa-CC 012 
102 TBH 100 MSSA  -  +  - t148 11 Singleton 
103 TBH 101 MSSA  - NT  + * * * 
104 TBH 102 MSSA  - NT  + * * * 
105 TBH 103 MSSA  -  +  - t292 8 spa-CC 701 
106 TBH 104 MSSA  -  +  - t030 6 spa-CC 012 
107 TBH 105 MSSA  -  +  + t891 11   
108 TBH 106 MSSA  -  +  - t1443 11 spa-CC 701 
109 TBH 107 MRSA  +  +  - t037 7 spa-CC 012 
110 TBH 108 MSSA  - NT  - * * * 
111 TBH 109 MSSA  -  +  + t5471 6 spa-CC 174 
112 
TBH 
110.a MSSA  -  +  - t1476 8 spa-CC 701 
113 
TBH 
110.b MRSA  +  +  - t037 7 spa-CC 012 
 
(+) = Positive for detection of the mecA, spa and pvl genes 
(-) = No detection (negative) of the mecA, spa and pvl genes 
(NT) = Non-typeable strains with no spa band 
(*) = Could not be further analysed due to non-typeable strains 
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8.3 APPENDIX C: Multiplex PCR gel images obtained after agarose gel 
Electrophoresis 
 
Images include a multiplex PCR for the detection of the mecA, pvl and spa genes. The 
pvl gene is approximately 80 bp, the mecA is 162 bp and the spa gene varies between 
200 and 500 bp. The negative (neg.) control excluded DNA. Positive controls 
included ATCC 49775 - PVL positive (+ve), MSSA and ATCC 43300 – PVL 
negative (–ve) MRSA). (M) = Molecular size marker (100 bp); (N/A) = excluded 
from all analysis. (RP: TBH) = Samples that were re-tested (Consisted of samples 
with no spa band. These isolates were confirmed to be S. aureus by phenotypic 
methods. Genotypic results revealed a lack of the spa gene, which could not be typed: 
Non-typeable strains). 
 
 
spa (variable)
mecA (162 bp)
vl (80 bp)p
 
Figure C1: Multiplex PCR agarose gel electrophoresis image # 1 
 
 
mecA (162 bp)
pvl (80 bp)
spa (variable)
Figure C2: Multiplex PCR agarose gel electrophoresis image # 2 
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mecA (162 bp)
pvl (80 bp)
spa (variable)
 
 
Figure C3: Multiplex PCR agarose gel electrophoresis image # 3 
 
 
 
 
 
 
 
 
spa (variable)
mecA (162 bp)
pvl (80 bp)
 
 
Figure C4: Multiplex PCR agarose gel electrophoresis image # 4 
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spa (variable)
mecA (162 bp)
pvl (80 bp)
 
Figure C5: Multiplex PCR agarose gel electrophoresis image # 5 
 
 
 
 
 
 
 
 
 
 
 
mecA (162 bp)
pvl (80 bp)
spa (variable)
 
Figure C6: Multiplex PCR agarose gel electrophoresis image # 6 
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Figure C7: Multiplex PCR agarose gel electrophoresis image # 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
mecA (162 bp)
spa (variable)
pvl (80 bp)
spa (variable)
mecA (162 bp)
pvl (80 bp)
 
Figure C8: Multiplex PCR agarose gel electrophoresis image # 8 
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Figure C9: Multiplex PCR agarose gel electrophoresis image # 9 
 
 
 
 
 
 
 
 
 
 
spa (variable)
mecA (162 bp)
pvl (80 bp)
spa (variable)
mecA (162 bp)
pvl (80 bp)
 
Figure C10: Multiplex PCR agarose gel electrophoresis image # 10 
 8.4 APPENDIX D: Ridom sequences and Geographical spread of all spa types 
Spa type Geographical Distribution Ridom Sequence of Spa types 
t002 
Aus, Bel, Can, Chi, Cro, Cyp, Czr, Den, 
Est, Fin, Fra, Ger, Hun, Ice, Isr, Ita, Jap, 
Jor, Leb, Mar, Net, New, Nor, Pol, 
Rom, SA, Spa, Swe, Swi, Tai, UK, 
USA 
 
26-23-17-34-17-20-17-12-17-16 
t012 
Aus, Bel, Can, Cyp, Czr, Den, Fin, Fra, 
Ger, Ice, Ita, Jor, Lat, Leb, Net, New, 
Nor, Pol, SA, Spa, Swed, Swi, UK, 
USA 
15-12-16-02-16-02-25-17-24-24 
t015 
Aus, Bel, Cro, Czr, Den, Fin, Fra, Ger, 
Hun, Ice, Ind, Ita, Lat, Net, New, Nor, 
Pol, Rom, SA, Spa, Swe, Swi, Tai, UK, 
USA 
08-16-02-16-34-13-17-34-16-34 
t018 
Aus, Bel, Can, Czr, Den, Fra, Ger, Ice, 
Ita, Jor, Net, New, Nor, Pol, SA, Spa, 
Swe, Swi, UK, USA 
15-12-16-02-16-02-25-17-24-24-24 
t021 
Aus, Bel, Den, Fin, Fra, Ger, Ice, In, Ita, 
Jor, Lat, Leb, Net, New, Nor, Pol, SA, 
Spa, Swe, Swi, UK, USA 
15-12-16-02-16-02-25-17-24 
t026 
Aus, Bel, Cro, Czr, Den, Fin, Fra, Ger, 
Net, New, Nor, Pol, Slo, SA, Spa, Swe, 
Swi, Tai 
08-16-34 
t030 
Aus, Bul, Chi, Cro, Cyp, Czr, Den, Fra, 
Ger, Leb, Net, Nor, Rom, SA, Swe, 
Swit, Tur 
15-12-16-02-24-24 
t037 
Aus, Bel, Bul, Can, Chi, Cro, Czr, Den, 
Fra, Ger, Ice, Ita, Jor, Lat, Leb, Mal, 
Net, New, Nor, Pol, SA, Spa, Swe, Swi, 
Tai, UK 
15-12-16-02-25-17-24 
t045 
Aus, Bel, Chi, Den, Fra, Ger, Isr, Jap, 
Net, New, Nor, SA, Spa, Swe, Swi, 
USA 
26-17-20-17-12-17-16 
t064 Aus, Bel, Can, Czr, Den, Ger, Ice, Isr, Net, Nor, SA, Swe, Swi, UK, USA 11-19-12-05-17-34-24-34-22-25 
t085 Bel, Den, Fin, Fra, Ger, Net, New, Nor, Pol, SA, Spa, Swe, Swi 07-23-12-34-34-12-23-02-12-23 
t127 
Aus, Bel, Chi, Cro, Cyp, Den, Fin, Fra, 
Ger, Ice, Ind, Lat, Leb, Net, New, Nor, 
Pol, Rom, SA, Spa, Swe, Swi, Tai, UK, 
USA 
07-23-21-16-34-33-13 
t148 Aus, Bel, Cro, Den, Fra, Ger, Ice, Ind, Net, Nor, Pol, SA, Spa, Swe, Swi, USA 07-23-12-21-12-17-20-17-12-12-17 
t174 Aus, Net, SA, Swe, UK 14-21-16-34-33-13 
t214 Den, Fra, Ger, Jor, Net, Nor, SA, Spa, Swe, UK 26-23-17-34-17-20-17-12-17-16-16 
t253 Bel, Den, Ger, Net, Nor, Pol, SA, UK 15-12-16-02-16-02-25-17-24-24-24-24 
t267 
Aus, Bel, Cyp, Den, Fra, Ger, Ita, Jor, 
Leb, Net, New, Nor, SA, Spa, Swe, Tai, 
UK, USA 
07-23-12-21-17-34-34-34-33-34 
t275 Aus, Bel, Chi, Ger, Net, New, Nor, SA, 15-12-16-02-25-17-24-24 
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Abbreviatians are as follows: 
 
(Aus) Austria; (Bel) Belgium; (Bul) Bulgaria; (Can) Canada; (Chi) China; (Cro) Croatia; (Cyp) 
Cyprus; (Czr) Czech Republic; (Den) Denmark; (Est) Estonia; (Fin) Finland; (Fra) France; (Gab) 
Gabon; (Ger) Germany; (Hun) Hungary; (Ice) Iceland; (In) India; (Ind) Indonesia, (Isr) Israel; (Ita) 
Italy; (Jap) Japan; (Jor) Jordan; (Lat) Latvia; (Leb) Lebanon; (Mal) Malaysia; (Mar) Martinique; 
(Net) The Netherlands; (New) New Zealand; (Nor) Norway; (Pol) Poland; (Rom) Romania; (SA) 
South Africa; (Swe) Sweden; (Slo) Slovenia; (Spa) Spain; (Swi), Switzerland; (Tai) Taiwan; (Tur) 
Turkey; (UK) United Kingdom; (USA) United States of America; (Zim) Zimbabwe. 
Swe, UK 
t287 Bel, Ger, Net, Nor, SA, Spa, Swe, Tai 04-12-17 
t292 Den, Ger, SA 11-12-17-34-24-34-22-25 
t306 Den, Fra, Ger, Jap, Net, Nor, SA, Swe, USA 26-23-17-34-17-20-17-12-17-17-16 
t311 Bel, Chi, Czr, Den, Fra, Gab, Ger, Leb, Net, New, Nor, SA, Spa, Swe, Swi, UK 26-23-17-34-20-17-12-17-16 
t317 SA, Spa 08-17-23-18-23-18-17 
t318 
Bel, Cap, Chi, Den, Fin, Fra, Ger, Ind, 
Lat, Leb, Net, Nor, Pol, SA, Spa, Swe, 
Swi, UK, USA 
15-12-16-16-02-16-02-25-17-24 
t346 Bel, Den, Fin, Fra, Ger, Jor, Net, Nor, Pol, SA, Swe, Swi, USA 07-23-12-34-12-12-23-02-12-23 
t375 Chi, Den, Fin, Ger, Net, Nor, SA, Spa, Swe 49-13-23-05-17-34-33-34 
t409 SA, Nor, Ger, Ind 60-61-34-22-34-17 
t433 Fra, Ger, Lat, Net, Nor, SA, Swi, USA, 15-12-16-16-02-16-02-25-17 
t451 Aus, Bel, Chi, Ger, Net, New, Nor, SA, Swe, UK 11-12-05-17-34-24-34-22-25 
t465 Den, Ger, SA 08-23-16-34-13-17-34-16-34 
t521 Fra, Ger, Ind, Net, Nor, SA, Zim 07-23-12-21-17-34-34-34-34-33-34 
t701 Bel, Den, Fra, Gab, Ger, Ind, Jap, Jor, Net, New, Nor, SA, Spa, Swe, Tai 11-10-21-17-34-24-34-22-25-25 
t888 Den, Fin, Ger, Nor, SA, Swe, Swi 07-23-21-24-33-17 
t891 Den, Fra, Ger, SA, Swi 26-23-13-23-31-05-17-25-17-25-28 
t1257 Den, Ger, Nor, SA 11-19-34-05-17-34-24-34-22-25 
t1443 SA 11-19-12-05-17-34-24-24-34-22-25 
t1476 Bel, Gab, Ger, Net, Nor, SA 11-10-17-34-24-34-22-25 
t1597 Fra, Ger, Ind, Net, Nor, SA, Zim 15-12-17-20-17-12-12-17 
t1848 Fra, SA 15-12-17-16-02-16-02-25-17 
t2360 SA 11-10-21-17-34-24-34-22-25-25-25 
t2393 Fra, Nor, SA, Swe, UK 07-12-21-17-13-13-13-34-33-34 
t2623 Aus, Net, SA 08-16-02-16-13-17-13-16-34 
t2763 SA 26-13-17-34-16-13 
t4576 Ger, SA 08-16-02-16-34-34-16-13 
t5471 SA 35-21-16-34-33-13 
t5472 SA 11-10-17-34-24-34 
t5473 SA 11-19-12-21-21-12-34-24-34-22-25 
t5474 SA 11-10-21-17-34-24-34-22-25-25-25-25 
 159
 8.5 APPENDIX E: spa Type Repeat Motif Alignments 
 
Table E1: The alignment of spa type repeat patterns within spa-CC 701 (Cluster 1) 
 
spa type   Repeat motif 
 
t064  11-19-     12-05-    -17-34-24-    -34-22-25 
t292  11-12-         -    -    -17-34-24-    -34-22-25 
t451  11-12-     05-         -17-34-24-    -34-22-25 
t701  11-10-     21-         -17-34-24-    -34-22-25-25 
t1257  11-19-34-05-         -17-34-24-    -34-22-25 
t1443  11-19-     12-05-    -17-34-24-24-34-22-25 
t1476  11-10-                    -17-34-24-    -34-22-25 
t2360  11-10-     21-         -17-34-24-    -34-22-25-25-25 
t5472  11-10-         -    -    -17-34-24-    -34 
t5473  11-19-     12-21-21-12-34-24-    -34-22-25 
t5474  11-10-     21-         -17-34-24-    -34-22-25-25-25-25 
 
 
 
Table E2: The alignment of spa type repeat patterns within spa-CC 012 (Cluster 2) 
 
spa type   Repeat motif 
 
t012  15-12-    -16-    -02-16-02-25-17-24-24 
t018  15-12-    -16-    -02-16-02-25-17-24-24-24 
t021  15-12-    -16-    -02-16-02-25-17-24 
t030  15-12-    -16-    -02-                     -24-24 
t037  15-12-    -16-    -02-          -25-17-24 
t253  15-12-    -16-    -02-16-02-25-17-24-24-24-24 
t275  15-12-    -16-    -02-          -25-17-24-24 
t318  15-12-    -16-16-02-16-02-25-17-24 
t433  15-12-    -16-16-02-16-02-25-17 
t1848  15-12-17-16-    -02-16-02-25-17 
 
 
Table E3: The alignment of spa type repeat patterns within spa-CC 002 (Cluster 3) 
 
spa type   Repeat motif 
 
t002  26-23-17-34-17-20-17-12-17-     -16 
t045  26-              -17-20-17-12-17-      -16 
t214  26-23-17-34-17-20-17-12-17-     -16-16 
t306  26-23-17-34-17-20-17-12-17-17-16 
t311  26-23-17-34-    -20-17-12-17-    -16 
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Table E4: The alignment of spa type repeat patterns within spa-CC 015 (Cluster 4) 
 
spa type   Repeat motif 
 
t015  08-16-02-16-34-13-17-34-16-34 
t465  08-23-    -16-34-13-17-34-16-34 
t2623  08-16-02-16-    -13-17-13-16-34 
t4576  08-16-02-16-34-         -34-16-13 
 
 
Table E5: The alignment of spa type repeat patterns within spa-CC 174 (Cluster 5) 
 
spa type   Repeat motif 
 
t127  07-23-21-16-34-33-13 
t174  14-    -21-16-34-33-13 
t5471  35-    -21-16-34-33-13 
 
 
Table E6: The alignment of spa type repeat patterns within spa-CC 346/085  
                  (Cluster 6) 
 
spa type   Repeat motif 
 
t346  07-23-12-               -34-    -12-12-23-02-12-23 
t085  07-23-12-               -34-34-12-    -23-02-12-23 
t5396  07-23-12-13-23-12-34-34-12-12-23-02-12-23 
 
 
Table E7: The alignment of spa type repeat patterns within Cluster 7, No founder 
 
spa type   Repeat motif 
 
t521  07-23-12-21-17-34-34-34-34-33-34 
t267  07-23-12-21-17-34-34-34-    -33-34 
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8.6 APPENDIX F: spa Repeat Unit Alignments 
 
Table F1: Alignment of the nucleotide sequences of repeats r19 and r12 
 
Repeat  Nucleotide sequence 
 
r19   AAAGAAGACAATAACAAGCCTGGC    
r12   AAAGAAGACAACAACAAGCCTGGT 
 
 
Table F2: Alignment of the nucleotide sequences of repeats r19 and r10 
 
Repeat  Nucleotide sequence 
 
r19   AAAGAAGACAATAACAAGCCTGGC 
r10   AAAGAAGACAATAACAAGCCTGGT 
 
 
Table F3: Alignment of the nucleotide sequences of repeats r21 and r05 
 
Repeat  Nucleotide sequence 
 
r21   AAAGAAGACAACAACAAGCCTGGC    
r05   AAAGAAGACAACAAAAAGCCTGGC  
 
 
Table F4: Alignment of the nucleotide sequences of repeats r21 and r12 
 
Repeat  Nucleotide sequence 
 
r21   AAAGAAGACAACAACAAGCCTGGC   
r12   AAAGAAGACAACAACAAGCCTGGT 
 
 
Table F5: Alignment of the nucleotide sequences of repeats r17 and r12 
 
Repeat  Nucleotide sequence 
 
r17   AAAGAAGACGGCAACAAGCCTGGT    
r12   AAAGAAGACAACAACAAGCCTGGT 
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Table F6: Alignment of the nucleotide sequences of repeats r16 and r23 
 
Repeat  Nucleotide sequence 
 
r16   AAAGAAGACGGCAACAAACCTGGT   
r23   AAAGAAGACGGCAACAAACCTGGC  
 
 
Table F7: Alignment of the nucleotide sequences of repeats r34 and r13 
 
Repeat  Nucleotide sequence 
 
r34   AAAGAAGACAACAAAAAACCTGGT    
r13   AAAGAAGACAACAACAAACCTGGT 
 
 
Table F8: Alignment of the nucleotide sequences of repeats r14 and r07 
 
Repeat  Nucleotide sequence 
 
r14   GAGGAAGACAACAACAAACCTGGC    
r07   GAGGAAGACAACAACAAACCTGGT  
 
 
Table F9: Alignment of the nucleotide sequences of repeats r14 and r35 
 
Repeat  Nucleotide sequence 
 
r14   GAGGAAGACAACAACAAACCTGGC    
r35   GAGGAAGACAACAAAAAACCTGGC    
 
 
 
